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ABSTRACT 
Rhythmic oscillations in neuronal activity display variations in amplitude (power) 
over a range of frequencies. Attention and cognitive performance correlate with increases 
in cortical gamma oscillations (40-70Hz) that are generated by the coordinated firing of 
glutamatergic pyramidal neurons and GABAergic interneurons, and are modulated by 
dopamine. In the medial prefrontal cortex (mPFC) of rats, gamma power increases during 
treadmill walking, or after administration of an acute subanesthetic dose of the NMDA 
receptor antagonist ketamine. Ketamine is also used to mimic symptoms of 
schizophrenia, including cognitive deficits, in healthy humans and rodents. Additionally, 
the ability of a drug to modify ketamine-induced gamma power has been proposed to 
predict its pro-cognitive therapeutic efficacy. However, the mechanism underlying 
ketamine-induced gamma oscillations is poorly understood. We hypothesized that gamma 
oscillations induced by walking and ketamine would be generated by a shared mechanism 
in the mPFC and one of its major sources of innervation, the mediodorsal thalamus (MD). 
Recordings from chronically implanted electrodes in rats showed that both treadmill 
walking and ketamine increased gamma power, firing rates, and spike-gamma LFP 
correlations in the mPFC. By contrast, in the MD, treadmill walking increased all three 
  ix 
measures, but ketamine decreased firing rates and spike-gamma LFP correlations while 
increasing gamma power. Therefore, walking- and ketamine-induced gamma oscillations 
may arise from a shared circuit in the mPFC, but different circuits in the MD. 
 
Recent work in normal animals suggests that dopamine D4 receptors (D4Rs) 
synergize with the neuregulin/ErbB4 signaling pathway to modulate gamma oscillations 
and cognitive performance. Consequently, we hypothesized that drugs targeting the D4Rs 
and ErbB receptors would show pro-cognitive potential by reducing ketamine-induced 
gamma oscillations in mPFC. However, when injected before ketamine, neither the D4R 
agonist nor antagonist altered ketamine’s effects on gamma power or firing rates in the 
mPFC, but the pan-ErbB antagonist potentiated ketamine’s increase in gamma power, 
and prevented ketamine from increasing firing rates. This indicates that D4Rs and ErbB 
receptors influence gamma power via distinct mechanisms that interact with NMDA 
receptor antagonism differently. Our results highlight the value of using ketamine-
induced changes in gamma power as a means of testing novel pharmaceutical agents. 
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CHAPTER ONE: Neuregulin, dopamine, cognitive function and gamma 
oscillations: role of D4 receptors 
1.1 Introduction 
 Schizophrenia is characterized by three distinct symptom clusters– positive, 
negative and cognitive. Historically, positive symptoms such as hallucinations and 
delusions have received the most attention, and are often improved by typical and 
atypical antipsychotics. In contrast, negative symptoms such as social withdrawal, lack of 
motivation and impaired social interactions, and cognitive impairments including deficits 
in attention, working memory and executive function are refractory to antipsychotics. 
The intractability of cognitive symptoms has been a major obstacle in the development of 
more effective therapies for schizophrenia, especially in light of epidemiological findings 
indicating that the severity of cognitive symptoms is more predictive of long-term course 
of the disease than positive symptoms (Green, 1996), and that cognitive impairments are 
present before the onset of the illness (Reichenberg et al., 2002). 
In the medial prefrontal cortex (mPFC), neural synchrony in the gamma 
frequency range (30-80Hz) is thought to play an important role in cognitive flexibility, 
working memory, and attention (Cannon et al., 2014; Gregoriou et al., 2015). Indeed, 
optogenetic inhibition of mPFC interneurons inhibits both gamma power and cognitive 
flexibility while activation of mPFC interneurons at gamma frequencies restores 
cognitive flexibility in cognitively impaired mice (Cho et al., 2015).  Additionally, it has 
been proposed that impairments in gamma oscillations play a key role in producing the 
cognitive deficits observed in psychiatric disorders such as schizophrenia and ADHD 
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(Pittman-Polletta et al., 2015; Sakurai et al., 2015). Subanesthetic doses of the NMDAR 
antagonist ketamine elicit psychotomimetic effects with concomitant increases in gamma 
power in healthy humans similar to those observed in patients with schizophrenia 
(Anticevic et al., 2015; Kocsis et al., 2013; Krystal et al., 1994). The gamma power 
increase induced by an acute subanesthetic dose of ketamine has been used as a possible 
biomarker for investigating the pro-cognitive therapeutic efficacy of novel 
pharmacological agents (Anderson et al., 2014; Hudson et al., 2016; Ma and Leung, 
2014). However, the mechanism underlying ketamine-induced gamma oscillations is 
poorly understood.  
While the importance of dopaminergic modulation of the PFC for proper 
cognitive functions is well supported by experimental evidence from nonhuman primates 
and rodents (Goldman-Rakic, 1995; Robbins and Arnsten, 2009), the ways in which 
altered dopamine (DA) activity contributes to gamma band activity in the PFC is poorly 
understood. During a treadmill-walking task, which requires attention, gamma power 
increases in the medial prefrontal cortex (mPFC) in rats with intact dopamine signaling, 
but not in rats with a lesion of the dopaminergic cells from the ventral tegmental area 
(VTA) and substantia nigra (Delaville et al., 2015). Additionally, the dopamine D4 
receptor (D4R), considered a major D2-type receptor, is prominently expressed in 
parvalbumin-expressing (PV+) interneurons (Andersson et al., 2012b), has the highest 
affinity for dopamine of any dopamine receptor (Rondou et al., 2010), and modulates 
gamma power and cognition in vivo (Nakazawa et al., 2015). Therefore, we hypothesized 
that signaling through the D4R would be fundamental to the walking-induced increase in 
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gamma oscillations. We further hypothesized that gamma oscillations induced by 
walking and ketamine would be generated by a shared mechanism in the mPFC, and one 
of its major sources of innervation, the mediodorsal thalamus (MD). 
Here I review the current state of research into the connection between gamma 
oscillations and cognition, the mechanisms of gamma oscillation generation, and the 
influence of NMDAR (NMDAR) antagonists on these oscillations. I further examine the 
role of dopamine in the modulation of network rhythms in the cortex, particularly the 
PFC and hippocampus, as evidence that dopamine signaling is potently involved in 
regulating theta and gamma oscillations has emerged.  I finish by focusing specifically on 
the D4R, a receptor strongly implicated in ADHD, and Neuregulin (NRG) signaling 
through ErbB4 receptors (ErbB4Rs), a pathway genetically implicated in schizophrenia. 
Recent studies have shown that dopamine signaling via D4R, in a close and synergistic 
relationship with the NRG/ErbB4R signaling pathway modulates gamma rhythms in the 
hippocampus and prefrontal cortex (Andersson et al., 2012b; Kocsis et al., 2014; 
Nakazawa et al., 2015). Taken together with the genetic association of the 7-repeat 
variant of the human DRD4 gene with increased risk for ADHD and altered gamma band 
responses (Demiralp et al., 2007; Gizer et al., 2009), we hypothesized that drugs targeting 
the D4Rs and ErbB receptors would show pro-cognitive potential by reducing ketamine-
induced gamma oscillations. Our results highlight the importance of testing the effects of 
novel pharmaceutical agents on gamma oscillations induced by ketamine as opposed to 
gamma oscillations observed in normal animals in the attempt to find pro-cognitive 
therapeutic agents.  
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1.2 Overview of gamma oscillations 
1.2.1 Mechanisms of gamma oscillation generation 
Oscillations in neuronal activity display variations in amplitude (power) over a 
range of frequencies (Fig 1.1D). Gamma oscillations (30-80Hz) are generated in one of 
three ways: 1) through recurrent networks of interneurons which inhibit one another for a 
specific period (ING gamma); 2) through synchronous excitatory activity from pyramidal 
cells onto interneurons (PING gamma), or 3) through synchronized excitation projected 
into the region from the thalamus or another cortical region (Tiesinga and Sejnowski, 
2009).  In interneuron generated (ING) gamma, when a small number of fast-spiking 
PV+ interneurons start spiking in synchrony, the inhibition on other excitatory pyramidal 
neurons and interneurons in the network prevents these neurons from spiking until the 
inhibition from the PV+ interneurons has ‘worn off’ (Fig 1.2C). This adjusts the timing 
of other neurons in the network to fire during the small time window without inhibition, 
thus increasing the number of neurons participating in the synchronized firing (Bartos et 
al., 2007; Tiesinga and Sejnowski, 2009). The decay time of the inhibition sets the 
maximum frequency of the oscillation (Buzsaki and Wang, 2012). Importantly, in ING, 
the interneurons themselves have sufficient excitation to spike in synchrony without a 
synchronized volley from neighboring pyramidal neurons, although ING gamma 
typically leads to synchronized spiking of pyramidal neurons as well (Whittington et al., 
2011). Experimentally, gamma activity can propogate in vitro in the absence of 
ionotropic glutamatergic signaling (Whittington et al., 1995), further supporting the ING 
models of gamma oscillations. By contrast, in pyramidal-interneuron generated (PING) 
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gamma, the inhibitory cells need synchronized inputs from the pyramidal neurons to 
increase the gamma power (Fig 1.2B&C). One prediction from the PING gamma model 
is that the firing rates of pyramidal neurons and gamma power should be closely 
correlated. It is hard to distinguish PING and ING gamma experimentally because either 
mechanism leads to the synchronized spiking of pyramidal neurons (Tiesinga and 
Sejnowski, 2009). 
Recordings from chronically implanted electrodes can be separated into local field 
potentials (LFPs) and spiking activity by low pass and high pass filtering respectively 
(Fig 1.1A&B). Consequently, researchers can examine the relationships between spikes 
and the phase of oscillations in different frequency ranges, which can be used to probe 
how certain oscillations are generated and how they influence neuronal activity (Ray, 
2015). These recordings are then used to inform computational models. Small 
modifications in NMDAR-mediated neurotransmission between pyramidal neurons and 
interneurons can produce prominent changes in frequency and power (Jadi et al., 2015; 
Neymotin et al., 2011). In fact, models predict that simply reducing NMDA receptor 
neurotransmission onto interneurons in the oriens layer of the hippocampus increases the 
gamma power in this region (Neymotin et al., 2011), which suggests that the blockade of 
NMDA receptors on some neurons may have greater influence on gamma power than 
blockade of NMDA receptors on other types of neurons. 
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Figure 1.1: Basics of gamma oscillations, adapted from Jia & Kohn (2011). (A) Local 
field potentials (LFPs) and single neuron activity comes from recordings of high 
impedance electrodes chronically implanted in brain tissue. This raw signal (B) is low-
pass filtered (<150Hz) to provide the LFP (pictured in C and D), and it is also high pass 
filtered (40kHz) to isolate spiking activity. A major focus of this thesis will be the timing 
of spikes in relationship to local field potentials. C,D, Example traces of LFPs from 
normal animals during spontaneous (ongoing) activity, and task-related recording 
conditions shown as raw traces (C), or as power spectra (D).  Note that in normal 
animals, gamma power increases as stimulus salience or task-difficulty increases. 
 
Finally, PV+ interneurons are both essential for the maintenance of gamma 
oscillations, and may be important in the etiology of schizophrenia (Bartos et al., 2007; 
Lewis et al., 2011). These PV+ interneurons form inhibitory connections with cell bodies 
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and axon initial segments of their pyramidal neuron targets. Moreover, they are 
extensively interconnected through electrical and chemical synapses (for excellent 
reviews, see: Bartos et al., 2007; Buzsaki and Wang, 2012; Whittington et al., 2011). The 
central role of PV+ interneurons in the generation of gamma rhythms has been 
demonstrated using optogenetic techniques in vivo and in vitro (Cardin et al., 2009; Sohal 
et al., 2009). Numerous postmortem studies in persons with schizophrenia have also 
shown changes in PV+ interneurons, in particular decreases in mRNA and protein 
expression of GAD67 and PV (Lewis et al., 2011), consistent with perturbed maturation 
of inhibitory PFC circuits during adolescence responsible for abnormal oscillation 
patterns in adulthood (Benes and Berretta, 2001; Beneyto and Lewis, 2011; Sullivan and 
O’Donnell, 2012). 
 
Figure 1.2: Schematic diagrams of ING and PING mechanisms. Adapted from 
Tiesinga & Sejnowski (2009). (A) A simplified representation of the laminar structure of 
the cortex. Inputs come in to layer 2/3 from other cortical regions (feedback), and other 
inputs come in to layer 4 from the thalamus (feedforward).  In both layers, reciprocally 
interconnected interneurons form ING networks and reciprocally connected networks of 
excitatory and inhibitory cells form PING networks. (B) Synchronous network activity 
can be generated via ING networks, in which interneurons synchrony arises because they 
and neighboring neurons can only spike during a time outside of the time of recovery 
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from the inhibition. The PING mechanism requires synchronous excitatory volleys to 
elicit a synchronous inhibitory volley from the interneurons. Thus the decay of inhibition 
sets the maximum frequency in both the ING and PING gamma. 
  
1.2.1 Cognition correlates with gamma band activity in humans and rodents 
Cognitive impairments arise from altered activity in the PFC. In normal humans, 
spontaneous gamma oscillation power, also referred to as ongoing gamma oscillation 
power, is low (Fig 1.1C). This gamma power increases in response to salient stimuli or 
cognitive task demands (Fig 1.1D). The difference between the task related gamma 
power and the spontaneous ongoing gamma power is called signal-to-noise. Patients with 
psychiatric disorders that influence cognition, such as ADHD and schizophrenia have 
reduced signal-to-noise gamma ratios in the PFC (Tost et al., 2005; Winterer and 
Weinberger, 2004). Local oscillatory network activity in cortical areas, in particular 
gamma-band rhythms (30-80 Hz), also correlates with working memory and selective 
attention (Benchenane et al., 2011; Cannon et al., 2014; Womelsdorf and Fries, 2007), 
and higher cognitive demands correlate with increased gamma power and coherence 
across different cortical areas (Barr et al., 2010; Cho et al., 2006). Children with ADHD 
appear to have enhanced ongoing gamma power that only increases slightly in response 
to a cognitive task  (Lenz et al., 2008), suggesting that a reduced signal-to-noise ratio in 
gamma power may contribute to the cognitive impairments related to ADHD. Similarly, 
numerous studies have shown that basal, evoked and induced gamma oscillations are 
altered in schizophrenic patients (for reviews, see Herrmann and Demiralp, 2005; 
Uhlhaas and Singer, 2010). Most of these studies focused on evoked oscillations in 
sensory cortices, in particular the auditory cortex for its prominent role in auditory 
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hallucinations. Patients with schizophrenia have elevated ongoing cortical gamma power 
(Minzenberg et al., 2010; Spencer et al., 2008; Williams et al., 2009), and have deficits 
upregulating gamma oscillations in response to cognitively demanding tasks (Barr et al., 
2010; Basar-Eroglu et al., 2007; Cho et al., 2006; Haenschel et al., 2009; Kissler et al., 
2000; Minzenberg et al., 2010). Taken together, these observations suggest that cognitive 
deficits are associated with reduced signal-to-noise relationships in regulation of gamma 
oscillations (Cho et al., 2006).  
Cognition also correlates with gamma band activity in rodents. A recent study in 
rodents provided the first causal link between gamma oscillations and cognition. 
Optogenetic inhibition of mPFC interneurons inhibits both gamma power and cognitive 
flexibility while activation of mPFC interneurons at gamma frequencies restores 
cognitive flexibility in cognitively impaired mice (Cho et al., 2015).  Nevertheless, 
increases in gamma power are not restricted to cognitive demand. In rats, gamma power 
correlates with arousal as well as cognition (McGinley et al., 2015a; Reimer et al., 2014). 
Both locomotion and arousal induce a clear spectral peak ~50Hz that is not observed 
during quiet wakefulness in the mPFC (Delaville et al., 2015) and the visual cortex 
(Vinck et al., 2015). This gamma range peak is not observed in the first few weeks after a 
lesion of dopaminergic innervation to the cortex (Delaville et al., 2015), suggesting that 
gamma range activity related to attention depends on dopaminergic neurotransmission.  
Subcortical brain structures may also play an important role in cognition 
(Kellendonk et al., 2006). For example, a subtle decrease in MD thalamus activity 
generated selective impairments in cognitive tasks typically ascribed to the activity of the 
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PFC by reducing beta range synchrony between the MD thalamus and mPFC 
(Parnaudeau et al., 2013).  Therefore, it is important to examine entire neural circuits, and 
not simply examine the PFC in isolation. 
1.3 Effects of ketamine 
1.3.1 Translation of ketamine effects from rodents to humans 
An acute, subanesthetic dose of the NMDAR antagonist ketamine produces 
psychomimetic effects in healthy human subjects (Krystal et al., 1994), which can be 
used as a face valid model of the positive, negative, and cognitive symptoms of 
schizophrenia  (Krystal et al., 1999; Stone et al., 2008, 2012). Ketamine also exacerbates 
the symptoms of patients with schizophrenia (Lahti et al., 1995).  It has also been used as 
an antidepressant in treatment resistant depression (Abdallah et al., 2015). When 
modeling an inherently human disorder, like schizophrenia, in animal models it is 
beneficial to recreate endophenotypes highly associated with the disorder. 
Endophenotypes are heritable biomarkers that cosegregate with the illness and include 
both behavioral and neurophysiological measures (Gottesman and Gould, 2003). For 
example, ketamine disrupts neurophysiological biomarkers in humans and rodents that 
are also disrupted in patients with schizophrenia such as auditory gating, mismatch 
negativity, and a positive deflection in the EEG for deviant auditory stimuli, known as the 
P300 (for a review, see Kocsis et al., 2013).  
NMDAR antagonism may provide clues into a potential etiology of 
schizophrenia. Indeed, patients with anti-NMDAR encephalitis have symptoms that 
mimic schizophrenia (Fischer et al., 2016). NMDAR hypofunction leads to increased 
  
11 
extracellular glutamate and overall increased excitation in the brain (Löscher et al., 1991; 
Moghaddam et al., 1997; Stone et al., 2012).  NMDAR hypofunction may help to explain 
atrophy and reduced GAD67 and PV expression in interneurons of postmortem brains 
from patients with schizophrenia (for a review, see Frohlich and Van Horn, 2014).  
Furthermore, postmortem evidence reveals decreased NR2A mRNA in interneurons of 
the prefrontal cortex of patients with schizophrenia (Woo et al., 2008a), with increased 
NR2A expression in specific sets of calbindin expressing interneurons (Woo et al., 
2008b). Taken together, NMDAR signaling in interneurons may be important for 
producing schizophrenia symptoms. 
Oscillatory alterations accompany all pharmacological manipulations that produce 
psychotomimetic behavior (Pittman-Polletta et al., 2015; Rosen et al., 2015a). An acute 
subanesthetic dose of ketamine increases cortical gamma power (30-80Hz) in humans 
(Anticevic et al., 2015; Hong et al., 2010; Shaw et al., 2015) and rodents (Ehrlichman et 
al., 2009; Kulikova et al., 2012; Lazarewicz et al., 2009; Meltzer et al., 2013; Pinault, 
2008; Shaffer et al., 2014). Ketamine also impairs  the acquisition and manipulation of 
working memory as well as verbal learning and attention in healthy human volunteers 
(for a review, see Gilmour et al., 2012). Similarly, NMDAR antagonism using MK-801 
causes significant impairments in spatial memory, sensory gating, and synaptic plasticity 
in rats (Blot et al., 2015; Manahan-Vaughan et al., 2008; Nikiforuk et al., 2016; Smith et 
al., 2011). In rodents, ketamine also reduces the signal-to-noise ratio of evoked gamma 
oscillations (Saunders et al., 2012), as observed in patients with schizophrenia. Many 
studies have explored the effects of ketamine in rodent models in an effort to gain further 
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insight into schizophrenia and the treatment of depression (Lodge and Mercier, 2015). 
One recent study suggests that the effects of ketamine on evoked gamma oscillations, and 
specifically the signal-to-noise ratio of gamma oscillations have more predictive power 
for potential therapeutics than ketamine’s effects on ongoing gamma oscillations (Hudson 
et al., 2016). Interestingly, long-term, but not acute treatment with neuroleptics that target 
dopamine signaling decreases ketamine-induced positive and cognitive symptoms in 
healthy human volunteers (Krystal et al., 1999; Lipschitz et al., 1997; Malhotra et al., 
1997). Likewise, long-term, but not acute treatment with neuroleptics that target 
dopamine signaling decreases ketamine-induced increases in gamma power and motor 
activity in rodents (Anderson et al., 2014; Jones et al., 2012). Taken together, these 
finding provide support that the ketamine model has predictive validity in testing drugs 
for pro-cognitive potential in schizophrenia and other psychiatric disorders (Gilmour et 
al., 2012).  
Increasing evidence suggests that effects of ketamine on gamma oscillation power 
are independent from its antidepressant-like effects. First, other NMDAR antagonists, 
such as MK-801 and phencyclidine (PCP) increase gamma power without exerting 
antidepressant effects (Autry et al., 2011; Zanos et al., 2016). Second, NR2B antagonists 
alone recapitulate ketamine’s antidepressant effects without altering gamma power or 
extracellular glutamate  in vivo (Jiménez-Sánchez et al., 2014; Kocsis, 2012; Li et al., 
2010; Miller et al., 2016). Intriguingly, a recent study implicates hydroxynorketamine 
(HNK), a ketamine metabolite, as mediating the acute antidepressant effects of ketamine 
independent of NMDAR inhibition. HNK still induces increases in gamma power, but 
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without increasing motor activity (Zanos et al., 2016).  Thus, it is possible that the 
antidepressant properties of ketamine, or its metabolite could be separated from its 
psychotomimetic properties by increasing its target specificity. 
1.3.2 Ketamine pharmacology 
While multiple NMDAR antagonists increase gamma power, ketamine binds 
many receptors, and one of these targets may also influence the circuit to increase gamma 
power. Ketamine is an noncompetitive antagonist of NMDARs which binds to NR2A and 
NR2B containing NMDARs equally (Frohlich and Van Horn, 2014). Of ketamine’s two 
enantiomers, S-ketamine has four times higher affinity for the NMDAR PCP binding site 
and  produces more psychiatric disturbances than R-ketamine (Oye et al., 1992). 
Ketamine also acts as a partial agonist of the dopamine D2 receptor and has weak affinity 
for serotonin 5HT2A receptors (Kapur and Seeman, 2002), both of which have been used 
as targets in antipsychotic treatments. Furthermore, ketamine has weak affinity for sigma-
1 receptors, which have been implicated in cognition and cerebral metabolism (Oye et al., 
1992). Interestingly, subchronic NMDAR antagonist administration reduced sigma 1 
receptor expression in the frontal cortex and hippocampus of mice (Kunitachi et al., 
2009), and patients with schizophrenia have reduced sigma 1 receptor expression in the 
cortex (Weissman et al., 1991). Finally, studies have observed weak affinity for ketamine 
to kappa receptors and muscarinic acetylcholine receptors as well (Frohlich and Van 
Horn, 2014). Additionally, at anesthetic doses, ketamine blocks sodium channels and Ih 
currents (Frohlich and Van Horn, 2014).  
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Ketamine has a significant influence on dopaminergic neurotransmission. 
Ketamine increases the firing rates of dopamine neurons in the VTA (Belujon and Grace, 
2014) and NMDAR antagonists increase extracellular dopamine (Löscher et al., 1991). 
Intriguingly, the GABAA receptor agonist muscimol reduces NMDAR antagonist induced 
increases in extracellular dopamine in the mPFC (Yonezawa et al., 1998), suggesting that 
NMDAR antagonism increases extracellular dopamine at least in part by the inhibition of 
GABA release from cortical interneurons. Furthermore, a PET study showed that the 
severity of ketamine-induced positive symptoms is correlated with dopamine release in 
the anterior cingulate cortex and lateral prefrontal cortex of healthy volunteers (Aalto et 
al., 2005), further establishing the relationship between NMDAR antagonism and 
dopamine.  
1.3.3 Ketamine’s effects on local neural circuits 
While it is well known that acute application of an NMDAR antagonist increases 
gamma power in the cortex, hippocampus, and other subcortical regions (Kocsis et al., 
2013), chronic application of NMDAR antagonists, and in vitro preparations have yielded 
mixed results. For example, in vitro ketamine decreases the power of kainate-induced 
gamma oscillations in the medial entorhinal cortex (Cunningham et al., 2006), but 
increases the power of kainate-induced gamma oscillations in the primary auditory cortex 
(Roopun et al., 2008). Chronic ketamine administration (2-4 weeks of 30mg/kg/day) 
causes decreases in gamma oscillation power and reduced number of PV+ interneurons 
(Kittelberger et al., 2012). These mixed results further complicate our understanding of 
how NMDAR antagonism increases gamma power. 
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Two hypotheses have been proposed to explain how NMDAR antagonism leads 
to increased excitation in the cortex. The disinhibition hypothesis proposes that low doses 
of ketamine selectively inhibit excitatory neurotransmission on cortical inhibitory 
interneurons, which in turn leads to the disinhibition of cortical pyramidal neurons. In the 
competing direct hypothesis, direct antagonism of NMDARs on pyramidal neurons 
induces a cell-autonomous form of homeostatic plasticity resulting in increased excitation 
(for a review, see Miller et al., 2016).  
In support of the disinhibition hypothesis, the NMDAR antagonist MK801 
increases the frequency of regular spiking putative pyramidal neurons in the PFC 
(Homayoun and Moghaddam, 2007a; Jackson et al., 2004)  and reduces the firing rates of 
putative fast-spiking interneurons (FSIs) in vivo (Homayoun and Moghaddam, 2007a). 
However, in a similar study in the orbitofrontal cortex, ketamine decreased the firing rate 
of putative interneurons, but had little effect on the firing rates of putative pyramidal 
neurons (Quirk et al., 2009). Contradicting this hypothesis, however, NMDAR 
antagonists actually increase the levels of extracellular GABA in the mPFC of rats 
(Chowdhury et al., 2012), indicating greater inhibitory neurotransmission after NMDAR 
antagonist application.  More recent experimental evidence calls this hypothesis into 
question.  
In order for the disinhibition hypothesis to be valid, tonically active NMDARs on 
interneurons must excite these neurons enough to maintain inhibitory synaptic tone and 
limit action potentials in pyramidal neurons (Miller et al., 2016). Indeed bath application 
of NMDA increases interneuron excitability in the CA1 and CA3 of the hippocampus in 
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acute slices (Mann and Mody, 2010; Xue et al., 2011). Under the disinhibition 
hypothesis, excitatory synapses onto interneurons should show higher dependence on 
NMDAR activation than pyramidal neurons. In support, NMDAR antagonists act with 
greater affinity on LTP in interneurons of the hippocampus than pyramidal neurons 
(Grunze et al., 1996). Furthermore, a GluN2B selective NMDAR antagonist reduced 
synaptic NMDAR-mediated currents and excitability in interneurons more than in 
pyramidal neurons (Hanson et al., 2013). However, even more experimental evidence 
suggests that NMDAR contribution to synaptic currents is stronger in pyramidal neurons 
than in PV+ interneruons (Hull et al., 2009; Rotaru et al., 2011; Wang and Gao, 2009). 
Indeed, in vitro electrophysiological studies suggest that AMPA receptor (AMPAR)-
mediated currents contribute at least three times more excitation to PV+ interneurons than 
NMDAR-mediated currents (Angulo et al., 1999; Carlén et al., 2012; Korotkova et al., 
2010; Rotaru et al., 2011; Wang and Gao, 2009). Additionally, quantitative electron 
microscopy revealed the highest expression of NMDARs in spine synapses onto 
pyramidal neurons and the lowest expression of NMDARs on PV+ interneurons in the 
hippocampus (Nyíri et al., 2003). Low concentrations of extracellular glutamate can 
provide a tonic depolarizing current via extrasynaptic NMDARs that increases the 
excitability of cells. It was further hypothesized that this tonic NMDAR-mediated current 
increase the excitability of PV+ interneurons more than pyramidal neurons; however, 
experimentally, it was shown that pyramidal neurons and interneurons have similar levels 
of basal activation (Povysheva and Johnson, 2012). Nevertheless, computation modeling 
studies suggest that non PV+ interneurons may actually play a greater role in NMDAR 
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antagonist induced disinhibition than PV+ basket cells (Neymotin et al., 2011). However, 
taken together, it appears that NMDAR-mediated currents are stronger in pyramidal 
neurons than in PV+ interneurons; therefore, the disinhibition hypothesis seems highly 
flawed. 
According to the direct hypothesis, direct antagonism of constitutively active 
NMDARs on pyramidal neurons induces increased cell-intrinsic excitation. One 
explanation for this is that NMDAR activation increases the synaptic expression of GIRK 
channels, which hyperpolarize cells and reduce spike frequency (Chung et al., 2009a, 
2009b). Therefore inhibiting NMDA receptors on pyramidal neurons would increase the 
excitability of those pyramidal neurons because GIRK channels would remain 
internalized. A second explanation involves tonic glutamatergic currents. Ambient 
glutamate produces a tonic current mediated mostly by NR2B-containing NMDARs 
(Miller et al., 2014). These receptors have a higher sensitivity to NMDAR agonists, a 
decreased sensitivity to Mg
2+
 block, and dominate the extrasynaptic receptor pool (Miller 
et al., 2016). In fact, selective gene deletion of NR2B- containing NMDARs from cortical 
pyramidal neurons increased the frequency of glutamate release onto pyramidal neurons 
in layers 2&3 of the PFC (Miller et al., 2014), indicating increased excitatory drive. 
Furthermore, blocking extrasynaptic ligand-gated ion channels such as NMDARs can 
influence the cable properties of dendrites modifying the spatial and temporal summation 
within pyramidal interneurons (Harnett et al., 2013; Makara and Magee, 2013). It follows 
from the direct hypothesis that NR2B-containing NMDARs are responsible for 
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ketamine’s effects on neuronal firing rates, but these changes are independent from the 
NR2A-mediated circuit that increases gamma oscillation power.  
Another recent hypothesis suggests that the NMDA/AMPA receptor-mediated 
current ratio in pyramidal neurons is responsible for changes in excitability and gamma 
power after ketamine administration. NMDAR antagonists require NR2A receptor 
inhibition to increase gamma power (Kocsis, 2012). Inhibition of the NR2A receptor also 
mediates the increase in extracellular glutamate after NMDAR antagonist administration 
(Jiménez-Sánchez et al., 2014). These two findings, taken together, implicate a change in 
proportion of glutamatergic signaling through the AMPAR vs. the NMDAR. Instead of 
merely reducing excitatory drive to neurons, NMDAR antagonism appears to excite these 
neurons through elevated extracellular glutamate signaling through AMPARs  (Maeng et 
al., 2008). Further supporting this hypothesized mechanism, ketamine requires AMPAR 
activity to increase gamma power (Zanos et al., 2016).  Additionally, ketamine increases 
AMPAR mediated activity in unstimulated hippocampal slices (Nosyreva et al., 2013) 
and increases AMPAR mediated activity in the prefrontal cortex (Moghaddam et al., 
1997). Together, these results indicate that ketamine increases gamma power by 
increasing the glutamatergic signaling through AMPARs. Recent evidence suggests that 
kainate receptors and metabotropic glutamate receptors may actually play an even larger 
role in generating and maintaining gamma oscillations in the absence of NMDA receptor-
mediated signaling (Lladó-Pelfort et al., 2016).  Intriguingly, the majority of NMDARs 
on PV+ interneurons express NR2A, and  these receptors have faster temporal dynamics 
than NMDARs on pyramidal neurons (Kim et al., 2005; Kinney et al., 2006), leaving 
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open the possibility that PV+ interneurons may be essential in mediating the rise in 
extracellular glutamate. Furthermore, selective reduction of AMPAR-mediated currents 
in PV+ interneurons reduced kainate-induced gamma power in vitro (Fuchs et al., 2007), 
further hinting that AMPAR signaling in PV+ interneurons may be vital for ketamine’s 
effects on gamma power. 
An additional approach for testing the role of NMDARs in specific populations of 
neurons in vivo involves directed gene deletion using cell-type specific promoters driving 
the expression of recombinase enzymes and conditional knockout alleles. Genetic 
ablation of NMDARs from PV+ interneurons increases ongoing gamma power and 
decreases stimulus-evoked gamma power (Carlén et al., 2012; Korotkova et al., 2010), 
again reproducing the endophenotype of reduced signal-to-noise ratio in gamma power 
observed after NMDAR antagonist administration. Similarly, in mouse models of 
NMDAR hypofunction in a mixed population of interneurons, ongoing local field 
potentials (LFPs) also show an increase in gamma power (Nakao and Nakazawa, 2014). 
Removing NR1-containing NMDARs from PV+ interneurons late in development 
increases the firing rates of putative pyramidal neurons and decreases synchrony with 
surrounding neurons (Belforte et al., 2010). Interestingly, genetic removal of NR1-
containing NMDA receptors from forebrain pyramidal neurons produced the same 
gamma oscillation pattern observed when NMDA receptors were removed from PV+ 
interneurons (Tatard-Leitman et al., 2015). Specifically, these mice displayed increased 
ongoing/spontaneous gamma power and decreased evoked gamma power (Tatard-
Leitman et al., 2015). Furthermore, pyramidal neurons from these mice spiked more 
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often, and increased the spontaneous EPSC frequency (Tatard-Leitman et al., 2015), 
suggesting that removing NMDA receptor-mediated currents from pyramidal neurons 
actually makes these cells more excitable. Overall, the endophenotypes observed after 
genetic removal of NMDA receptors from PV+ interneurons lends support to the 
disinhibition hypothesis, and the endophenotypes observed after genetic removal of 
NMDA receptors from pyramidal neurons lends support to the direct hypothesis. 
Surprisingly, both genetic manipulations decrease the signal-to-noise ratio of gamma 
power and increase the excitability of pyramidal neurons, so it remains unclear which cell 
type is more important for mediating the effects of ketamine.  
 It remains an open question how the spiking of individual neurons contributes to 
NMDAR antagonist induced gamma power. Ensemble recordings in freely moving rats 
have shown that the NMDAR antagonist MK-801 increases the firing rates, decreases 
burst activity, and disorganizes the spiking of putative pyramidal neurons (Jackson et al., 
2004; Molina et al., 2014), all of which may reduce the efficiency of information 
transmission. In fact, the correlation between spike rate and gamma oscillations was 
reduced after MK801 administration (Wood et al., 2012), with spiking becoming more 
random (Molina et al., 2014). Therefore it is plausible that changes in firing rate make 
little, if any contribution to changes in low gamma-range local field potential. Increases 
in firing rates may still contribute to increases in high gamma power over a large range 
(Ray and Maunsell, 2011). 
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1.3.4 Ketamine’s effects systems-level circuits 
While the majority of research has focused on high frequency gamma oscillations, 
low frequency oscillations are also disturbed after NMDAR antagonism and in 
schizophrenia. Ketamine reduces delta, theta, and alpha oscillations in response to 
auditory clicks  in humans (Hong et al., 2010). Patients with schizophrenia frequently 
show enhanced delta frequency (1-5Hz) activity (Galderisi et al., 2009; Itil et al., 1972). 
Interestingly, NMDAR antagonists applied to the mediodorsal thalamus generate 
irregular, low frequency (0.5-1.5Hz) delta rhythms in the medial prefrontal cortex (Kiss 
et al., 2011a, 2011b).  Furthermore, locally applied NMDAR antagonists do not modify 
delta oscillations in the mPFC when applied there, but increase mPFC delta rhythms 
when applied to the thalamus (Kiss et al., 2011b). Additionally, theta-gamma cross 
frequency coupling is impaired by acute NMDAR blockade, specifically through the 
antagonism of NR2A-containing NMDARs (Kocsis, 2012).  Further work is needed to 
understand the relationship between ketamine-induced changes in low frequency 
oscillations and high frequency oscillations, and the relationship between NMDAR 
antagonism in the thalamus and cortex. 
Ketamine influences brain connectivity in a variety of ways. In human fMRI, 
patients with schizophrenia show hyperconnectivity during the early stages of the illness 
while chronic schizophrenia is marked by dysconnectivity  (Anticevic et al., 2015). 
Indeed, patients with schizophrenia typically show decreased functional connectivity 
between thalamic and cortical regions (Lynall et al., 2010). At rest, some groups have 
observed that ketamine increases functional connectivity in healthy human volunteers 
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(Anticevic et al., 2015; Driesen et al., 2013a); while, other groups have observed 
reductions in connectivity between the mPFC and default mode network and affective 
network (Scheidegger et al., 2012). This suggests that ketamine may be a better model of 
early stage schizophrenia at the systems level. 
In healthy volunteers, working memory tasks activate a task-related network and 
reduce the activity of the default mode network. After ketamine administration, this anti-
correlated relationship between the two circuits is greatly reduced (Anticevic et al., 
2012), reflecting a reduced signal-to-noise ratio in the relationship between these 
networks.  Furthermore, during a working memory task, ketamine bilaterally decreases 
functional connectivity in the dorsolateral prefrontal cortex connectivity (Driesen et al., 
2013b). Together with ketamine-induced hyperconnectivity during rest, this finding 
suggests that ketamine reduces signal-to-noise in circuit pathways. 
Results from metabolism studies complicate findings from MRI studies. Ketamine 
increases metabolism in the mPFC while decreasing metabolism in the dorsal reticular 
thalamic nucleus, a major source of inhibitory innervation to the mediodorsal thalamus 
(Dawson et al., 2013). Additionally, ketamine increases the functional connectivity of the 
prelimbic PFC to the dorsal reticular thalamic nucleus and concurrently decreases the 
functional connectivity of the PFC to the mediodorsal thalamus (Dawson et al., 2013).  
However, a later study by the same investigators found increased functional connectivity 
between the PFC and MD thalamus (Dawson et al., 2014).  Further work is necessary to 
elucidate ketamine –induced changes in functional connectivity and determine how these 
changes relate to schizophrenia. 
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1.3.5 Dose-related effects of ketamine 
NMDAR antagonists have dramatically different functions depending on dose. At 
low doses, ketamine evokes psychotomimetic behavior and acts as an antidepressant 
(Abdallah et al., 2015; Berman et al., 2000; Krystal et al., 1994; Zarate et al., 2006). 
Interestingly, the exact same doses of ketamine (0.3-0.5mg/kg in humans, 5-10mg/kg in 
rodents) are used to induce the symptoms of early stage schizophrenia in healthy 
volunteers and rapidly treat depression and reduce suicidal idealization resistant to 
antidepressant treatment (Abdallah et al., 2015; Belujon and Grace, 2014; Carreno et al., 
2015; Corlett et al., 2013; Frohlich and Van Horn, 2014). Ketamine also reduces 
depressive symptoms in rodent models of depression, and blunts the effects of 
uncontrollable stress (Amat et al., 2016; Belujon and Grace, 2014; Carreno et al., 2015; 
Li et al., 2010). Although street use of ketamine is illegal, racemic ketamine is also used 
recreationally at unknown doses for its psychomimetic effects (Lodge and Mercier, 
2015).  At higher doses (5-10mg/kg in humans, 70-100mg/kg in rodents), ketamine 
induces anesthesia. Ketamine is mostly used as an anesthetic in children due to its short 
half-life (Rowland, 2005; Shaffer et al., 2014). In both humans and rodents, therapeutic 
doses of ketamine are ~15% of the anesthetic dose. These dose-dependent effects of 
ketamine provide support for the direct hypothesis as stated above because at low levels, 
ketamine acts predominantly on extrasynaptic GluN2B-containing receptors, which are 
much more likely to be basally active, and at higher concentrations ketamine acts 
predominantly on synaptic NMDARs, which are less active, but appear to be responsible 
for changes in oscillations, and potentially its dissociative effects.  
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1.4 Overview of dopamine in the PFC 
1.4.1 Dopaminergic innervation and modulation of the prefrontal cortex 
The PFC integrates sensory, motor, and affective information to perform 
executive control of goal-directed behaviors (Fuster, 2001; Miller and Cohen, 2001), and 
it has long been appreciated that the dopamine system plays an important role in 
modulating information processing in the PFC (Goldman-Rakic, 1995; Robbins and 
Arnsten, 2009). Anatomically, three major dopaminergic projections emanate from the 
ventral mesencephalon, which have been named as mesostriatal, mesolimbic, and 
mesocortical pathways (Björklund and Dunnett, 2007). These pathways originate from a 
fairly small number of neurons with extensive collateralization in their respective target 
areas, such as striatum, amygdala and the PFC (Björklund and Dunnett, 2007). Within the 
mesocortical pathway, frontal cortical areas receive much denser innervation compared to 
posterior primary sensory areas (Berger et al., 1991; Björklund and Dunnett, 2007). The 
dopaminergic projection neurons that send long-range axons to innervate target neurons 
in the prefrontal cortical regions are mostly located in the ventral tegmental area (VTA) 
of the midbrain (Björklund and Dunnett, 2007; Lammel et al., 2008), and they comprise 
the mesoprefrontal dopaminergic circuit. Early on, the dopamine system was thought to 
be generally overactive in schizophrenia, as drugs targeting dopamine receptors acted as 
antipsychotics. However, this hypothesis was later refined to account for results from 
imaging and genetic studies suggesting hypofrontality and hypofunction of the prefrontal 
dopamine system (Davis et al., 1991; Meyer-Lindenberg et al., 2002). This revised 
dopamine hypothesis of schizophrenia posits that hyperactivity of the mesostriatal 
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pathway and hypofunction of the mesoprefrontal dopamine system occur simultaneously, 
although their causal relationship is a matter of current debate (Simpson et al., 2010) 
Although the growth of the mesoprefrontal dopaminergic axons is initiated 
prenatally (Kalsbeek et al., 1988; Verney et al., 1982), studies in both non-human 
primates and rodents indicate that this innervation matures much later in life. In 
particular, prefrontal dopaminergic axons continue to develop throughout adolescence, 
reaching a higher level of innervation density in early adulthood compared to that in the 
preadolescent period (Benes et al., 2000; Kalsbeek et al., 1988; Lambe et al., 2000; 
Rosenberg and Lewis, 1995).  
A key structural feature of the mesoprefrontal dopaminergic innervation is the 
density of axonal boutons of the VTA projection neurons (Benes et al., 2000; Berger et 
al., 1985; Kalsbeek et al., 1988; Lambe et al., 2000; Rosenberg and Lewis, 1995). Axonal 
boutons on the mesoprefrontal dopaminergic axons have enriched expression of the 
dopamine-synthesizing enzyme tyrosine hydroxylase (TH) and contain synaptic vesicles 
for dopamine release (Goldman-Rakic et al., 1989; Miner et al., 2003; Séguéla et al., 
1988). Some of these boutons form synaptic contacts with excitatory or inhibitory 
neurons in the PFC, while others may simply serve as dopamine release sites without any 
apposition to post-synaptic specializations (Descarries and Mechawar, 2000; Goldman-
Rakic et al., 1989; Séguéla et al., 1988; Smiley and Goldman-Rakic, 1993). The existence 
of synaptic and non-synaptic dopaminergic boutons suggests both synaptic and diffuse 
volume transmission by dopamine neurons, although the exact proportions of these types 
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of boutons appear to be highly variable across species and regions (Descarries and 
Mechawar, 2000).  
Dopamine release from axonal boutons is triggered by the firing activities of 
dopamine neurons (Schultz, 2007). The dopamine neurons normally fire in two distinct 
activity patterns that have been characterized as being either tonic or phasic (Schultz, 
2007). Tonic firing consists of regular or irregular spiking at frequencies less than 10 Hz, 
typically 3-4 Hz, and are prevalent in dopamine neurons when animals are in the resting 
state (Grace et al., 2007; Hyland et al., 2002; Robinson et al., 2004). In contrast, phasic 
firing consists of bursts of action potentials at frequencies higher than 10 Hz, are often 
correlated with reward-predicting, novelty or motivationally salient events (Bromberg-
Martin et al., 2010; Cohen et al., 2012; Schultz, 2007). Tonic extracellular dopamine 
concentrations are estimated between 5 and 50 nM at the dopamine terminals, and phasic 
dopamine release increases this concentration by 30 to 100 nM (Lavin et al., 2005; 
Wightman and Robinson, 2002). 
Throughout the brain, D1Rs and D2Rs are widely distributed, while D3Rs, D4Rs 
and D5Rs display considerably weaker or more restricted expression (Bentivoglio and 
Morelli, 2005). Unlike in the striatum, dopamine receptor expression in cortical areas 
generally does not exhibit clear cell type or pathway-specific patterns. Evidence from 
different approaches suggests that both D1- and D2-type receptors occur presynaptically 
and postsynaptically on pyramidal neurons and interneurons (Bentivoglio and Morelli, 
2005). Dopamine receptors are expressed most prominently in the deep cortical layers 
where the dopamine innervation is densest, but can be found in the superficial layers as 
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well. Furthermore, based on mRNA distribution, D1R and D2R expressing cells tend not 
to overlap except in layer 5, suggesting some regional or laminar selectivity of dopamine 
receptor expression (Santana et al., 2009). Interestingly, although more pyramidal 
neurons than GABAergic interneurons express the D1R, a greater proportion of 
interneurons express D1R, because of the prevalence of pyramidal neurons relative to 
interneurons (Santana et al., 2009). 
1.4.2 Dopamine and cognition 
Dopamine neuron activity modulates the activity of PFC neurons during cognitive 
tasks and motivational behaviors (Goldman-Rakic, 1995; Grace et al., 2007; Robbins and 
Arnsten, 2009), whereas deficiencies in mesoprefrontal dopaminergic circuits in humans 
are associated with major psychiatric disorders in humans such as schizophrenia, 
attention deficit/hyperactivity disorders (ADHD), and addiction (del Campo et al., 2011; 
Goldstein and Volkow, 2011; Winterer and Weinberger, 2004). A major cognitive 
function mediated by the PFC is working memory, which allows for the active 
maintenance of relevant information to guide subsequent actions (Brozoski et al., 1979). 
Prefrontal dopamine effects are concentration-dependent, such that both too little and too 
much dopamine lead to reduced cognitive performance (Sawaguchi and Goldman-Rakic, 
1994; Vijayraghavan et al., 2007). Subjects with low prefrontal dopamine levels due to a 
Met-to-Val substitution in the catechol-O-methyltransferase (COMT) gene show reduced 
performance in working memory and executive function tasks (Goldberg et al., 2003). 
Furthermore, amphetamine administration, which increases dopamine levels, improves 
prefrontal efficiency in Val homozygotes but decreases efficiency in Met homozygotes 
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(Mattay et al., 2003). These findings have led to the proposal of an inverted U-shaped 
functional response curve to increasing dopamine in the PFC. 
1.4.3 Cellular effects of dopamine 
At the cellular level, working memory is encoded by the persistent activities of 
stimulus-selective neuronal assemblies in the PFC (Goldman-Rakic, 1995), and 
dopamine signaling plays an important role in optimizing the signal-to-noise ratio in 
prefrontal neural representations (Vijayraghavan et al., 2007; Williams and Goldman-
Rakic, 1995). Transient increases in extracellular dopamine enhance evoked repetitive 
firing and suppress spontaneous firing for an extended period in pyramidal neurons in 
anesthetized animals (Lavin et al., 2005). In contrast, rapid dopamine reduces the firing 
activity of interneurons from the PFC in anesthetized animals (Tierney et al., 2008). More 
recent work using different combinations of optogenetic stimulation of dopaminergic 
fibers suggests that tonic dopamine may have opposite effects from phasic dopamine at 
the synaptic level (Rosen et al., 2015b). In vitro, dopamine can increase the excitability of 
FSIs and the frequency of GABA release, but has mixed effects on pyramidal neuron 
glutamatergic synapses and excitability (Gonzalez-Islas and Hablitz, 2003; Gulledge and 
Jaffe, 2001; Kröner et al., 2007; Penit-Soria et al., 1987; Tseng and O’Donnell, 2004; 
Zhou and Hablitz, 1999). By modulating cortical inhibition, dopamine decreases noise 
and has the potential to modulate excitation/inhibition balance and network oscillations. 
Despite a plethora of research, there is no unified view on the effects of dopamine 
on PFC neuron function (Seamans and Yang, 2004). This is in part due to the challenges 
in interpreting data derived through the use of dopamine itself or general dopamine 
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agonists that broadly activate dopamine receptor signaling in different cell types and 
subcellular compartments and thereby trigger complex and frequently opposing cellular 
and circuit effects. Receptor-specific agonists and antagonists, used at selective 
concentrations, have therefore been instrumental in dissecting the effects of distinct 
dopamine receptor types on neuronal function. 
 D1R activation increases the excitability of both FSI and pyramidal neurons and 
increases GABAAR and NMDAR-mediated currents in pyramidal cells (Cepeda et al., 
1992; Gao and Goldman-Rakic, 2003; Seamans et al., 2001; Trantham-Davidson et al., 
2008, 2014; Tseng and O’Donnell, 2004; Yang and Seamans, 1996; Zheng et al., 1999); 
but see (Gorelova et al., 2002). Therefore, enhanced inhibition keeps spontaneous firing 
low and enhanced excitability keeps recurrent network activity high when pyramidal 
neurons receive stimulation.  In contrast, activation of D2-type receptors decreases 
NMDA, AMPA and GABAA receptor mediated currents in pyramidal neurons, allowing 
more spontaneous firing, and weakening connections between cells (Li et al., 2009; 
Rosen et al., 2015b; Seamans et al., 2001; Trantham-Davidson et al., 2008; Tseng and 
O’Donnell, 2007a; Zheng et al., 1999); but see (Gonzalez-Islas and Hablitz, 2003). 
Selective D2R activation makes it easier to release the contents of working memory and 
redirect attention to new rules (Floresco et al., 2006). Notably, rapid (<1s) application of 
small localized doses of D1- and D2-type receptor agonists by iontophoresis elicits 
effects on pyramidal neuron excitability that are opposite to those observed with 
treatments applied on a longer time scale, providing more evidence for the fundamental 
differences in cellular responses to phasic and tonic modes of receptor activation (Moore 
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et al., 2011). Furthermore, phasic dopamine appears to increase shaeffer collateral 
pathway responses via D1R activation whereas low levels of dopamine simulating tonic 
dopamine neuron firing depress  shaeffer collateral pathway responses via a D4R-
dependent mechanism (Rosen et al., 2015b). Although activation of D1- and D2-type 
receptors typically act through opposing signaling pathways, they often synergize in the 
modulation of neuronal properties. For instance, D1-type and D2-type receptors work 
synergistically to enhance spike-timing dependent LTP (t-LTP) (Xu and Yao, 2010). T-
LTP enhances the storage of information in neural networks in which pyramidal neurons 
fire infrequently (Singer, 1993). Specifically, D2-type receptor activation suppresses 
GABA release from local interneurons that typically gate the induction of t-LTP, and D1-
type receptor activation at excitatory synapses allows t-LTP at an extended time window 
(Xu and Yao, 2010). Therefore, dopamine facilitates synaptic potentiation in cortical 
circuits. Gamma oscillations also may serve as a temporal template for t-LTP (Axmacher 
et al., 2006). Thus dopamine may also enhance t-LTP through the modulation of gamma 
oscillations. 
1.4.4 Dopamine and gamma oscillations 
Rhythmic oscillations are a basic feature of neural networks, and reflect the 
temporal and spatial integration of large numbers of neurons within and across brain 
regions. A large number of psychiatric and neurological disorders, including 
schizophrenia, ADHD, autism, epilepsy and Alzheimer’s disease, display altered gamma 
frequency oscillations within the PFC and cortico-subcortical networks (Herrmann and 
Demiralp, 2005). While the importance of network oscillations for cognitive function has 
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long been known, only a few studies have examined the role of dopamine in PFC 
oscillations.  
 Available evidence from human and rodent EEG studies suggests that dopamine 
increases the power of neural oscillations in the PFC, but has little effect on their 
induction or frequency. Persons with prolonged event-related increases in dopamine due 
to polymorphisms in the dopamine transporter gene DAT1 show an increase in evoked 
gamma power in response to target stimuli (Demiralp et al., 2007). In healthy subjects, 
antagonizing D2R with haloperidol reduces gamma power in response to attended stimuli 
in the contralateral hemisphere (Ahveninen et al., 2000). Similarly, the increase in 
gamma power in the mPFC observed during a treadmill walking task which requires 
attention is dependent on dopamine (Delaville et al., 2015). A 6-hydroxydopamine (6-
OHDA) lesion to the substantia nigra eliminates this peak for ~3 weeks. Surprisingly, it 
later returns, perhaps due to another compensatory mechanism (Delaville et al., 2015). 
Additionally, rats with ketamine-induced gamma oscillations show a reduction in gamma 
power in the cortex when given either clozapine or haloperidol, both antipsychotics that 
target D2-type receptors (Anderson et al., 2014; Jones et al., 2012). Dopamine is also 
important for increased coherence of gamma rhythms between the internal globus 
pallidus and the motor cortex, a process known as ‘motor binding’ that underlies the 
organization of normal voluntary movement (Engel et al., 2005).  
Theta oscillations are a predominant frequency in the hippocampus during active 
behavior, and depleting dopamine in the hippocampus decreases theta activity 
(Nakagawa et al., 2000), while injecting dopamine or apomorphine into the medial 
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septum increases hippocampal theta oscillations (Miura et al., 1987). Moreover, direct 
infusion of dopamine into the PFC of anesthetized rats increases theta oscillation 
coherence between the PFC and the hippocampus, a process that is believed to underlie 
reward prediction (Benchenane et al., 2011). These findings suggest that dopamine can 
augment the power of theta and of gamma oscillations, and increase the coherence of 
distributed networks oscillating at theta frequencies.   
In slices with intact dopaminergic projections, exogenous dopamine can dose-
dependently modulate cyclical changes in resting membrane potential called up-and 
down-states (Kroener et al., 2009). Gamma oscillations can be induced in slices by 
electrical stimulation or by agonists for kainate or metabotropic acetylcholine receptors. 
Dopamine increases the power and duration of stimulation-induced gamma oscillations in 
hippocampal area CA1 (Wójtowicz et al., 2009), but decreases the power and duration of 
carbachol induced oscillations in CA1 (Weiss et al., 2003) and kainate-induced 
oscillations in CA1 and CA3 (Wójtowicz et al., 2009), but see (Andersson et al., 2012b). 
These variances might be partly explained by differences in the mechanisms underlying 
each type of oscillation, and by differences in dopamine receptor activation. Nonetheless, 
pharmacological analysis of the involvement of dopamine in in-vitro gamma oscillations 
has proven informative. For example, antipsychotics including clozapine and haloperidol 
inhibit cholinergic hippocampal CA3 gamma oscillations (Schulz et al., 2012). Clozapine 
also suppresses synchronized pyramidal network activity in layer 5 of the PFC (Gao, 
2007). Furthermore, activation of the D1-type receptors decreases carbachol-induced 
gamma oscillation power (Weiss et al., 2003), while D4R activation increases gamma 
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oscillation power in the hippocampus in kainate-induced oscillations(Andersson et al., 
2012a; see also Section 1.5.7). These findings show that dopamine effects on oscillations 
are complex and depend on a large number of factors.  
1.4.5 Modulation of fast-spiking interneuron properties by dopamine 
Even small changes in interneuron function can produce large changes in gamma 
oscillations (Kopell et al., 2000; Whittington et al., 2011). Three key determinants of the 
power and frequency of gamma oscillations are 1) the magnitude and 2) kinetics of 
synaptic inhibition between interneurons, and 3) the driving excitatory current onto 
interneurons (Traub et al., 1996). Networks of FSI interconnect through chemical and 
electrical synapses that augment gamma activity by increasing FSI sensitivity to coherent 
excitatory inputs. Nonselective stimulation of dopamine receptors by exogenous 
dopamine appears not to change the electrical coupling of interneurons through gap 
junctions (Towers and Hestrin, 2008). However, selective activation of D1-type receptors 
reduces coupling (Hampson et al., 1992) while activation of D2-type receptors increases 
coupling (Onn and Grace, 1994), suggesting opposing effects of different dopamine 
receptor types. Moreover, dopamine acting through D1-type receptors decreases the 
amplitude of IPSCs in FSI (Towers and Hestrin, 2008). Dopamine also changes the 
intrinsic properties of FSI by increasing the firing rate of PV+ FSIs in vivo (Tseng et al., 
2006), and in vitro (Gao and Goldman-Rakic, 2003; Gorelova et al., 2002; Kröner et al., 
2007; Trantham-Davidson et al., 2008; Zhou and Hablitz, 1999); but see (Tierney et al., 
2008). 
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By reducing spontaneous firing in PV+ interneurons, dopamine augments 
temporal precision and thereby sharpens the spike timing of FSI (Gao and Goldman-
Rakic, 2003; Tierney et al., 2008). Furthermore, D1-type and D2-type receptors increase 
the amplitude and opening kinetics of the h-current, an inwardly rectifying 
hyperpolarization-activated nonselective cation current, in interneurons (Wu and Hablitz, 
2005). Likewise, dopamine activation reduces potassium currents, increasing the 
probability of repetitive firing (Gorelova et al., 2002; Schreiber et al., 2004). 
Computational modeling suggests that D4Rs may modify potassium currents to increase 
gamma power (Kuznetsova and Deth, 2008), although experimental verification is still 
pending. See sections 1.5.6 and 1.5.7 for a detailed discussion of D4R effects on synaptic 
and intrinsic properties and on gamma oscillations. 
1.4.6 Maturation of dopamine signaling 
As discussed earlier, PFC circuits finish maturing during adolescence and early 
adulthood, a period of high vulnerability to first psychotic episode in persons with 
schizophrenia. Maturation involves concomitant changes in responses to dopamine, 
receptor composition in FSI, and gamma-band activity during cognitive performance. 
From childhood to early adolescence, gamma frequency oscillations dominate most 
cortical regions, and their power correlates with increases in cognitive performance 
(Uhlhaas et al., 2009). Strikingly, gamma oscillations ebb during adolescence then 
increase dramatically in early adulthood (Uhlhaas et al., 2009). At the end of this period, 
dopamine exerts strong control over excitation/inhibition balance and thereby aids in the 
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selection of adequate behavioral responses and the suppression of poor behavioral 
choices (O’Donnell, 2011). 
 Dopamine receptor expression and signaling change with age in rodents 
(O’Donnell, 2011) . D1Rs, D2Rs, and D4Rs increase in density in the PFC through 
adolescence, and then show a reduction in adult animals (Andersen et al., 2000; 
Brenhouse et al., 2008; Naneix et al., 2012); but see (Tarazi and Baldessarini, 2000). 
Furthermore, the D1-type receptor agonist SKF38393 increases the intrinsic excitability 
of FSI in slices from both adult (PD>50) and juvenile (PD<35) rats, while the D2-type 
receptor agonist quinpirole increases FSI excitability in post- but not pre-pubertal slices 
(Tseng and O’Donnell, 2007b). Similarly, in slices from prepubertal rats, co-
administration of a D1-type agonist and NMDA only excites pyramidal neurons for tens 
of milliseconds, but in adults it creates plateau depolarizations lasting several hundred of 
milliseconds (Tseng and O’Donnell, 2005).  
Mature FSI have faster membrane oscillations and spikes, less adaptation, and 
less NMDAR contribution (Belforte et al., 2010; Goldberg et al., 2011; Okaty et al., 
2009; Rotaru et al., 2011; Wang and Gao, 2009, 2010). Dopamine innervation and 
signaling might play a role in the development of FSI and in shaping this mature 
phenotype. Treatment with dopamine or coculture with mesencephalic slices accelerates 
PV+ interneurons maturation in rat organotypic slices from the frontorbital cortex and 
increases the density of PV+ cells in deep cortical layers (Porter et al., 1999; Ross and 
Porter, 2002). Moreover, elevation of prenatal dopamine levels by intrauterine cocaine 
exposure increases the ramification of PV+ interneurons in the anterior cingulate, a 
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cortical area receiving dense dopaminergic innervation, but not the primary visual cortex, 
an area that receives little dopaminergic innervation (Wang et al., 1995). Conversely, 6-
OHDA lesions in the medial forebrain bundle cause a reduction of the density of PV 
expressing cells in the zona incerta of the diencephalon without reducing the total number 
of cells, suggesting that dopamine is required for the maintenance of a mature FSI 
phenotype (Heise and Mitrofanis, 2005). These findings are consistent with the notion 
that the dopamine system is a critical modulator of GABAergic interneurons during 
postnatal maturation of cortical connectivity (O’Donnell, 2011), and that persons with 
schizophrenia exhibit reduced PV and GAD67 immunoreactivity (Lewis et al., 2011). 
Hence, one possible treatment goal in schizophrenia might be the preservation or 
restoration of normal FSI function.  
1.5 Properties of the dopamine D4 receptor 
1.5.1 Historical identification of the D4R 
Following the cloning of the genes and cDNAs for the prototypical D2R and 
D1R, the gene for the human dopamine D4R (gene symbol: DRD4) was isolated in 1991 
by homology cloning in an effort to identify additional D2-related receptors (Van Tol et 
al., 1991). Similar to the other D2-type receptors, it contains short amino-terminal 
extracellular and carboxyl-terminal intracellular tail domains, and a fairly long third 
intracellular loop. DRD4 orthologs in humans and other higher primates additionally 
contain a polymorphic (2-10) number of tandem 48 nucleotide repeats located in the 
sequence encoding the third cytoplasmic loop (Van Tol et al., 1992), with 4 and 7 repeats 
being the most common variants overall but with substantial regional and ethnic 
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differences in frequencies (Chang et al., 1996). D4R variants show different potencies for 
dopamine. Using the amplitude of G protein-induced inwardly rectifying potassium 
currents to determine receptor activation, dopamine was 5 times more potent at the D4.2 
and D4.7 receptor variants than the D4.4 receptor variant (Wedemeyer et al., 2007). 
However, the D4.7 receptor is two times less effective than the D4.2 or D4.4 receptor at 
inhibiting cyclic AMP production (Asghari et al., 1995). The D4.7 variant is associated 
with increased risk for ADHD (see Section 1.5.2), and altered cortical gamma oscillation 
power (Demiralp et al., 2007). 
1.5.2 Pharmacological properties and involvement in psychiatric disorders 
Initial pharmacological analyses indicated that D4R has a higher affinity for 
clozapine than the closely related D2R, and was therefore proposed to consitute the main 
pharmacological target of this efficacious atypical antipsychotic receptors (Van Tol et al., 
1991). In contrast to typical or first-generation antipsychotics, extrapyramidal effects are 
observed to a lesser extent, or not at all, in patients treated with clozapine. While these 
findings generated excitement early on, subsequent studies argued against the possible 
utility of D4R-targeting drugs to treat the positive symptoms of schizophrenia. Most 
importantly, novel, more selective D4R antagonists such as L-745,870 and sonepiprazole 
were largely ineffective as neuroleptics in clinical trials (Bristow et al., 1997; Corrigan et 
al., 2004; Kramer et al., 1997). Consistent with this, clozapine is known to target 
numerous other receptor systems with low nanomolar affinities, including serotonergic 
(5-HT2), muscarinic and β-adrenergic receptors (Baldessarini and Frankenburg, 1991), 
and it was concluded that its efficacy as a neuroleptic reflected a much more complex 
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multi-target pharmacology with a significant contribution from serotonergic receptors 
(Meltzer and Huang, 2008). These findings, taken together with genetic association 
studies that largely failed to identify DRD4 polymorphic variants as risk factors (Jonsson 
et al., 2003), dampened enthusiasm to pursue the D4R as a promising antipsychotic drug 
target for schizophrenia. 
However, the D4R soon re-emerged as a genetic risk factor for ADHD, a 
heterogeneous but highly heritable syndrome characterized by a variable combination of 
persistent, pervasive and developmentally inappropriate levels of inattention, 
hyperactivity and impulsiveness that typically lead to poor academic performance (APA, 
1994). Perturbations of catecholaminergic pathways are a leading hypothesis in ADHD, 
and dopaminergic drugs such as methylphenidate are clinically efficacious. Consistent 
with this, numerous ADHD candidate genes including DRD4, DAT1, COMT, MAOA and 
DBH are integral parts of the catecholaminergic neurotransmission system. Both case-
control and family-based association studies reported increased transmission of the 
polymorphic DRD4.7 variant (for example, LaHoste et al., 1996; Rowe et al., 1998; 
Smalley et al., 1998; Swanson et al., 1998) and other polymorphisms (Arcos-Burgos et 
al., 2004; Barr et al., 2000) in children diagnosed with the syndrome. Subsequent meta-
analyses supported a linkage between the DRD4.7 allele and ADHD (for example, 
Faraone et al., 2001; Maher et al., 2002). 
1.5.2.1 Cognitive effects of acute D4R activation 
Although D4R antagonists proved ineffective as antipsychotics, D4R targeting 
drugs have been examined in cognitive tasks in monkeys and rodents. For the most part, 
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D4R agonists increase working memory performance and fear acquisition according to an 
inverted U-shaped response curve (Bernaerts and Tirelli, 2003; Browman et al., 2005; 
Murai et al., 2014; Nakazawa et al., 2015; Woolley et al., 2008); but see (Nayak and 
Cassaday, 2003). Interestingly, D4R antagonists have paradoxical promnesic effects at 
low doses (Zhang et al., 2004). Specifically, low doses of D4R antagonists reverse 
working memory deficits induced by stress or chronic PCP administration in monkeys 
(Arnsten et al., 2000; Jentsch et al., 1999). Furthermore, rats with low baseline memory 
performance showed the greatest improvements to low doses of the D4R antagonist L-
745,870 and impairments at high doses, while rats with high baseline memory 
performance were impaired by administration of L-745,870 at every concentration 
(Zhang et al., 2004).. In the rat, intra-mPFC injection of L-741,741, another highly 
selective D4R inhibitor, blocks the acquisition (but not expression) of fear conditioning 
and the encoding of emotional memory by mPFC neurons (Laviolette et al., 2005). 
Conversely, mPFC injection of the D4R agonist PD168077 increases the salience of sub-
threshold foot shocks while it blocks the acquisition of fear conditioning in response to 
supra-threshold foot shocks (Lauzon et al., 2009; Tye et al., 2009). Additionally, the D4R 
agonists A-412997 and PD168077 enhance memory for aversive stimuli according to an 
inverted U-shaped curve (Browman et al., 2005), but have also shown linear increases in 
working memory performance in a similar procedure and a novel object recognition 
paradigm (Bernaerts and Tirelli, 2003; Woolley et al., 2008). Taken together, these 
results suggest that the D4R mediates memory consolidation of both normal and 
emotionally salient experiences, and that the intensity of the stimulus interacts with 
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dopamine signaling through D4Rs. 
1.5.3 D4R expression in fast-spiking PV+ interneurons 
A number of studies have found D4R mRNA and protein in PV+ interneurons of 
both the PFC and the hippocampus. Expression in these neurons was first observed in the 
monkey by double immunohistology using a carefully characterized polyclonal antibody 
against the extracellular aminoterminus of the receptor (Mrzljak et al., 1996). 
Immunoreactive cells were found in PFC layers III-V and in hippocampal area CA1. In 
both areas, strongly labeled PV-interneurons were accompanied by lightly labeled 
pyramidal neurons. This study also found intense D4R immunoreactivity in the rodent 
globus pallidus (homologous to the primate external globus pallidus), and thalamic 
reticular nucleus, which are both made up entirely of GABAergic projection neurons. 
Evidence for D4R expression in PV-positive interneurons also comes from a single-cell 
RT-PCR study of acutely isolated rat PFC neurons (Vysokanov et al., 1998). Moreover, 
reporter gene expression was detected in PFC pyramidal neurons and interneurons, some 
of them expressing PV, in mice harboring a bacterial artificial chromosome (BAC) 
transgene in which the green fluorescent protein was expressed under the transcriptional 
control of the Drd4 locus (Noain et al., 2006). Two groups additionally investigated D4R 
expression in GABAergic interneurons using double-in situ hybridization for D4R and 
GAD67, and identified co-expressing cells in layer V of the monkey PFC (de Almeida 
and Mengod, 2010; de Almeida et al., 2008) and in the mouse hippocampus (Andersson 
et al., 2012b). The latter study also employed double-immunohistochemistry using an 
antibody raised against the extracellular amino-terminus of the rat D4R (Ariano et al., 
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1997) and found that the majority (71%) of D4R+ neurons in areas CA1 and CA3 co-
express PV and that conversely 21% of PV-interneurons co-express D4R. In aggregate, 
what emerges from all these findings is the notion that in the PFC, both local GABAergic 
interneurons and pyramidal neurons express D4R transcript and protein while in the 
hippocampus the evidence favors D4R expression largely in GABAergic interneurons. 
1.5.4 Behavioral phenotypes of mice lacking D4R function 
1.5.4.1 Locomotor effects 
An initial behavioral analysis of mixed-background Drd4
-/-
 mice revealed 
locomotor hypoactivity and increased sensitivity to locomotor-stimulating effects of 
acute ethanol, cocaine and methamphetamine injections, indicative of deficits in 
nigrostriatal function (Rubinstein et al., 1997). Amphetamine hypersensitivity was 
confirmed in a subsequent study using Drd4
-/-
 mice congenic on the C57Bl/6J 
background, and expanded to also include altered behavioral sensitization to repeated 
amphetamine injections (Kruzich et al., 2004). At the neurochemical level, Drd4
-/-
 mice 
exhibit altered striatal dopamine metabolism (Rubinstein et al., 1997), and lower baseline 
and KCl-evoked extracellular striatal dopamine levels (Thomas et al., 2007). In contrast, 
dopamine synthesis and turnover in the PFC of mutant mice is not different (Rubinstein 
et al., 2001). Evidence in favor of a role of the D4R in regulating motor activity also 
comes from studies reporting that D4R antagonism restores normal locomotor activity in 
periadolescent rats rendered transiently hyperactive by neonatal 6-OHDA lesions (Zhang 
et al., 2001). These lesions reduce dopaminergic projections to the forebrain and serve as 
a neurodevelopmental model of ADHD with good face validity, reproducing a number of 
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its core symptoms. Strikingly, 6-OHDA-mediated hyperactivity is absent in Drd4
-/-
 mice 
(Avale et al., 2004). Although these findings strongly suggest a role for the D4R in 
mediating behavioral responses to perturbed dopamine function in the striatum, it remains 
unclear if these effects originate, as suggested, in a hyperexcitable PFC or elsewhere, and 
what molecular and cellular D4R-dependent processes underlie them.  
1.5.4.2 Cognitive effects 
The involvement of the D4R in cognitive functions, in particular avoidance 
behavior and emotional learning, has been analyzed in both mutant mice as well as in 
acute pharmacological paradigms (see Section 1.5.2.1). Dulawa and colleagues found that 
novelty-induced behavioral responses were reduced in Drd4
-/-
 mice compared to wild-
type controls with little effect on anxiety (1999). While this report concluded that D4R 
deficiency did not affect avoidance behavior, a different study found Drd4
-/-
 mice exhibit 
heightened anxiety in the elevated plus maze and light/dark preference exploration tests 
that was ameliorated by ethanol and the benzodiazepine midazolam (Falzone et al., 
2002). The fact that these anxiolytic drugs work by increasing GABAergic transmission, 
taken together with prominent D4R expression in the PFC, striatal dopamine 
dysregulation and increased excitability of PFC neurons from mutant mice (Rubinstein et 
al., 2001), was interpreted as indicative of altered PFC control of striatal dopamine 
release in Drd4
-/-
 mice. On the other hand, acute pharmacological inhibition of D4R in 
the rat medial PFC by L-745,870 injection was shown to be anxiolytic in the elevated 
plus maze and shock-probe burial test (Shah et al., 2004). Taken together, these findings 
suggest that the D4R is involved in emotional learning, but that the effects of receptor 
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interference depend on the experimental approach utilized (acute/local/pharmacological 
vs. chronic/global/genetic). Consistent with this notion, studies have found secondary 
changes in Drd4
-/-
 mice, including upregulation of D1- and NMDAR expression and 
increased striatal glutamate that might reflect compensatory responses to a lack of D4R 
function in mutant mice (Gan et al., 2004; Thomas et al., 2009).  
Consistent with the notion of altered PFC function, micro-PET imaging 
experiments indicate reduced baseline PFC glucose metabolism in Drd4
-/-
 mice 
(Michaelides et al., 2010). Moreover, methylphenidate decreases PFC glucose 
metabolism in normal mice but increases it in mutants (Michaelides et al., 2010). It is 
unclear to what extent these metabolic changes are directly linked to the lack of D4R 
function in these mice, or to compensatory changes like the ones mentioned above. 
Interestingly, while Drd4 homozygous mice are normal in behavioral tests of attention 
and impulsivity (Helms et al., 2008; Young et al., 2011), Drd4 heterozygous mice exhibit 
less response inhibition in the 5 choice – continuous performance task (Young et al., 
2011). This observation is consistent with a lack of secondary neurochemical changes in 
Drd4
+/-
 mice (Thomas et al., 2007) and might therefore represent a true hypomorphic 
D4R phenotype that is not occluded by compensatory neural adaptations observed in the 
full mutants. 
1.5.5 Synaptic effects of D4Rs 
1.5.5.1 Effects on cortical microcircuits 
Cellular effects of D4R signaling in neurons have mostly been studied using 
electrophysiological recordings in brain slices, acutely dissociated neurons or long-term 
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neuron cultuResearch Importantly, many of the effects discussed below were observed 
using high concentrations of the D4R agonist PD168077 that may also activate 
adrenergic α1A and α2C as well as serotonergic 5HT1A receptors (Moreland et al., 
2005). At the local circuit level, Onn and colleagues found that in PFC slices with intact 
synaptic connections between axon collaterals and recorded neurons, D4R inhibition 
causes complex evoked spike discharges in pyramidal neurons, but only with intact 
GABAergic transmission (2006). The authors suggest that dopamine signaling bi-
directionally regulates PFC pyramidal neuron excitability via D1R and D4R-dependent 
pathways, respectively, and that D4Rs reduce pyramidal neuron excitability through their 
tonic activity by low ambient levels of dopamine. Consistent with these results, Drd4
-/-
 
mice exhibit hyperexcitability of PFC pyramidal neurons and are more sensitive to 
bicuculline (Rubinstein et al., 2001). Although these findings indicate a possible role of 
D4Rs in promoting GABAergic transmission onto PFC pyramidal neurons, acute 
assessments of the effects of pharmacological D4R perturbations on GABAergic 
interneuron function have yielded mixed results (Gao, 2007; Gorelova et al., 2002). The 
possibility that D4R effects might vary between different cortical areas has to be 
considered as well, as pharmacological data from the prelimbic cortex suggest that D4Rs 
actually facilitate pyramidal neuron firing (Ceci et al., 1999). A different study in the 
mPFC found the D4R activation did not significantly influence the intrinsic excitability 
of pyramidal neurons, but increased the excitability of FS PV+ interneurons (Trantham-
Davidson et al., 2014). These increases in excitability after D4R activation were mediated 
by the Kv3.1/3.2 channel, and were not observed in animals with chronic alcohol 
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exposure during development. Despite increases in PV+ interneuron excitability after 
D4R activation, evoked IPSCs measured on pyramidal neurons decreased after bath 
application of the D4R agonist (Trantham-Davidson et al., 2014).  
1.5.5.2 Inhibition of ionotropic receptors 
Various studies using neuronal preparations from the PFC, the hippocampus and 
the rodent globus pallidus have consistently found pharmacological D4R activation to 
decrease postsynaptic currents and surface expression of both excitatory and inhibitory 
ionotropic receptors (see Tables 1 and 2). GABA current amplitude and surface 
expression of GABAAR β2/3 clusters are decreased in PFC pyramidal neurons after 
treatment with relatively high concentrations (30 µM) of the D4R agonist PD168077 
(Graziane et al., 2009; Wang et al., 2002). Agonist treatment also reduces GABAA IPSCs 
in globus pallidus GABAergic neurons in wild-type mice but not in Drd4
-/-
 mice (Shin et 
al., 2003). However, D4R activation does not affect GABA current amplitude in 
hippocampal pyramidal neurons during ongoing kainate-induced oscillations (Andersson 
et al., 2012a). These data correlate with the expression of D4Rs on PFC pyramidal and 
globus pallidus GABAergic neurons (Ariano et al., 1997; Mrzljak et al., 1996), but not in 
hippocampal pyramidal neurons (Andersson et al., 2012b), and suggest that effects on 
GABAergic transmission are cell-autonomous. 
D4R stimulation also reduces NMDA and AMPA receptor-mediated currents. 
NMDAR-mediated currents and surface expression decrease in acutely isolated PFC and 
hippocampal pyramidal neurons in response to agonist treatment (Beazely et al., 2006; 
Kotecha et al., 2002; Wang et al., 2003), although the downstream signaling pathways 
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may differ between the PFC and hippocampus (see Section 1.5.6). Similar effects were 
reported in pyramidal neurons from acute PFC slices (Trantham-Davidson et al., 2014), 
in projection neurons of the lateral amygdala (Martina and Bergeron, 2008), and in 
hippocampal area CA1 where NMDAR-dependent induction of LTP induction in stratum 
oriens was inhibited by D4R activation (Herwerth et al., 2012). Intriguingly, in PFC 
slices from animals treated with the NMDAR antagonist PCP, a psychotomimetic drug 
that can elicit effects remarkably similar to the symptomology of schizophrenia (Jentsch 
et al., 1999), D4R activation no longer inhibits NMDAR-mediated currents, although the 
cellular mechanisms underlying this effect are not known (Wang et al., 2006). 
In pyramidal neurons of the PFC, but not the hippocampus, acute D4R activation 
was also shown to reduce baseline AMPAR-mediated currents and surface expression in 
pyramidal neurons (Andersson et al., 2012a; Kwon et al., 2008; Yuen et al., 2010); but 
see (Gu et al., 2006; Rubinstein et al., 2001). High concentrations of PD168077 also 
reduce baseline AMPAR-mediated currents and surface expression in PFC interneurons 
(Graziane et al., 2009). Furthermore, recent data suggest that D4R effects on AMPARs 
may at least in part be state-dependent. In cultured hippocampal neurons expressing the 
D4R, agonist treatment has no effect of baseline AMPAR surface expression but 
internalizes GluA1-containing AMPARs following a chemical form of LTP (Kwon et al., 
2008). In PFC pyramidal cells, PD168077 decreases AMPAR-mediated currents when 
slices are pretreated with bicuculline to increase overall activity but increases AMPAR-
mediated currents in slices pretreated with TTX to reduce overall activity (Yuen and Yan, 
2011; Yuen et al., 2010). D4Rs also reverse early LTP at Schaeffer collateral-to-CA1 
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glutamatergic synapses by reversing AMPAR EPSCs back to pre-LTP levels (Kwon et 
al., 2008). New evidence suggests that this may be a circuit-based effect.  Dopamine 
released from VTA fibers increases the EPSPs from the Schaeffer collateral pathway onto 
PV+ interneurons in the pyramidal layer through the activation of D4 receptors (Rosen et 
al., 2015b). This produces feedforward inhibition which suppresses the EPSPs from the 
Schaeffer collateral pathway onto pyramidal neurons in the CA1 (Rosen et al., 2015b).  
Intriguingly, brief dopamine release via optogenetic dopaminergic fiber stimulation 
decreased EPSPs at Schaeffer collateral-to-CA1 glutamatergic synapses, whereas tonic 
dopamine bath application, or bursts of optogenetic activity increased EPSPs at these 
synapses (Rosen et al., 2015b), demonstrating that tonic and phasic dopamine produce 
different circuit-level responses via the D4 receptor. Taken together, with the observation 
that Drd4
-/-
 mice have dramatic increases in glutamatergic signaling (Rubinstein et al., 
2001), these data suggest that the D4R is involved in homeostatic processes that serve to 
maintain overall glutamatergic excitability within a physiological range. 
postsynaptic
current 
Increase/ 
Decrease 
Cell Type Region Citations 
AMPA 
↑at low 
synaptic 
activity 
Pyramidal PFC 
Yuen and Yan, 2011; Yuen et al., 
2010; but see Rubinstein et al., 
2001; Onn et al., 2006 
AMPA 
↓ at high 
synaptic 
activity 
Pyramidal 
PFC, 
Hippocampus 
Kwon et al., 2008; Yuen et al., 
2010; Yuen and Yan, 2011 
AMPA ↓ Interneuron PFC 
Yuen and Yan, 2009; Yuen et al., 
2010 
NMDA ↓ Pyramidal PFC, Kotecha, Oak, et al., 2002; 
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hippocampus, 
lateral 
amygdala 
Wang, Zhong, et al., 2003; 
Beazely et al., 2006; Wang et al., 
2006; Martina and Bergeron, 
2008; Herwerth et al., 2012, 
Trantham-Davidson et al., 2014 
GABA ↓ 
Pyramidal, 
various 
others 
PFC, 
hippocampus, 
septal nucleus, 
thalamus, 
globus 
pallidus, 
subthalamic 
nucleus, 
substantia 
nigra 
Wang et al., 2002; Shin et al., 
2003; Florán et al., 2004a, 
2004b; Asaumi et al., 2006; 
Acosta-García et al., 2009; 
Graziane et al., 2009; Gasca-
Martinez et al., 2010; 
Govindaiah et al., 2010; 
Andersson et al., 2012a, 
Trantham-Davidson et al., 2014 
VGCC ↓ 
Pyramidal, 
granule 
cells 
PFC, 
cerebellum 
Mei et al., 1995; Wang et al., 
2006 
K
+
 channel: 
inward 
rectifying 
↑  
Cultured 
Neurons 
Werner et al., 1996; Pillai et al., 
1998; Lavine et al., 2002; 
Wedemeyer et al., 2007 
K
+
 channel: 
outward 
current 
↓ 
Fast-spiking 
interneurons 
Hippocampus Andersson et al., 2012a 
K+ channel: 
delayed 
rectifier 
↑ 
Fast-spiking 
interneurons 
PFC Trantham-Davidson et al., 2014 
Table 1. Postsynaptic effects of D4R activation on evoked and mini amplitudes, and changes in firing rate.  
 
Presynaptic 
release 
Increase/ 
Decrease 
Cell 
Type 
Region Citations 
AMPA ↓ Pyramidal PFC Rubinstein et al., 2001 
AMPA 
No 
change 
Interneur
on 
PFC, 
hippocampus 
Yuen and Yan, 2009; Andersson 
et al., 2012a 
GABA ↓ Various Hypothalamus, Azdad et al., 2003; 
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septal nucleus, 
thalamus 
Baimoukhametova et al., 2004; 
Asaumi et al., 2006; Gasca-
Martinez et al., 2010 
 
Table 2. Presynaptic effects of D4R receptor activation (PSP frequency). 
1.5.5.3 Effects on ion channels 
D4R activation decreases voltage-gated calcium channel currents in acute PFC 
slices and cultured cerebellar granule cells (Mei et al., 1995; Wang et al., 2006). 
Heterologously expressed D4Rs also couple to GIRK channels in Xenopus oocytes 
(Wedemeyer et al., 2007; Werner et al., 1996) through a Gβγ-dependent mechanism 
(Pillai et al., 1998). In principle, both activities are well suited to reduce neurotransmitter 
release from presynaptic nerve terminals. Consistent with this notion, the D4R agonist 
PD168077 reduces the frequency of mIPSCs onto layer 5 pyramidal neurons indicative of 
reduced GABA release from local interneurons (Gao, 2007). Moreover, D4Rs modulate 
transmitter release in various midbrain regions receiving GABAergic projections from 
the globus pallidus (Acosta-García et al., 2009; Asaumi et al., 2006; Baimoukhametova et 
al., 2004; Florán et al., 2004a, 2004b; Gasca-Martinez et al., 2010). As mentioned earlier, 
globus pallidus GABAergic neurons express high levels of D4R (Mrzljak et al., 1996).  
Ablation of globus pallidus neurons by kainate injection prevents the inhibitory effects of 
PD168077 in the thalamic reticular nucleus and the substantia nigra (Acosta-García et al., 
2009; Gasca-Martinez et al., 2010). Effects on presynaptic calcium currents may also 
contribute to reduced glutamate release (Romo-Parra et al., 2005; Rubinstein et al., 2001; 
Yuen et al., 2010).  
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1.5.6 D4R signaling partnerships 
Dopamine receptors were initially classified according to their ability to positively 
or negatively couple to adenylyl cyclase to promote the production of the intracellular 
second messenger cAMP. Additionally, D2-type receptors mediate many of their 
physiological functions via liberation of Gβγ subunits and subsequent modulation of 
effectors such ion channels and receptors either by direct binding or by activation of 
intracellular signaling pathways such as phospholipase C and MAP kinase. For general 
reviews on dopamine signaling pathways downstream of heterodimeric G-proteins the 
reader is referred to a number of excellent earlier reviews on the subject (Beaulieu and 
Gainetdinov, 2011; Gainetdinov et al., 2004; Greengard et al., 1999; Missale et al., 1998). 
I will instead focus on signaling partnerships of the D4R with other G-protein coupled 
receptors (GPCR) and with receptor tyrosine kinases (RTK) in the regulation of neuronal 
function, as many of the described D4R effects in the central nervous system are tightly 
linked to the functional association with other receptor systems. These synergistic 
partnerships encompass both direct and functional interactions between receptors.  
1.5.6.1 Partnerships with G-protein coupled receptors 
It is now widely accepted that dopamine receptors and other GPCRs can form 
homomeric and heteromeric structures, and that these multimolecular aggregates can 
affect both ligand binding as well as signaling characteristics of their constituent subunits 
(Ferre et al., 2007, 2009). Recent studies have shown that the D4R heteromerizes with the 
both the long and the short forms of the D2R (Borroto-Escuela et al., 2011; González et 
al., 2012a). Furthermore, neurochemical evidence suggests that interactions between D4R 
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and D2S receptors mediate dopamine modulation of neurotransmitter release from 
corticostriatal glutamatergic projections where these receptors are co-expressed 
(González et al., 2012a).  Intriguingly, heteromerization with D2S receptors was 
observed with D4R variants harboring 2 or 4, but not 7 tandem repeats, and engineered 
mice with the human 7-repeat version knocked into the mouse Drd4 locus failed to show 
increased glutamate release in the striatum in response to co-activation of D2Rs and 
D4Rs (González et al., 2012a). These findings are especially relevant in light of the 
implication of the 7-repeat allele of the human DRD4 gene in psychiatric disorders. A 
second interaction was recently reported between the D4R and α1B or β1 adrenergic 
receptors in the pineal gland where these receptors synergize to regulate circadian 
melatonin synthesis (González et al., 2012b). 
1.5.6.2 D4R partnerships with receptor tyrosine kinases 
Functional interactions between GPCRs and RTKs have been known for many 
years (Daub et al., 1996). These interactions are typically functional, rather than physical, 
and mostly manifest as transactivation of a RTK by a GPCR (Ferguson, 2003). An early 
example of transactivation of a dopamine receptor involves the regulation of NMDAR 
function and surface expression by D4Rs (see Section 1.5.5.2). The downstream 
signaling pathway linking D4R activation in PFC neurons involves protein kinase A 
inhibition and activation of protein phosphatase 1, effects typically attributed to canonical 
inhibitory G-protein signaling (Wang et al., 2003). However, D4R-mediated NMDAR 
internalization in hippocampal neurons depends not on PKA inhibition, but rather on 
transactivation of the platelet-derived growth factor receptor (PDGFR), and involves 
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activation of a phospholipase C / IP3 / Ca
2+
 signaling pathway (Kotecha et al., 2002). 
Interestingly, NMDAR internalization in the PFC in response to PDGFR transactivation 
by dopamine is mediated by D2Rs but not D4Rs (Beazely et al., 2006). This is one of 
many examples of a significant region-specific difference in the intracellular signaling of 
the D4R. The D4R is also tightly linked to the acute effects of the NRG/ErbB4R 
signaling pathway in the central nervous system (see Section 1.6.4 and 1.6.5). 
1.5.7 D4R and gamma oscillations 
D4R activation simultaneously increases gamma-frequency LFP power and 
measures of cognition. The D4R agonist A-412,997 increases gamma power in 
prefrontal, occipital and parietal cortices in awake, behaving rodents (Kocsis et al., 2014). 
Furthermore, a partial D4R agonist, Ro 10-5824 concurrently increases frontal cortical 
gamma power and performance on the object retrieval detour task  in marmosets 
(Nakazawa et al., 2015). Moreover, indirect evidence already exists that D4Rs in the 
human cortex modulate gamma oscillations. Carriers of the 7-repeat DRD4 allele 
(DRD4.7) show enhanced evoked and induced gamma oscillations in the frontal and 
association cortices in response to auditory stimuli (Demiralp et al., 2007). This increase 
in evoked gamma oscillations does not discriminate between target and filler stimuli, 
suggesting that it is harder for subjects to distinguish between salient and distracting 
stimuli, a finding that is consistent with the association of the DRD4.7 allele with ADHD 
and potentially cognitive function in other psychiatric disorders (see Section 1.5.2). 
Importantly, the 7R variant has half the potency of more common third-loop repeat 
variants for inhibiting cAMP (Asghari et al., 1995) and less effectively forms 
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heterodimers with the long and short variants of the D2R (Borroto-Escuela et al., 2011; 
González et al., 2012a). If the modulation of gamma rhythms in individuals carrying the 
DRD4.7 polymorphism is indeed compromised, the prediction would be that normal D4R 
function enhances signal-to-noise ratios by suppressing gamma rhythms in response to 
non-salient sensory stimuli. At least in principle, the finding that D4Rs decrease 
AMPAR-mediated currents in interneurons in the PFC (Yuen and Yan, 2009), and that 
decreased excitatory drive onto PV+ interneurons reduces gamma oscillation power 
(Rotaru et al., 2011), correlates well with increases in gamma in subjects carrying the 
DRD4.7 allele. 
As touched upon previously, patients with schizophrenia have elevated ongoing 
gamma power and reduced sensory-evoked or task-related gamma power (see Section 
1.2.1). It follows that lowering the ongoing gamma power in a patient with schizophrenia 
would increase the signal-to-noise ratio of the evoked oscillations during sensory 
perception and cognitive tasks. Given that fact that the D4R agonist increases gamma 
power in normal animals (Kocsis et al., 2014), and it is hypothesized that lowering 
baseline gamma power will have pro-cognitive effects in schizophrenia patients (Gilmour 
et al., 2012), the D4R antagonist may actually be a better pro-cognitive target, as the D4R 
antagonist could be expected to lower ongoing gamma oscillation power in schizophrenia 
patients. On the other hand, humans with a subsensitive variant of the D4R, which in 
principle may mimic the effects of D4R antagonism, have reduced signal-to-noise ratios 
for gamma oscillations in response to auditory stimuli (Demiralp et al., 2007). It remains 
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to be seen whether a D4R agonist or antagonist will have a greater effect on gamma 
oscillations in an animal model of schizophrenia. 
An investigation into the cellular effects of D4R signaling revealed that 
PD168077 enhances spike coherence and phase-coupling of action potentials to gamma 
oscillations in FSI, suggesting that D4R activation enhances gamma power by 
augmenting the synchronized inhibition of pyramidal neurons (Andersson et al., 2012a). 
Notably, pharmacological activation of other dopamine receptors, or direct application of 
dopamine, had no effect on gamma power per se. However, an enhancement of gamma 
power by dopamine was unmasked by simultaneous application of the D1-type receptor 
blocker SCH23390, indicating that D1-type receptors antagonize the effects of D4Rs on 
gamma oscillations (Andersson et al., 2012b). 
Interestingly, D4R-mediated augmentation of gamma power is sensitive to 
blockade of NMDARs by AP5, although AP5 has no effect on gamma power in vitro per 
se (Andersson et al., 2012b). NMDARs on FSI have long been considered critical for 
normal excitation/inhibition balance in cortical microcircuits, and have been at the center 
of the glutamate hypofunction theory of schizophrenia (Coyle et al., 2006; Lisman et al., 
2008; Nakazawa et al., 2012). Indeed, compelling evidence from gene targeting studies 
suggest an important role of NMDARs on FSI for the proper maturation of cortical 
circuits and the emergence of gamma oscillations during development that diminishes in 
the mature brain (Belforte et al., 2010; Korotkova et al., 2010). Likewise, 
electrophysiological studies in wild-type mice show that excitatory postsynaptic 
potentials (EPSPs) on FSI have large contributions from NMDARs in juveniles that 
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diminish during maturation (Rotaru et al., 2011; Wang and Gao, 2009). In mature FSI, 
excitatory drive is dominated by AMPARs to ensure high temporal precision between 
excitation and spiking (Rotaru et al., 2012). Notably, since NMDARs have slower 
kinetics than AMPARs, the summating properties of excitatory synapses with a large 
NMDAR contribution make them less suitable to support gamma rhythms. Given that 
D4Rs internalize NMDARs (see Section 1.5.5.2), a simple explanation might be that D4R 
improves excitation-spiking coupling by removing NMDARs from excitatory synapses of 
FSI to increase gamma power. Indeed, blockade of NMDARs increases gamma power in 
vivo (Pinault, 2008), and this is not observed if AMPARs are simultatneously inhibited 
(Zanos et al., 2016). Yet, if this were true, blocking NMDARs would occlude rather than 
inhibit the D4R effect on gamma power, and would increase gamma power even in the 
absence of D4R agonist. However, as mentioned earlier, this was not observed in vitro 
(Andersson et al., 2012a). I performed a similar experiment in vivo and observed that 
ketamine occluded the effect of D4R agonists on gamma power in the mPFC, but not the 
MD thalamus. Further work is necessary to explore this region-specific difference. 
1.6 Overview of neuregulin-ErbB signaling 
Neuregulins (NRGs) comprise a family of secreted and membrane bound factors 
characterized by the presence of an epidermal growth factor-like motif and that signal 
through ErbB RTKs to regulate a diverse array of developmental and acute processes in 
the peripheral and central nervous systems (Buonanno and Fischbach, 2001; Mei and 
Nave, 2014). Moreover, genes for both neuregulin 1 (NRG1) and ErbB4Rs have been 
identified as risk factors for schizophrenia (Mei and Xiong, 2008;Buonanno, 2010). 
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1.6.1 Genetic association with schizophrenia 
Small mutations in the genes encoding NRGs and ErbB receptors endow an 
increased risk for developing schizophrenia. Single nucleotide polymorphisms (SNPs) in 
the NRG1 gene have been associated with schizophrenia in many, but not all population 
and genome-wide association (GWAS) studies (for excellent reviews, see Buonanno, 
2010; Mei and Xiong, 2008).  Indeed, people with the “schizophrenia risk” haplotype of 
NRG1 show many of the endophenotypic traits involved in schizophrenia including  
reduced paired-pulse inhibition (PPI), abnormal gamma oscillation activity, reductions in 
IQ, and a higher risk for the development of psychosis or unusual thoughts (Hall et al., 
2006; Hong et al., 2008; Krug et al., 2008).  Furthermore, the mRNA for NRG1 types 1, 
2, and 4 are enriched in the PFC and hippocampus of brains from schizophrenia patients 
(Hashimoto et al., 2004; Parlapani et al., 2010).  Additionally, cortical slices from 
patients with schizophrenia have higher levels of phosphorylated ErbB4R and enhanced 
NRG1 effects reducing NMDAR activity (Hahn et al., 2006). SNPs in ErbB4 have also 
been genetically associated with schizophrenia (Agim et al., 2013; Nicodemus et al., 
2006, 2010; Silberberg et al., 2006). Indeed, ErbB4R transcript and protein expression is 
higher in the PFC of patients with schizophrenia (Joshi et al., 2014; Silberberg et al., 
2006). This elevated ErbB4R expression is associated with reductions in PFC 
interneurons (Joshi et al., 2014). These findings highlight the relative importance of 
NRG1/ErbB signaling in interneurons as compared to pyramidal neurons in conferring 
disease risk.  
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1.6.2 NRG/ErbB receptor role in development 
In the developing cortex, most glutamatergic neurons differentiate in the 
ventricular and subventricular zones and migrate laterally whereas interneurons 
differentiate in the ganglionic eminences and migrate tangentially to their final 
destinations. After migration, both types of neurons generate axons and dendrites to form 
neural circuits (Mei and Nave, 2014). Furthermore, NRG1 regulates myelination of 
nerves in the peripheral nervous system, but not the central nervous system, indicating 
that it promotes the activity of Schwann cells, but may not play a role in oligodendrocytes 
(Brinkmann et al., 2008).  
NRG1-ErbB4Rsignaling is critical for the migration, maturation and 
synaptogenesis onto interneurons.  Interneurons express ErbB4Rs as early as embryonic 
day 13 in the mouse (Yau et al., 2003), and these receptors appear to guide interneurons 
to their final destinations (Flames et al., 2004). Interestingly, deletion of the ErbB4R 
reduces the number of cortical interneurons, but not when the deletion happens after 
embryonic day 13.5 (Fazzari et al., 2010; Flames et al., 2004).  Similarly, deletion of 
NRG1 has no effect on cortical or hippocampal development (Brinkmann et al., 2008).  
Furthermore, NRG1 and ErbB4R signaling promotes the formation and maturation of 
excitatory synapses on interneurons. Specifically, mice with genetic deletion of ErbB4R 
from interneurons have reduced mEPSC frequency, and fewer puncta with glutamatergic 
signaling markers such as vGlut-1, PSD-95 and GluA1 (del Pino et al., 2013; Fazzari et 
al., 2010; Ting et al., 2011).  Indeed, ErbB4Rs stabilize PSD-95, which promotes the 
maturation of glutamatergic synapses (Ting et al., 2011).  Additionally, 
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ErbB4Rexpression is critical in the synaptogenesis of PV+ chandelier cells, but not 
basket cells onto pyramidal neurons (del Pino et al., 2013; Fazzari et al., 2010).  
Similarly, overexpressing NRG1 type 3 in pyramidal neurons increased the density of 
chandelier cell axonal boutons onto pyramidal neurons (Fazzari et al., 2010). Finally, 
ErbB4R signaling is not essential for the formation of synapses between interneurons.  
Indeed, GABAergic synapses onto PV+ basket cells formed appropriately in the absence 
of ErbB4Rsignaling in interneurons (Yang et al., 2013b).  
In excitatory neurons, NRG1-ErbB4R signaling still plays a role in proper 
development, even though it is likely that ErbB4 is not expressed in these cells. NRG1 
signaling through ErbB4R stimulates neurite outgrowth in hippocampal neurons and 
cerebellar granule cells (Cahill et al., 2012; Krivosheya et al., 2008). Genetic deletion of 
ErbB2Rs and ErbB4Rs in the central nervous system reduced the density of dendritic 
spines in cortical and hippocampal pyramidal neurons (Barros et al., 2009), but deletion 
of ErbB4Rs specific to pyramidal neurons did not alter mEPSC frequency or the density 
of dendritic spines (Fazzari et al., 2010).  Interestingly, mEPSC frequency and the density 
of dendritic spines on pyramidal neurons were reduced in mice lacking ErbB4Rs on PV+ 
interneurons (del Pino et al., 2013; Yin et al., 2013a), providing evidence that 
interneurons express ErbB4, but pyramidal neurons do not. Indeed, multiple studies 
suggest that ErbB4Rs are restricted to GABAergic neurons in the developing and adult 
brain (Fazzari et al., 2010; Neddens and Buonanno, 2010; Vullhorst et al., 2009; Woo et 
al., 2007).  Changes in dendritic spine density in pyramidal neurons are most likely the 
result of compensatory effects related to the lack of ErbB4Rs in PV+ interneurons. 
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NRG-ErbB signaling also may modify the expression of ionotropic receptors. 
Genetic removal of ErbB2 and ErbB4 receptors had no effect on the expression of 
NMDA of GABAA receptors in vivo (Gajendran et al., 2009). In contrast, NRG-β isoform 
increased NR2C mRNA more than 100-fold in cerebellar granule cells, and this effect 
was blocked by the NMDAR antagonist AP5 in vitro (Ozaki et al., 1997).  
1.6.3 Synaptic effects of ErbB4R 
1.6.3.1 Ionotropic receptors 
Neuregulin 1 modulates GABA receptor (GABAR)-mediated currents and the 
excitability of interneurons, but has mixed effects on basal AMPAR-mediated and 
NMDAR-mediated currents.  In general, NRG1 does not change glutamatergic currents 
in hippocampal CA1 neurons (Chen et al., 2010; Huang et al., 2000; Iyengar and Mott, 
2008; Kwon et al., 2005).  Mice lacking ErbB4Rs on PV+ interneurons show increased 
sEPSC frequency in pyramidal neurons and PV+ interneurons (del Pino et al., 2013), 
suggesting that NRG1 signaling through ErbB4R typically decreases glutamate release 
onto pyramidal neurons in normal animals. Interestingly, NRG2 signals through ErbB4Rs 
in cortical interneurons to internalize NMDARs and decrease NMDAR-mediated currents 
(Vullhorst et al., 2015).  Notably, while one group observed that NRG1 attenuates 
NMDAR-mediated currents in PFC pyramidal neurons (Gu et al., 2005), this has never 
been reproduced (Vullhorst et al., 2015). Soluble NRG1 signaling through ErbB4Rs 
promotes GABA release (Chen et al., 2010; Woo et al., 2007), and both pharmacological 
inhibition and genetic removal of the ErbB4R reduces GABA transmission, increases the 
firing of pyramidal neurons and enhances LTP in slices (Chen et al., 2010; Kwon et al., 
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2005; Pitcher et al., 2008), indicating that ErbB4R signaling is important in generally 
inhibiting brain activity. Furthermore, ErbB4R promotes the endocytosis of GABAARα1 
in cultured hippocampal interneurons, which decreases the amplitude and decay kinetics 
of inhibitory signaling in these interneurons (Mitchell et al., 2013).  This ErbB4R-
mediated endocytosis of GABA occurs without ErbB4’s receptor tyrosine kinase activity 
(Mitchell et al., 2013). 
1.6.3.2 Effects on ion channels 
NRG1 indirectly decreases the firing rate of PFC pyramidal neurons (Wen et al., 
2010), and has mixed effects on interneurons. Both endogenous and exogenous NRG1 
signals through ErbB4Rs to increase the excitability of PV+ interneurons in mouse 
cortical layers 2-3, and has similar effects in the hippocampus, but with much smaller 
magnitudes (Li et al., 2012). Specifically, NRG1 hyperpolarizes the action potential 
threshold by inhibiting Kv1.1 channels (Li et al., 2012).  In contrast, genetic deletion of 
ErbB4Rs from PV+ interneurons increases the spontaneous firing of hippocampal PV+ 
interneurons at resting membrane potentials, increases evoked spiking using current 
ramps, and decreases rheobase currents (del Pino et al., 2013), indicating that ErbB4Rs in 
PV+ interneurons normally decreases intrinsic excitability. However, these changes in 
excitability occur in the absence of significant changes in action potential threshold or 
latency, suggesting a potential indirect effect. Also, a different study showed that genetic 
deletion of ErbB4Rs from PV+ interneurons decreases the spontaneous and evoked firing 
of cortical PV+ interneurons (Yang et al., 2013b). Furthermore, in dissociated 
hippocampal ErbB4-expressing neurons or cerebellar granule cells NRG1 does not 
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increase intrinsic excitability (Janssen et al., 2012; Yao et al., 2013). In fact, NRG1 
reduces the excitability of hippocampal interneurons by decreasing voltage-gated sodium 
currents (Janssen et al., 2012) in ErbB4-expressing neurons, and chronic, but not acute 
NRG1 increases transient outward potassium currents in immature, but not adult neurons 
(Yao et al., 2013). These findings could imply that NRG1 requires intact neural circuits 
to increase the excitability of PV+ interneurons, which leaves open the possibility that 
modified dopamine levels may play a role in the effects of NRG1 on excitability. 
1.6.4 Long-term potentiation 
NRG1/ErbB4R signaling inhibits the induction, and reverses the early expression, 
of long-term potentiation (LTP) at CA3->CA1 glutamatergic synapses (Huang et al., 
2000;Kwon et al., 2005;Shamir et al., 2012).  Furthermore, neutralizing endogenous 
NRG1 pharmacologically or genetically removing ErbB4Rs promotes the establishment 
of LTP, revealing that NRG1 regulates synaptic plasticity (Agarwal et al., 2014; Chen et 
al., 2010; Pitcher et al., 2008).  Interestingly, established LTP cannot be reversed by 
NRG1, suggesting a time-dependence of LTP reversal (Pitcher et al., 2011). A possible 
mechanism for LTP reversal is that NRG1 reduces AMPAR mediated EPSCs at 
potentiated synapses and stimulates the internalization of surface AMPARs, but not in the 
presence of ErbB receptor tyrosine kinase inhibitors, suggesting that NRG1 signaling 
through ErbB receptors help neurons internalize AMPARs at potentiated synapses (Kwon 
et al., 2005). However, this does not directly explain how glutamatergic synapses 
depotentiate because when ErbB4Rs are removed from pyramidal neurons, NRG1 still 
reverses LTP (Chen et al., 2010). In accordance with the evidence that ErbB4R signaling 
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is specific to interneurons, acute NRG1 treatment does not suppress LTP in the 
hippocampus of mice with a genetic deletion of ErbB4R from PV+ interneurons (Chen et 
al., 2010; Shamir et al., 2012). Surprisingly, acute LTP reversal by NRG1 is still 
observed when GABAA receptor signaling is blocked (Kwon et al., 2005; Pitcher et al., 
2011). Exactly how ErbB4R signaling on PV+ neurons reduces LTP without GABAA 
receptor signaling remains a mystery.  
An alternative explanation for ErbB4R-mediated LTP reversal includes a role for 
changes in tonic dopamine levels.  LTP reversal by NRG1 critically depends on the 
activation of D4Rs (Kwon et al., 2008). Taken together with the finding that NRG1 
infusion in the dorsal hippocampus triggers dopamine release, this suggests that 
NRG1/ErbB4R signaling regulates hippocampal LTP via a dopamine/D4R pathway 
(Kwon et al., 2008). There are two established mechanisms by which D4R activation can 
depotentiate synapses. First, D4R activation can reduce NR2B-containing NMDAR-
mediated currents during LTP in the presence of GABAA receptor inhibitors (Herwerth et 
al., 2012). Second, D4Rs can increase the EPSPs from stimulation of the Shaeffer’s 
collateral pathway onto PV+ interneurons which in turn decreases the EPSPs recorded 
from pyramidal neurons due to feedforward inhibition (Rosen et al., 2015b). However, it 
is not known if the ErbB4 and D4 receptor systems interact in the same or across 
different cell types, or which signaling pathways link their activation to the removal of 
synaptic AMPARs that seems to underlie LTP reversal by NRG1 and D4R agonists.  
Three hypotheses emerge for the interaction of D4Rs and ErbB4Rs: (1) D4Rs and 
ErbB4Rs interact directly on PV+ interneurons, but not pyramidal neurons. (2) ErbB4Rs 
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are not expressed on pyramidal neurons, but help mediate an increase in tonic dopamine 
so that D4Rs on pyramidal neurons are activated. (3) D4Rs and ErbB4Rs interact within 
dopaminergic fibers, which would explain why D4R antagonists and NRG1 can both 
increase extracellular dopamine (Broderick and Piercey, 1998; Kwon et al., 2008). In 
support of the first hypothesis, ErbB4Rs are undetectable in pyramidal neurons (Vullhorst 
et al., 2009;Neddens et al., 2011) while both ErbB4Rs and D4Rs are expressed in 
GABAergic cells including PV+ interneurons (Mrzljak et al., 1996;Andersson et al., 
2012b). Additionally, inhibition of LTP induction and reversal of LTP are absent from 
mice with targeted deletions of ErbB4Rs in PV+ interneurons (Chen et al., 2010;Shamir 
et al., 2012), and absent in the pharmacological blockade of D4Rs. Finally, both receptors 
synergize in the modulation of hippocampal gamma oscillations (Andersson et al., 
2012b) that critically depend on PV+ interneurons. In support of the second hypothesis, 
others have observed effects of D4R activation in pyramidal neurons, including the 
regulation of LTP through NR2B-containing NMDARs (Herwerth et al., 2012). One 
major criticism of this hypothesis is that dopamine increases LTP through D1-type 
receptors (Huang and Kandel, 1995; Otmakhova and Lisman, 1996), so it is unclear why 
a D4R mediated effect would overpower this D1-type receptor mediated effect. 
Dopamine neurons shift from tonic (1-4Hz) to phasic (10-30Hz) firing rates in response 
to salient and rewarding stimuli (Schultz, 2007). Recent work has shown that phasic 
dopamine (as mimicked by 25 seconds of light bursts that optogenetically stimulated 
dopamine release) increases Shaeffer’s collateral pathway EPSP through D1R signaling 
while tonic dopamine release (as mimicked by short bursts of optogenetically stimulated 
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dopamine release, or bath application of dopamine) decreases Shaeffer’s collateral 
pathway EPSP via feedforward inhibition from increased PV+ neuron activity mediated 
by D4R signaling (Rosen et al., 2015b). Therefore, given that NRG1 increases the 
extracellular dopamine in a manner that reflects a rise in tonic dopamine, it follows that 
D4R-mediated dopaminergic signaling would predominate. 
1.6.5 Effects on gamma oscillations 
Early studies in acute rodent slices showed that NRG signaling via ErbB4 
potently augments kainate-induced gamma oscillations in hippocampal area CA3 (Fisahn 
et al., 2009). Additionally, mice with a full genetic ErbB4R deletion have reduced 
gamma LFP power compared to wildtype mice in vitro (Fisahn et al., 2009). 
Furthermore, NRG1 increases the spiking synchrony of pairs of PFC pyramidal neurons 
or interneurons, but not when GABAergic signaling is inhibited (Hou et al., 2014). 
Additionally, NRG1 does not increase the gamma power in mice with FSI-specific 
ablation of ErbB4R  (Hou et al., 2014). Given that NRG/ErbB4R effects on LTP reversal 
in CA1 critically depend on D4R signaling, it was plausible to hypothesize that NRG1 
effects on gamma oscillation power also depend on D4R signaling. Indeed, D4R 
inhibition by L-745,870 largely blocks the potentiating effects of NRG1 on gamma 
oscillations (Andersson et al., 2012b). Conversely, PD168077 increases gamma power, 
albeit to a lesser extent than ErbB4R activation by NRG1, suggesting that NRG1/ErbB4R 
signaling engages multiple signaling systems that synergistically augment gamma 
oscillations. Neither PD168077 nor NRG1 induce gamma oscillations in naïve slices, 
indicating that their modulatory effects impinge on ongoing oscillations (Fisahn et al., 
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2009;Andersson et al., 2012b). Interestingly, in vivo, genetic deletion of ErbB4Rs from 
FSIs increases gamma power (31-100Hz) recorded in the pyramidal layer of 
hippocampus CA1 during locomotion compared to wild type mice (del Pino et al., 2013). 
Furthermore, this conditional ErbB4R deletion reduces the theta (4-8Hz) coherence and 
cross-correlation between the CA1 of the hippocampus and the mPFC of anesthetized 
mice (del Pino et al., 2013). Finally, PV+ interneuron-specific ablation of ErbB4Rs leads 
to an increase in spontaneous seizures (Tan et al., 2012). Taken together, endogenous 
NRG signaling through the ErbB4 receptor appears to participate in the generation of 
gamma oscillations. 
1.6.6 Effects on behavior 
Too much or too little NRG/ErbB signaling causes behavioral changes that mimic 
symptoms of schizophrenia in rodents. Specifically, mice with genetic deletion of 
ErbB4Rs from interneurons display hyperactivity and deficits in fear conditioning, 
paired-pulse inhibition (PPI), and working memory (Chen et al., 2010; del Pino et al., 
2013; Shamir et al., 2012; Wen et al., 2010). Moreover, mice lacking NRG1 processing 
enzymes have similar behavioral impairments (Tamura et al., 2012). Surprisingly, an 
increase in NRG1 signaling by transgenically overexpressing NRG1 type 1 causes similar 
behavioral deficits as well (Agarwal et al., 2014; Deakin et al., 2012; Luo et al., 2014; 
Yin et al., 2013b), suggesting that NRG/ErbB signaling may follow an inverted u-shaped 
curve, like that seen for dopamine signaling. 
Conversely, NRG1 treatment has the potential to reduce behavioral and 
glutamatergic effects in the ketamine-model of schizophrenia. Acute ICV or systemic 
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administration of NRG1 ECD has no effect on spontaneous behavior, but prevents PCP-
induced hyperactivity and deficits in PPI (Engel et al., 2015). Interestingly, NRG1 
treatment again followed a U-shaped dose response curve with too little or too much 
NRG1 having only a small effect on PCP-induced hyperactivity.  Furthermore, reverse 
microdialysis of 10nM NRG1 reduces extracellular glutamate in the PFC and 
hippocampus and reduces PCP-induced increases in GABA in the hippocampus (Engel et 
al., 2015).  
1.7 Specific Aims 
Although D4R antagonists are not efficacious antipsychotics, D4R targeting drugs 
still hold potential as adjunct therapies to ameliorate the cognitive deficits seen in 
schizophrenia (see, for example Furth et al., 2013). If the effects of D4R stimulation on 
pharmacologically induced gamma oscillations in vivo are indeed indicative of a 
potentiating effect on induced or evoked oscillations in other neocortical areas, one might 
speculate that agonists may actually be more effective than antagonists at improving 
cognitive function in individuals with schizophrenia, as evidenced by some animal 
studies. However, if these changes in gamma power better reflect ongoing oscillations, 
then an antagonist may be more effective at improving cognitive function.  
 In the following studies, I examine the effects of D4R activation and inhibition on 
ionotropic receptors in PV+ interneurons and pyramidal neurons in an attempt to 
construct the mechanisms by which D4Rs modulate gamma oscillations (Chapter 2). I 
then compare treadmill-walking-induced gamma oscillations with those induced by 
ketamine at the LFP and single neuron level in the rat mPFC and MD thalamus. I then 
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test the D4R agonist and antagonist’s ability to modulate gamma oscillations and single 
neuron activity in each brain region before and after ketamine administration (Chapter 3). 
Finally, I systemically inject a pan-ErbB antagonist, JNJ-28871063 and observe changes 
in LFP and single neuron activity before and after ketamine administration (Chapter 4). 
Together, these studies increase our understanding of how D4R and ErbB activity 
modulate gamma power in vivo, with the hope that this can guide drug discovery for 
better treatment of the cognitive symptoms of schizophrenia.  
These findings offer new and exciting avenues to think about the involvement of 
dopamine neurotransmission in network activity. However, one must be mindful of the 
many complexities of D4R signaling when designing and interpreting meaningful 
experiments. These include the likelihood that the cellular D4R expression pattern varies 
in different cortical regions, that drug effects on D4R function might be dose-dependent 
and that the receptor might engage in different signaling partnerships in different cells or 
subcellular compartments. With proper consideration for these important issues, I believe 
that these investigations into the role of dopamine and ErbB signaling hold great promise 
for a better understanding of the relationship between neuromodulators and rhythmic 
network activity that underlies cognitive processes. 
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CHAPTER TWO: The effects of dopamine D4 receptor agonism and antagonism in 
vitro 
2.1 Introduction 
Parvalbumin-expressing interneurons (PV+ interneurons) are essential for the 
generation and maintenance of gamma oscillations (Bartos et al., 2007). Indeed, 
optogenetic silencing of PV+ interneurons suppresses gamma power (Sohal et al., 2009), 
and random optogenetic excitation of PV+ interneurons induces gamma oscillations via 
feedback inhibition (Cardin et al., 2009).  Gamma oscillations arise in networks of FSIs 
interconnected by chemical and electrical synapses (see Bartos et al., 2007). Most FSIs 
are PV-expressing basket cells that form inhibitory connections with ~60 other PV-
expressing basket cells  and form perisomatic connections with hundreds of pyramidal 
neurons (Sik et al., 1995), allowing them to coordinate the spike timing of hundreds of 
neurons. Furthermore, PV+ interneurons faithfully release GABA in response to 
depolarization (Hefft and Jonas, 2005), and generate action potentials about once per 
gamma cycle during the ascending phase of the oscillation, both in vitro (Gloveli et al., 
2005; Hájos et al., 2004) and in vivo (Tukker et al., 2007).  Surprisingly, an early study 
that used tetanic stimulation to evoke gamma oscillations in the CA1 of the hippocampus 
in vitro revealed that gamma oscillations can be maintained without ionotropic excitatory 
transmission (Whittington et al., 1995). Idealized computational models revealed how 
gamma oscillations can be generated by mutual inhibition between mildly excited 
interneurons (called I-cells) in ING models, or through I-cells responding to synchronous 
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excitatory volleys from pyramidal neurons (called E-cells) in PING models (Tiesinga and 
Sejnowski, 2009).  
However, brain networks do not exist in isolation, and PV+ interneurons are not 
the only neurons involved in gamma oscillations.  The three key determinants of the 
power and frequency of gamma oscillations are (1) the magnitude and (2) kinetics of 
synaptic inhibition between interneurons, and (3) the driving excitatory current onto 
interneurons (Traub et al., 1996).  In most ING or PING computational models , gamma 
power is determined by excitation onto PV+ FSIs (Jadi et al., 2015), and pyramidal 
neurons provide the greatest source of excitation onto PV+ interneurons (Gulyás et al., 
1999). However, activation through gap junctions plays an excitatory role as well  
(Tamás et al., 2000). Although PV+ interneurons are highly interconnected, the majority 
of inhibitory innervation from PV+ interneurons onto other PV+ interneurons is 
dendritic, while the majority of somatic inhibitory innervation onto PV+ interneurons is 
from vasoactive intestinal peptide (VIP)-expressing interneurons (Hioki et al., 2013). 
Furthermore, ~25% of the dendritic inhibition onto PV+ interneurons is from 
somatostatin (SOM)-expressing interneurons (Hioki et al., 2013). Therefore, focusing 
solely on PV+ interneurons fails to capture the entire picture of the excitation-inhibition 
balance involved in neural synchrony. Given that the dynamics of network inhibition is 
fundamental in setting the power and frequency of gamma oscillations, I examined 
inhibitory currents in pyramidal neurons and both PV+ and non-PV expressing 
interneurons, as well as the intrinsic excitability of interneurons themselves.  
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Dopamine directly influences FSIs to affect neural synchrony. For instance, 
activation of D1 and D4 receptors (D4Rs) reduce gap junction coupling between 
interneurons (Hampson et al., 1992; Li et al., 2013; Onn and Grace, 1994), and 
exogenous dopamine increases the evoked firing rate of FSIs in vivo (Tseng et al., 2006) 
and in vitro (Gorelova et al., 2002; Trantham-Davidson et al., 2008). Dopamine also acts 
through D1 receptors to decrease inhibitory postsynaptic currents (IPSCs) in FSIs 
(Towers and Hestrin, 2008).  Activation of the D4R also directly affects neural 
synchrony, potentially through its activity in PV+ interneurons (Furth et al., 2013). The 
D4R has a high affinity for dopamine (Rondou et al., 2010) and may be activated at low 
concentrations of the endogenous dopamine present in the brain slice (Acosta-García et 
al., 2009; Onn et al., 2006; Rubinstein et al., 2001). Furthermore, basal levels of 
dopamine may activate D4Rs on PV+ interneurons to influence long-term potentiation 
(Rosen et al., 2015b).  Therefore, it is important to examine both the effects of D4R 
antagonism and D4R agonism on GABAergic signaling, as D4Rs may be constitutively 
active.  
Dopamine D4R expression is sparse in the hippocampus cornu ammonis 1 (CA1) 
and cornu ammonis 3 (CA3). Only 25% of PV+ interneurons contain the D4R in CA1 
and CA3 (Andersson et al., 2012b), but 71% of D4R-expressing neurons are PV+ 
interneurons in the same areas (Andersson et al., 2012b). Therefore, the majority of the 
effects of D4R activation may arise through its effects on PV+ interneurons. It is also 
possible, however, that the D4R has more widespread localization than we can currently 
detect. Radioligand binding studies suggest that there may be more D4Rs than can be 
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easily detected by immunohistochemistry or in situ hybridization. In fact, a quantitative 
radioligand study estimated that putative D4Rs represent about half of all D2-type 
receptors in the prefrontal cortex and hippocampus (Tarazi et al., 1997). Further evidence 
suggesting a more widespread expression of D4Rs is the fact that small molecule D4R 
agonists and antagonists work at nanomolar concentrations in the slice (Andersson et al., 
2012a, 2012b; Kwon et al., 2008) and in mediating cognitive effects in vivo (Bernaerts 
and Tirelli, 2003; Clifford and Waddington, 2000; Patel et al., 1997; Zhang et al., 2004). 
Despite the rich literature regarding the modulation of PV+ interneurons by dopamine, 
the function of the dopamine D4R in regulating voltage-gated and ligand-gated ion 
channels in interneurons is mostly unknown. 
The dorsal hippocampus is also critically involved in spatial working memory and 
other cognitive tasks, while the ventral hippocampus is critically involved in stress and 
emotions (Fanselow and Dong, 2010). Previous research in our lab focused on dopamine 
D4 receptor (D4R) activation in O-LM interneurons from the stratum oriens of the dorsal 
hippocampus (CA1)  for three reasons: (1) These interneurons are easy to identify; (2) the 
dorsal hippocampus receives dopaminergic innervation from the VTA (Jay, 2003); (3) 
pharmacological manipulations in the dorsal hippocampus may play a significant role in 
the therapeutic efficacy of cognitive enhancers. This previous work revealed that D4R 
activation decreased the amplitude of evoked AMPA-mediated currents on a select group 
of interneurons (n=5 of 8 cells) from the stratum oriens of CA1 of the hippocampus 
(Buonanno lab, unpublished results). Furthermore, dopamine D4R activation increased 
the frequency of both spontaneous and miniature inhibitory postsynaptic currents (sIPSCs 
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and mIPSCs respectively; sIPSCs, n=6 cells; mIPSCs, n=6 cells) in pyramidal neurons 
from the pyramidal layer of the CA1 of the hippocampus, and this effect was blocked by 
D4R antagonists (Buonanno lab, unpublished results). Miniature IPSCs are recorded in 
the presence of the voltage-gated sodium channel blocker tetrodotoxin; therefore, 
changes in frequency observed after D4R activation reflect presynaptic changes in the 
release probability that is independent from action potential activity. These results 
indicate that the dopamine D4R acts presynaptically in interneurons to increase the 
probability of release of GABA vesicles at synapses onto pyramidal neurons. Finally, 
activation of the dopamine D4R resulted in one of two patterns in mIPSC activity 
recorded from interneurons from the stratum oriens of CA1 of the hippocampus. 
Dopamine D4R activation either increased the frequency of mIPSCs on interneurons 
(n=3 of 6 cells) or decreased the mIPSC amplitude in a separate population of 
interneurons (n=3 of 6 cells; Buonanno lab, unpublished results).  As both evoked AMPA 
receptor mediated amplitudes and miniatute GABA-ergic amplitudes decreased in some 
interneurons, but not others, it became important to classify these interneurons. However, 
the original recordings were performed in wild-type mice and the cells were not filled 
with any intracellular markers, such as biocytin. Therefore, it was neither possible to 
further distinguish the interneurons using morphological characteristics, nor using their 
expression of calcium binding proteins and neuropeptides. Therefore, I recorded from 
mouse lines (PV/Tom) with red fluorescent marker TOMATO expressed in PV+ 
interneurons to distinguish PV+ interneurons from non-PV expressing interneurons. 
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To better understand how dopamine D4R activation and inhibition can modulate 
network activity both in vitro and in vivo, I examined how D4R agonists and antagonists 
alter synaptic inhibition onto both excitatory pyramidal neurons and inhibitory 
interneurons, and I examined how D4R agonists and antagonists influence the intrinsic 
excitability of PV+ interneurons. Specifically, I applied D4R agonists and antagonists 
separately to PV+ interneurons, non-PV+ interneurons, and pyramidal neurons and 
recorded mIPSCs to look specifically at the pre- and post-synaptic influence of the D4R, 
rather than those determined by action potential related activity.  I also examined how 
D4R activation and inhibition influenced the intrinsic excitability of PV+ interneurons by 
recording action potentials evoked by somatic current injections to determine changes in 
the action potential threshold, rheobase currents, and spike shape. Because all neurons in 
the stratum oriens of the CA1 are interneurons, I recorded from neurons in PV/Tom mice 
to distinguish PV+ interneurons from non-PV expressing interneurons to determine 
whether the effects of the D4R are specific to PV+ interneurons. Furthermore, as I was 
planning to make in vivo recordings from layers 3-5 of the medial prefrontal cortex 
(mPFC), I investigated whether D4R activation in PV+ interneurons of the mPFC would 
have the same effects that it had on interneurons of the stratum oriens of the dorsal 
hippocampus CA1 (dhCA1). 
2.2 Materials and Methods 
2.2.1 Animals 
The PV-Cre mouse line Pva1b
tm1(cre)Arbr
, expressing Cre recombinase from the 
Pva1b locus by insertion of the gene into its 3′ untranslated region, and a mouse line 
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expressing tdTomato fluorescent protein from the Rosa26 locus (Ai14) were obtained 
from The Jackson Laboratory (Hippenmeyer et al., 2005). Both lines were received on a 
mixed 129×C57BL/6J background, backcrossed in our facility for two generations to 
C57BL/6J wild type mice and have thus been maintained inbred. Mice were kept on a 
12/12 hour light/dark schedule with access to food and water ad libitum. Animals were 
treated in accordance with the National Institutes of Health Animal Welfare guidelines. 
All procedures were approved by the NIH animal care and use committee. Every effort 
was made to minimize the number of animals used and their discomfort. 
2.2.2 Drugs 
CNQX (6- cyano-7-nitroquinoxaline-2,3-dione) disodium salt, DL-D-2-amino- 5-
phosphonopentanoic acid (AP5), tetrodotoxin (TTx) citrate, the D4R agonist PD168077, 
and the D4R antagonist L745870 were all purchased from Tocris (Ballwin, MO) and 
dissolved in water. About half of the D4R agonist was dissolved in DMSO, before it 
became known that it would also dissolve in water. All stock solutions were stored at 4 
°C, −20 °C, or −80 °C according to the manufacturer’s suggestions, and diluted on the 
day of use. Stock solutions and picrotoxin (Tocris) were diluted in ACSF immediately 
before bath application. 
2.2.3 Slice preparation 
  Coronal prefrontal and hippocampal slices (300 µm) from 4-7 week-old male and 
female mice were prepared in ice-cold ACSF containing (in mM):  124 NaCl, 25 
Na2HCO3, 11 glucose, 2.5 KCl, 1.3 MgCl2, 2.5 CaCl2, 1.25 NaH2PO4, bubbling with  
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95% O2, 5%CO2 (carbogen). Slices were incubated in a holding chamber at 32 °C for 1 h 
in ACSF saturated with carbogen, and then transferred to 23 °C ACSF and kept for at 
least 1 h before recording. Slices were transferred to a submerged recording chamber 
continuously perfused at 2mL/min at 32- 35°C with ACSF. 
2.2.4 Electrophysiology 
Whole cell patch-clamp recordings were performed with borosilicate glass 
microelectrodes (2-8 MΩ). A multiclamp 700A amplifier equipped with a Digidata 
1322A data acquisition board and pClamp10 software (Molecular Devices) was used.  
Recorded data were sampled at 20-50kHz and filtered at 10kHz using pClamp and 
analyzed with Clampfit (Molecular Devices) or AxoGraph. Bridge balance and access 
resistance were monitored during recordings and experiments with >20% change were 
discarded. Data was also discarded if action potentials did not overshoot 0mV throughout 
the length of the recording.  
2.2.5 Current clamp 
To examine intrinsic excitability, membrane potential was set at -70mV before 
current injection protocols, and neurons were held in a membrane test protocol in voltage 
clamp between current clamp recordings. Synaptic currents were blocked with CNQX 
(10 μM), AP5 (25 μM), and picrotoxin (100 μM).  Glass recording electrodes were filled 
with a potassium gluconate-based internal solution (in mM): 125 K-gluconate, 20 KCl, 
10 HEPES, 0.5 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 10 phosphocreatine, at pH 7.2 adjusted 
with KOH (290mOsm). After recording an initial baseline for 10–12 min, a D4R agonist 
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or D4R antagonist was bath-applied until a stable response was attained (10-12 min). The 
rheobase current was measured with a series of 500ms, 50pA hyperpolarizing and 
depolarizing current steps (-200 to +700pA), and defined as the smallest current injection 
needed to elicit an action potential. Action potentials were identified from current clamp 
recordings using a threshold of 50mV/ms in the first derivative membrane voltage. To 
measure AP waveform, a suprathreshold depolarizing current was injected for 5 ms. 
Action potential amplitude was measured as the absolute difference between the action 
potential peak and the voltage threshold of action potential initiation. AP duration was 
measured at the half-maximal amplitude. After-hyperpolarization amplitude was 
calculated as the difference between the average voltage in the 1ms preceding the action 
potential, and the minimum voltage in the 5ms after the action potential peak using the 
average of the first 25 action potentials in a recording. Latency, rise-time, half-width, 
decay, and inter-event interval were also extracted. 
2.2.6 Voltage clamp 
To examine inhibitory synaptic currents, sIPSCs and mIPSCs were recorded at a 
holding potential of -70mV throughout the experiment. Inhibitory postsynaptic currents 
were collected in the presence of 10µM CNQX and 25 µM DL-AP5 to block AMPA and 
NMDA receptors respectively. mIPSCs were collected in the presence of 1µM TTX to 
block action potential initiated neurotransmitter release. After recording an initial 
baseline for 10–12 min, a D4R agonist or D4R antagonist was bath-applied until a stable 
response was attained (10-12 min). Glass recording electrodes were filled with a cesium-
chloride based internal solution (in mM): 130 CsCl, 8 NaCl, 10 HEPES, 0.5 EGTA, 4 
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Mg-ATP, 0.3 Na-GTP, 10 phosphocreatine, 5 QX-314 (pH 7.2, 290 mOsm). For each 
recording, IPSCs were identified using template-based detection software (Clampfit 10) 
and were visually confirmed. Events with amplitudes less than 2.5 times the noise (root 
mean square) were excluded from the analysis. Miniature IPSC averages were based on 
more than 200 events. Decay kinetics were analyzed from non-overlapping events and 
determined with a single-exponential curve fitting. 
2.2.7 Statistics 
Data are represented as mean ± SEM. Statistical analyses were performed using 
GraphPad Prism 6. All data were analyzed with paired Student's t test when comparing 
two groups, unless otherwise noted. P values below 0.05 were considered statistically 
significant. 
2.2.8 Immunohistochemistry 
Following recordings, biocytin-filled neurons were fixed in 4% PFA-PBS 
containing 4% sucrose overnight at 4° C, followed by blocking with 10% donkey serum 
PBS for an additional 2 hours. Slices were washed several times with PBS and incubated 
in the same blocking buffer overnight with the addition of 0.1% Triton-X 100 to 
permeabilize the cell membrane and block intracellular unreacted aldehydes. Following 
this blocking step, primary mouse monoclonal antibody against parvalbumin (Sigma) was 
applied at 1:500 in the same blocking buffer. Slices were washed in PBS several times, 
followed by incubation with fluorescently labeled secondary antibodies (Texas Red dye-
conjugated Goat anti-Mouse IgG, Jackson Laboratories for parvalbumin, Alexa 488, 
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Sigma for biocytin) in the blocking buffer at room temperature for 1 hour. Slices were 
then washed with PBS, incubated in a 10% glycerol cryoprotective solution for more than 
45 minutes and recut to 70 µm on a freezing microtome. Slices were washed and 
mounted on slides in MOWIOL (CalBiochem). Laser scanning confocal images were 
acquired using an LSM510 (Zeiss) and all channels set to an airy unit of 1. Fast-spiking 
cells are either chandelier cells, or basket cells (Markram et al., 2004), and were 
morphologically classified accordingly.  
2.3 Results 
2.3.1 GABA receptor-mediated currents in pyramidal neurons  
The D4R has the ability to modify presynaptic GABA release. In the 
hypothalamus, thalamic reticular nucleus, or septal nucleus,  D4R agonists decreased the 
frequency of GABA release (Asaumi et al., 2006; Baimoukhametova et al., 2004; Gasca-
Martinez et al., 2010). However, in the hippocampus, D4R agonists increased the 
frequency of GABA release onto pyramidal neurons (unpublished results, Buonanno lab). 
D4R agonists also decrease postsynaptic GABA-mediated currents (Graziane et al., 2009; 
Shin et al., 2003; Wang et al., 2002) (but see Andersson et al., 2012a), and acute 
inhibition of the D4R increases total GABA release from globus pallidus into the 
substantia nigra  (Acosta-García et al., 2009).  Therefore, I examined GABA-mediated 
currents in pyramidal neurons of the mPFC to determine whether the D4R effect was 
region specific. The D4R agonist (PD168077 100nM) did not significantly influence the 
frequency (+2%) or amplitude (-1%) of spontaneous IPSCs (both p>0.05, paired t-test, 
n=4) in layer 5 of the mPFC (data not shown). Therefore, I recorded from the dorsal 
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hippocampus CA1 (dhCA1) pyramidal layer to reproduce earlier results. In the pyramidal 
layer of the dhCA1, the D4R agonist (PD168077 100-200nM) also did not significantly 
influence the frequency (-7%) or amplitude (-4%) of miniature IPSCs (both p>0.05, 
paired t-test, n=6, data not shown). I ordered fresh reagents, recorded from pyramidal 
neurons in the CA1 again, and still found no significant differences (both p>0.05, paired 
t-test, n=3, data not shown).  
To determine whether D4R antagonists modified synaptic inhibition onto 
pyramidal neurons in dhCA1, I recorded mIPSCs from these neurons before and after 
bath application of the D4R antagonist. The D4R antagonist (L-745,870 50nM) increased 
the GABA release probability from interneurons onto pyramidal neurons by about 2.0 Hz 
(+17%, p<0.05, paired t-test) and increased the amplitude of these currents in the 
pyramidal neurons by 6.0 pA in a manner that trends toward significance (+22%, 
p=0.054, paired t-test, n=4, Fig2.1). This indicates that D4R inhibition increases 
presynaptic GABA release onto pyramidal neurons, and suggests a postsynaptic change 
in GABA receptor signaling within pyramidal neurons. 
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Figure 2.1: D4R inhibition increases presynaptic GABA release onto pyramidal 
neurons in dorsal hippocampus. (A) Representative trace before and 10 minutes 
after administration of L745870 (50nM). All recordings were made at 32 degrees in the 
presence of CNQX (10µM) and DL-AP5 (25 µM) to block AMPA and NMDA receptors 
respectively. (B) Schematic representation of the experiment. (C) Graphs show the 
mIPSC frequency and amplitude before drug application (baseline) and 10 minutes after 
administration of the D4R antagonist. *:p<0.05, $:p<0.1, paired t-tests, n=4.6. 
  
2.3.2 GABA receptor-mediated currents in interneurons 
To understand how D4R activation modulates GABAergic neurotransmission 
onto interneurons themselves, I recorded mIPSCs from PV+ interneurons and non PV-
expressing interneurons from the dhCA1 in PV/Tom mice before and after bath 
application of the D4R agonist PD168077 (200nM). Activation of the D4R reduced the 
frequency of GABA release onto PV+ interneurons by 3.9Hz (+30%, p<0.05) and 
reduced the amplitude of GABAR-mediated currents by 5.5pA (p<0.01, n=5, paired t-
tests, Fig2.2A&D).  Reductions in average amplitude may arise from a decrease in high 
amplitude events, an increase in events near the detection threshold, or both. Plotting the 
cumulative distribution function of each IPSC event revealed a decrease in high 
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amplitude events and an increase in the density of the events near the threshold detection 
(near 10 pA, Fig2.2D). If the amplitude of some events decreased below the detection 
threshold, this could also explain the apparent reduction in event frequency. Averaging 
200 IPSCs together and measuring the kinetics revealed that IPSCs tend to decay more 
slowly after D4R activation (p=0.06, n=3, Fig2.2C). This suggests a possible shift in the 
composition of synaptic GABAARs, such as the internalization of receptors with rapid 
decay kinetics, like α1-subunit containing receptors (Okada et al., 2000). In contrast, D4R 
activation had no significant influence on the amplitude of GABA-mediated currents in 
non-PV expressing interneurons (+6%, p>0.05, paired t-test, n=4), but reduced the 
frequency of GABA release onto these neurons by 1.3Hz (-25%, p<0.05, paired t-test, 
n=4). This suggests a presynaptic effect of D4R activation that decreases GABA release 
at synapses between interneurons. Surprisingly, in PV+ interneurons in layer 5 of the 
mPFC the D4R agonist, PD168077 (100nM), did not significantly influence the 
frequency (+6%) or amplitude (+7%) of mIPSCs (both p>0.05, paired t-test, n=7, data not 
shown). This indicates that the effect of D4R activation is brain-region specific. 
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Figure 2.2: D4R activation decreases presynaptic GABA release onto PV+ 
interneurons in the dorsal hippocampus CA1. (A) Representative trace before and 10 
minutes after administration of PD168077 (200nM). All recordings were made at 32 
degrees in the presence of TTX (1 µM), CNQX (10µM) and DL-AP5 (25 µM) to block 
action potentials, AMPA and NMDA receptors respectively. (B, Top) 200 representative 
IPSCs averaged before (black) and 10 minutes after (red) bath application of PD168077 
(200nM). Bottom, same mIPSCs normalized by amplitude to show the differences in 
decay kinetics. (C) Schematic representation of the experiment. (D) Graphs show the 
mIPSC frequency and amplitude before drug application (baseline) and 10 minutes after 
administration of the D4R agonist. Right, cumulative distributive function reveals that a 
smaller percentage of high amplitude events after D4R agonist administration. *:p<0.05, 
**:p<0.01, paired t-tests, n=6. 
 
To determine whether D4R antagonists modified synaptic inhibition onto PV+ 
interneurons in the mPFC, I recorded mIPSCs from PV+ interneurons before and after 
bath application of the D4R antagonist. The D4R antagonist, L745870 (50nM), did not 
significantly influence the frequency (+1%) or amplitude (+4%) of mIPSCs (both p>0.05, 
paired t-test, n=3). There were not enough artifact-free recordings from the interneurons 
in the dhCA1 to make any conclusions about the effects of D4R antagonists on 
GABAergic neurotransmission in this region. 
2.3.3 Excitability of PV+ interneurons 
To determine whether D4R inhibition affected the intrinsic excitability or action 
potential characteristics of PV+ neurons, I somatically injected current into PV+ neurons 
in layer 5 of the mPFC of PV/Tom mice.  In layer 5 PV+ neurons, the D4R antagonist 
hyperpolarized the action potential voltage threshold by 5.06mV (p <0.05), decreased the 
amplitude by 10.19mV (p <0.05), and decreased the afterhyperpolarization amplitude by 
2.15mV (p <0.01) compared to baseline (Fig2.3, paired t-tests). The antagonist also 
increased excitability (Fig2.3C), by shortening the latency to the first action potential at 
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each current injection by an average of 0.93ms (starting with the current injection 50pA 
after the rheobase for each cell, p<0.001, paired t-test). Additionally, the average 
interspike interval decreased by 1.5ms (starting with the current injection 50pA after the 
rheobase for each cell, p<0.05, paired t-test). These changes suggest that D4Rs modify 
sodium (Na
+
) and potassium (K
+
) currents with endogenous levels of dopamine in the 
slice. Vehicle recordings from PV+ interneurons did not show significant changes in 
voltage threshold or action potential shape over time (p>0.05), indicating that these 
effects were not artifacts. Unlike recordings performed with the agonist and vehicle, PV+ 
interneurons receiving the D4R antagonist rarely required a more negative holding 
current later in the recording (0/7 vs. 6/22).  There were no significant changes in input 
resistance (average change antagonist -4.1% vs. vehicle & agonist -1.5%, both p>0.05), 
indicating no significant changes in leak currents at -70mV. Taken together, the D4R 
antagonist increases the cell-intrinsic excitability of PV+ interneurons in layer 5 of the 
mPFC. 
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Figure 2.3: D4R antagonists increase the excitability of PV+ interneurons in layer 5 
of the mPFC. A, A representative average of the first 25 action potentials at baseline 
(red) and after 10 minutes of L745870 (50nM) bath application (blue) in a PV+ 
interneuron from layer 5 of the mPFC. The normalized trace sets traces equal at Vthreshold. 
B, Significant reduction in afterhyperpolarization (left) and spike amplitude (right) 
suggest possible changes in Na
+
 or K
+
 conductances. C, Action potential threshold (left), 
average latency (middle) and interspike interval (right) all reveal an increase in overall 
neuron excitability (n=5, *p<0.05, **p<0.01, paired t-test). 
 
In contrast, application of the D4R agonist, PD168077 (200nM), did not 
significantly alter action potential half-widths or afterhyperpolarization amplitudes 
produced from hippocampal PV+ interneurons (p>0.05, n=6, paired t-test) in agreement 
with Andersson et al (2012a). However, I observed subtle changes in spike amplitudes 
and decay times. Spike amplitude decreased by 3.49mV (p<0.05, n=6, paired t-test) and 
decay time increased by 22.89µs (p<0.01, n=6, paired t-test). 
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2.4 Discussion 
In the current study, I administered a D4R agonist or D4R antagonist to slices 
from the dhCA1, or mPFC, and recorded from PV+ or non-PV expressing interneurons 
and pyramidal neurons.  I analyzed the effects of dopamine D4R activation on PV+ 
interneurons and determined that the D4R reduced GABAR-mediated currents 
postsynaptically, and slowed the decay kinetics of mIPSCs. These confirmed previous 
findings in the lab showing that a subpopulation of interneurons had decreased 
postsynaptic GABAR-mediated currents, and suggests that this subpopulation was in fact 
PV+ interneurons. I also observed that D4R antagonism increased the frequency and 
amplitude of GABAR-mediated currents in pyramidal neurons, contrary to previous 
findings from our lab demonstrating that D4R agonism increased the frequency of 
GABAR-mediated currents in pyramidal neurons. While this might suggest a potential U-
shaped curve, such that D4R agonism or antagonism increases the frequency of GABA 
release onto pyramidal neurons, I failed to reproduce earlier findings that the D4R agonist 
increased the frequency of GABAR-mediated currents in pyramidal neurons. I also failed 
to reproduce previous findings in the lab that D4R agonism increased the frequency of 
GABA-mediated currents in a separate population of interneurons. Finally, I observed 
that D4R agonism had little effect on the intrinsic excitability of PV+ interneurons, but 
D4R antagonism increased their intrinsic excitability.  
2.4.1 Expression patterns 
D4R agonists decreased the frequency and amplitude of IPSCs in PV+ 
interneurons in the dhCA1, but not from PV+ interneurons in layer 5 of the mPFC. 
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Dopamine receptor expression patterns vary between brain regions.  While dopamine 
projections in layer 5 of the mPFC are relatively plentiful, these projections into the 
hippocampus are difficult to detect (Björklund and Dunnett, 2007). Therefore, the 
hippocampus may have lower endogenous levels of dopamine, resulting in more D4Rs 
with free ligand-binding sites. However, D4R mRNA expression is highest in layer 5 of 
the prefrontal cortex (de Almeida and Mengod, 2010; Lidow et al., 1998), while only 
21% of PV-expressing interneurons express D4R at levels high enough to detect via in 
situ hybridization in the hippocampus (Andersson et al., 2012b).  It is probable that many 
of the neurons involved in this study simply did not express the D4R. While many PV+ 
interneurons do not express the D4R, there is no reliable way to determine whether a cell 
expresses the D4R. The D4R is hard to detect with an antibody because it is expressed at 
low levels and does not form obvious puncta. We have attempted to use single cell PCR 
and post-hoc immunohistochemistry to determine whether a cell express the D4R, but 
currently we were unable to detect the D4R at the single cell level. 
Furthermore, the expression and intracellular function of the D4R depends on 
brain region and cell type. While pyramidal neurons from the hippocampus decreased 
NMDA currents after D4R activation with a high dose of agonist (10µM PD168077), 
pyramidal neurons from the prefrontal cortex showed no change in NMDAR-mediated 
current amplitude (Beazely et al., 2006). Even within brain regions, dopamine may have 
differential effects. For instance, dopamine increases pyramidal  neuron excitability in the 
prelimbic cortex, but not in the neighboring infralimbic cortex or cingulate gyrus  (Ceci 
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et al., 1999). Further research is needed to better understand why D4R activation 
dichotomous effects on PV+ interneurons in the mPFC versus the dhCA1. 
2.4.2 GABAergic currents 
Careful examination of the concentrations of the D4R agonist used in other 
investigations is important, as it would be easy to ascribe off-target effects of 
pharmacological agents to the D4R’s mechanism of action. D4R agonists and antagonists 
work in the nanomolar range; however, most studies using these drugs have used 
concentrations well above the EC50 for other related receptors (Tocris website). For 
instance, the D4R agonist PD168077, binds to 5HT1A receptors at ~250nM and binds to 
α2c receptors at ~440nM in HEK cells (Moreland et al., 2005). While I used 100-200nM 
of the D4 agonist PD-168077, the concentrations used in other studies in slice are 
between 10 and 50μM. Unfortunately, agonists have rarely been used in conjunction with 
antagonists or in knockout animals  (for an exception see Yuen et al., 2010), so it is 
unclear which effects ascribed to the D4R may actually be related to off-target drug 
activity. Furthermore, rapid release of dopamine from dopaminergic fibers can produce 
the opposite effects of bath-applied dopamine (Rosen et al., 2015b). It is important, 
therefore, to remain cautious about how the effect of long-term D4R activation due to 
bath application relates to phasic dopamine release in vivo.  
No clear picture emerged about how D4R activation influences GABAergic 
signaling onto pyramidal and interneurons. I found no significant difference in the 
amplitude of mIPSCs in pyramidal neurons or non-PV expressing interneurons after D4R 
activation. This confirmed a previous study using low concentrations of the D4R agonist 
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in the hippocampus (Andersson et al., 2012a), but contrasted with two studies using 
higher agonist concentrations in the globus pallidus and prefrontal cortex (Shin et al., 
2003; Wang et al., 2002). GABAR-mediated currents in PV+ interneurons in the dhCA1 
decreased with D4R activation. Previous studies suggest that GABAR-mediated current 
reductions in other neuronal types involves the internalization of GABAAR β2/3 receptors 
(Graziane et al., 2009).  Additionally, I observed no significant change in IPSC frequency 
in pyramidal neurons in the mPFC after D4R activation. Although previous work in our 
lab showed that D4R activation increases mIPSC frequency in pyramidal neurons, other 
literature revealed a decrease in IPSC frequency in the hypothalamus, thalamus, and 
septal nucleus (Asaumi et al., 2006; Azdad et al., 2003; Baimoukhametova et al., 2004; 
Gasca-Martinez et al., 2010). Therefore, the D4R appears to have different presynaptic 
activity in different brain regions. Furthermore, I observed that D4R activation decreased 
the frequency of GABA release onto PV+ and non-PV interneurons in the dhCA1. This 
may arise from synapse-specific differences in D4R expression and release probability.  
In pyramidal neurons, the probability of release from a given axon depends on the 
postsynaptic contact (Scanziani et al., 1998), therefore synapses between two PV+ 
neurons may act differently from PV+ interneuron synapses onto pyramidal neurons. 
D4R inhibition presented an equally perplexing picture as to its influence on 
GABAergic signaling. While D4R activation had little effect on GABA-mediated 
currents in pyramidal neurons, the D4R antagonist increased the frequency and amplitude 
of GABA-mediated currents in pyramidal neurons in the dhCA1, suggesting both a 
presynaptic and postsynaptic effect of D4R activation. However, D4R inhibition had little 
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effect on GABA-ergic currents in PV+ interneurons in the mPFC. Three possible 
explanations for these findings emerge: 1) D4Rs are mainly expressed in PV+ 
interneurons where they stay active at low levels, decreasing interneuron excitability and 
mIPSC frequency through two unique mechanisms, such as the modification of 
potassium channels in the interneuron soma (Bean, 2007), and modification of quantal 
release at the presynaptic terminal (Borisovska et al., 2013). 2) D4Rs are mainly 
expressed in astrocytes where they regulate intracellular calcium levels and GABA 
uptake to modulate extracellular GABA concentration to influence the frequency of 
mIPSCs (Kang et al., 1998) and where they are able to influence mIPSC amplitude onto 
interneurons more strongly than on pyramidal neurons (Shigetomi et al., 2012). 3) D4Rs 
are scattered at low levels throughout many cell types and brain areas. When activated, 
these receptors maintain a  homeostatic balance (Yuen et al., 2010), therefore, either 
activation or inactivation of these receptors in a relatively quiescent preparation causes a 
plethora of changes which enhance the overall activity of the network. 
2.4.3 Excitability 
Inhibition of D4Rs increases PV+ interneuron excitability in one of two ways: it 
may work through an intrinsic mechanism, or it may increase extracellular dopamine in 
the slice. One recent study showed that D4Rs increased FSI excitability through 
Kv3.1/3.2 channels (Trantham-Davidson et al., 2014).  However, these recordings were 
performed at non-specific doses of the D4R agonist PD 168077 (40µM instead of 100 
nM). A study using more appropriate agonist concentrations also observed that D4R 
activation decreased an outward rectifying potassium current recorded from FSIs, but 
  
90 
only at voltages above -10mV (Andersson et al., 2012a). Given that outward K
+
 currents 
repolarize the membrane during an action potential, reducing these currents will increase 
the half-width of the action potential more than modifying action potential voltage 
threshold. The action potentials of PV+ interneurons did not widen significantly with 
D4R activation; however, with the D4R antagonist, there was a trend toward narrower 
action potentials (half-width = 44.5 µs faster, p=0.08). D4R agonists have also been 
shown to decrease G-protein inwardly-rectifying potassium (GIRK) currents 
(Wedemeyer et al., 2007), so inhibiting these receptors may increase GIRK currents to 
influence neuronal excitability. Earlier recordings from FSIs suggested that inhibition of 
D4Rs had no effect on their excitability as revealed by membrane depolarization 
(Gorelova et al., 2002). However, this measure fails to capture the effects of the D4R on 
voltage-gated ion channels and instead focuses on the leak currents active near the 
neuron’s resting potential. The faster latencies, reduced afterhyperpolarizations and 
changes in AP amplitude such as those I have observed (Fig2.3) often reflect changes in 
voltage-gated Na
+
 and K
+
 currents.  
The hypothesis that inhibition of D4Rs increase PV+ interneuron excitability by 
increasing extracellular dopamine in the slice is attractive because it provides a 
potentially common pathway for both NRG1 and D4R to increase intrinsic excitability. 
Dopamine levels increase in the PFC after application of a D4R antagonist (Broderick 
and Piercey, 1998) and in the hippocampus after application of NRG1 (Kwon et al., 
2008). Dopamine alone increases FSI excitability in the prefrontal cortex through the 
activation of D1-type receptors (Gorelova et al., 2002), and increases the excitability of 
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pyramidal neurons (Ceci et al., 1999). Dopamine’s effect on pyramidal neurons was 
reversed by 10 µM of the D4R antagonist L745870; although the specificity of the drug 
at this concentration is questionable. Likewise, D2-type dopamine receptors regulate 
calcium currents (Bender et al., 2010), axonal potassium currents (Kole et al., 2007; Yang 
et al., 2013a), Na
+
 currents (Maurice et al., 2001), and Ih currents (Campanac and 
Hoffman, 2013), all of which contribute to a neuron’s excitability (Bean, 2007). 
Furthermore, NRG1 increases FSI excitability in slices through the phosphorylation of a 
Kv1 channel (Li et al., 2012), but decreases the excitability of ErbB4-expressing cultured 
hippocampal neurons by reducing Na
+
 currents (Janssen et al., 2012). More signaling 
pathways are intact in slices than in cultured neurons, therefore NRG1 activation may 
increase dopamine levels in a slice, but not a cultured set of neurons thereby influencing 
excitability via dopamine in the slice, and via intrinsic properties in the culture.  Finally, 
PV+ interneurons lacking ErbB4Rs have greater spontaneous activity than PV+ 
interneurons with ErbB4Rs (del Pino et al., 2013). This suggests that ErbB4R activation 
may inhibit the intrinsic excitability of PV+ neurons at baseline. 
Two aspects of the recording methods are worthy of discussion. 1)  Before each 
recording, I reset the membrane potential to -70mV (± 3 mV) in order to cancel out 
changes in tonic GABA or NMDA receptor mediated currents. This also allowed me to 
examine changes in the same set of ionic currents. Although I did not see a significant 
change in holding current (8± 8pA at baseline vs. 0± 41pA 10 minutes after the 
antagonist), resetting the membrane potential to -70mV may have masked a significant 
depolarization or voltage-gated current (Owen et al., 2013). However, there was no 
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significant change in membrane resistance, as would be expected if tonic currents were 
changing. 2) Cells often display different excitability patterns when stimulated 
extrasynaptically versus somatically. I chose to only examine somatic current injections 
to avoid potential confounds with changes in glutamatergic signaling.  
I consistently experienced problems reproducing the results of a senior 
electrophysiologist. In attempts to standardize our recordings, I made recordings from the 
brain region that she did. I also tried using her set of reagents, making new reagents, 
using mice of different age ranges and sexes, and doubling the doses of the D4R agonist, 
but I was unable to replicate her findings. I went through and re-analyzed her data to 
ensure that we used the same data analysis techniques. Her recordings showed clear 
effects while mine did not.  The only variable not tested was the recording apparatus 
itself. Due to the inability to replicate previous findings, I focused my efforts on in vivo 
recordings of single neurons and gamma frequency local field potential (LFP). 
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CHAPTER THREE: Neuronal correlates of ketamine and walking induced gamma 
oscillations in the medial prefrontal cortex and mediodorsal thalamus 
3.1 Introduction 
In the mPFC, neural synchrony in the gamma frequency range (30-80Hz) is 
thought to play an important role in cognitive flexibility, working memory, and attention 
(Cannon et al., 2014; Gregoriou et al., 2015). Indeed, optogenetic inhibition of mPFC 
interneurons inhibits both gamma local field potential (LFP) power and cognitive 
flexibility while activation of mPFC interneurons at gamma frequencies restores 
cognitive flexibility in cognitively impaired mice (Cho et al., 2015).  Previous work from 
our lab has shown increases in gamma LFP power in the rodent mPFC during a treadmill 
walking task that requires attention (Delaville et al., 2015). Gamma power increases have 
also been observed during locomotion and arousal in the visual cortex (McGinley et al., 
2015a; Niell and Stryker, 2010; Vinck et al., 2015).  Additionally, it has been proposed 
that impairments in gamma oscillations play a key role in producing the cognitive deficits 
observed in psychiatric disorders such as schizophrenia (Pittman-Polletta et al., 2015; 
Sakurai et al., 2015). Cognitive deficits often precede the onset of psychosis, and show 
the least improvement after antipsychotic treatment (Green, 2006; Minzenberg and 
Carter, 2012). Specifically, many studies find that patients with schizophrenia have 
elevated ongoing cortical gamma power, and exhibit task-related deficits in gamma 
power modulation during sensory perception and cognitively demanding tasks (Cho et 
al., 2006; Jadi et al., 2015; Minzenberg et al., 2010).  
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Ketamine-induced gamma power in rodents has been used as a physiological 
correlate of psychosis and possible biomarker for investigating the efficacy of 
antipsychotics (Gilmour et al., 2012; Hudson et al., 2016). In healthy humans, an acute, 
subanesthetic dose of ketamine induces the symptoms of early stage schizophrenia, such 
as cognitive impairments, perceptual distortions and hallucinations (Krystal et al., 1994) 
and increases ongoing gamma power (Anticevic et al., 2015; Hong et al., 2010; 
Muthukumaraswamy et al., 2015; Shaw et al., 2015). Similarly, in rats, an acute, 
subanesthetic dose of ketamine increases motor activity, incoordination, and ongoing 
cortical and thalamic gamma power (Hakami et al., 2009; Kocsis et al., 2013; Saunders et 
al., 2012). Further insight into the mechanisms by which ketamine increases gamma 
power within cortical local circuits and within the thalamus may be useful for 
understanding its clinical relevancy. Therefore, this study seeks to further characterize 
gamma oscillations induced by ketamine by comparing these oscillations to physiological 
gamma oscillations induced by walking in the mPFC and one of its major sources of 
innervation, the MD thalamus, at the LFP and single neuron levels. 
Given that reduction of ketamine-induced cortical gamma power has been 
proposed to predict antipsychotic drug efficacy, we also tested the ability of a dopamine 
D4 receptor (D4R) agonist to decrease ketamine-induced gamma power. The D4R has 
emerged as a potential pro-cognitive target in schizophrenia due to its expression in the 
mPFC (Mrzljak et al., 1996), and the ability of D4R agonists to increase gamma power 
and cognitive performance (for a review, see Furth et al., 2013; Nakazawa et al., 2015). 
Furthermore, D4R antagonists reverse cognitive deficits induced by stress or chronic 
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NMDAR antagonism in monkeys (Arnsten et al., 2000; Jentsch et al., 1999). Finally, the 
D4R antagonist can prevent other neuromodulators, such as neuregulin 1, which has 
repeatedly been genetically associated with the risk for schizophrenia (Buonanno, 2010), 
from increasing gamma power (Andersson et al., 2012b). Consequently, the D4R may 
constitute a potential target for modulating gamma oscillation power in the ketamine 
model of schizophrenia.  
The present study examined the effects of an acute subanesthetic dose of ketamine 
on the LFP and single neuron activity of the mPFC and MD thalamus of a rat performing 
a treadmill walking task. We analyzed the effects of ketamine on spike-LFP relationships 
in each structure to provide insight into the ways in which neuronal spiking correlates 
with changes in locally synchronized gamma oscillations and to ascertain whether 
ketamine increases gamma power through a distinct mechanism in the MD thalamus 
versus the mPFC. Finally, we tested the influence of a dopamine D4R agonist and 
antagonist on ketamine-induced gamma. 
3.2 Materials and Methods 
All experimental procedures were conducted in accordance with the NIH Guide 
for Care and Use of Laboratory Animals and approved by NINDS Animal Care and Use 
Committee. We attempted to minimize the number of animals used and their discomfort. 
3.2.1 Rats and behavioral paradigm 
Male Long Evans rats (Charles River, Frederick, MD, USA), weighing 280–300 
g, were housed with ad libitum access to chow and water in environmentally controlled 
conditions with a 12:12 h light:dark cycle (lights off at 9:00h). Rats were handled daily 
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the week before surgery and trained to walk on a circular treadmill as previously 
described (Avila et al., 2010). The treadmill walking task requires attentiveness, as the 
rats have to maintain a consistent walking speed in order to avoid being pushed by a 
stationary paddle placed on the treadmill (Fig 3.1B).  
 
3.2.2 Surgical procedures 
Two electrodes were implanted for recording LFP and spikes from the left 
prelimbic mPFC, and the left MD thalamus during the same surgery (Fig 3.1A). Rats 
were anesthetized with 75 mg/kg ketamine and 0.5 mg/kg medetomidine (i.p.) and placed 
in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA), with head-fixed 
with atraumatic ear bars.  Holes were drilled in the skull above the target coordinates for 
the mPFC (AP: +3.6 mm from the bregma, ML: +0.6 mm from the sagittal suture and 
DV: 3.6 mm from the skull surface), and MD thalamus (AP: -2.5 mm from the bregma 
suture, ML: +0.5 mm from the sagittal suture and DV: 5.8 mm from the skull surface; 
Fig3.1A). Electrode bundles consisted of 8 stainless steel teflon-insulated microwires 
plus an additional 9
th
 wire with no insulation on the distal ~1 mm of the recording tip 
with lower impedance serving as a local reference (Brazhnik et al., 2012; Delaville et al., 
2015; Dupre et al., 2016). They were implanted in the target regions and secured to the 
skull with screws and dental cement. Ground wires from each set of electrodes were 
wrapped around a screw located above the cerebellum. After completion of surgeries, 
0.15% of ketoprofen in 0.9% NaCl solution was given subcutaneously (s.c.), and 
atipamezole (0.3-0.5 mg/kg, s.c.) was administered to reverse the effect of medetomidine. 
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During the first week of postoperative recovery, the rat’s diet was supplemented with 
fruit and bacon treats. Rats were retrained at the circular treadmill walking task after the 
fourth postoperative day. 
3.2.3 Behavioral analysis 
A web camera (Logitech) was mounted next to the circular treadmill in order to 
provide behavioral data synchronized with the electrophysiological recordings. To 
quantify how ketamine affected behavior, an independent experimenter assessed the 
rodent’s behavior using 50-second video epochs with treadmill-off and treadmill-on. 
Behavior with the treadmill-on was scored from before the ketamine injection (baseline) 
and 15 minutes after the ketamine injection, and behavior with the treadmill-off was 
scored from baseline and 13 minutes after the ketamine injection. 
When the treadmill was off, the rat was still inside the circular treadmill track and 
the paddle was down so that it could not walk the treadmill freely. In this condition, 
untreated rats entered states of attentive or inattentive rest, but ketamine-treated rats were 
either hyperactive, or ataxic. To evaluate motor activity, we measured the number of 
seconds that the rat spent moving his trunk or limbs (but not its head). Ataxia was scored 
according to the following scale (adapted from Cho et al., 1991; Cui et al., 2014): (0) 
inactive or coordinated movements, (1) awkward or jerky movements or loss of balance 
while rearing, (2) frequent falling or partial impairment of antigravity reflexes, (3) the 
inability to move beyond a small area and to support body weight and (4) inability to 
move except for twitching movements. The stereotypic rating scale was also adapted 
from (Cho et al., 1991). Briefly, we quantified the number of head-bobs, turns, and the 
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number of seconds spent backpedaling. Head-bobs included side-to-side or vertical head 
movements, and turns involved a 180 degree turn so that the rat’s direction in the 
treadmill had changed.  
During treadmill-on epochs, an independent experimenter recorded the number of 
turns, the number of times that the rat hit the paddle, and the duration the rat spent being 
pushed by the paddle. Paddle hits counted for any of the rat’s body parts other than the tip 
of his tail. Comparisons between baseline and ketamine treatment were made using 
paired t-tests for each behavioral measure. 
3.2.4 Electrophysiological recordings 
Extracellular spike and LFP recordings were collected for every experiment using 
Plexon (Dallas, TX) and Spike2 (CED, Cambridge, UK) systems as described in 
(Delaville et al., 2015). Both spikes and LFPs were referenced to the scraped 9
th
 wire. 
Spikes were sampled at 40kHz and LFPs were sampled at 2kHz. Action potentials were 
amplified (10,000x) and band pass filtered (0.3-8 kHz). LFPs were amplified (2000x) and 
band pass filtered (0.7-150 Hz). Discriminated spike and LFP signals were digitized, 
stored and analyzed using Spike2 data acquisition and analysis software. 
Baseline recordings consisted of at least two five-minute epochs of 
counterclockwise walking and two 40 second epochs of inattentive rest without artifacts. 
After drug injections, the rat repeated a pattern of walking for 4 minutes and treadmill-off 
for one minute for the first 25 minutes, then the treadmill was turned off for the final 4 
minutes before the next injection. Direct observation and videotaped motor behavior were 
used to identify artifact-free 100-second intervals within the treadmill walking epochs 
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and 40 to 100 second intervals from treadmill-off epochs. Any epoch of either behavior 
showing artifacts was excluded. The circular treadmill‘s speed was set at 9 to 11 rotations 
per minute. 
3.2.5 Experimental conditions and drugs 
Starting one week after the surgery, recording sessions were conducted once a 
week with at least six days between each recording. Table 3 shows the order of the three 
experiments and Table 4 shows the time course of each experiment. Treadmill on and off 
recordings at post-surgical day 7 were obtained from 15 rats. Ten rats participated in the 
experiments described in Table 3 and the remaining five rats were used in a separate 
study.  
Rats that participated in the D4R dose response curve experiments were randomly 
assigned to receive the vehicle or D4R agonist first (n=6). The D4R agonist A-412997 
(Tocris, MN) and antagonist L-745,870 (Tocris) were dissolved in saline and injected at 
1mL/kg subcutaneously. Doses of the agonist were chosen based on Kocsis and 
colleagues (2014) so that the final cumulative dose was 3mg/kg of A-412997. Injections 
were given every 30 minutes in ascending order from 0.3mg/kg through 1.5mg/kg A-
412997, as described in Table 4.  
The second experiment (Ascending doses of ketamine, n= 8, Table 4) consisted of 
two consecutive 5mg/kg doses of racemic ketamine-hydrochloride (Akorn, IL) 
administered subcutaneously one hour apart. This paradigm was chosen because 
ketamine has long-term effects on behavior, and 5 and 10 mg/kg ketamine are the two 
most commonly used doses in other rodent studies (Amat et al., 2016; Li et al., 2010; 
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Pinault, 2008). The two-dose paradigm allowed us to probe whether a cumulative dose of 
10mg/kg ketamine would have similar effects to a single 10mg/kg dose. This experiment 
was performed on a different day from the final anesthetic dose, although all three doses 
are compared.  
In the final experiment, we employed a drug testing paradigm similar to the one 
used by Jones and colleagues (2012) in which a pretreatment was administered 30 
minutes before an injection of ketamine (n=6, Table 4). In short, we recorded 30 minutes 
of baseline, followed by an injection of one of three pretreatments – saline, 3mg/kg A-
412997, the D4R agonist, or 5mg/kg L-745,870, the D4R antagonist. Each drug was 
administered according to a random design. Thirty minutes after the pretreatment, a 
single injection of 10mg/kg ketamine was given subcutaneously, and recordings 
continued for the next 100 minutes. Therefore every rat was his own control. The final 
anesthetized recording was combined with the last experimental recording in about half 
of the rats and started 100 minutes after the ketamine injection. If the rat had already 
received 10mg/kg ketamine, then the final dose was 90mg/kg. Otherwise 100mg/kg of 
ketamine was administered subcutaneously as the final ataxia-inducing dose.  
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Group Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
N= 4 rats D4R/vehicle dose response 
curves: rats randomly 
assigned to receive vehicle 
of D4R agonist first 
D4R 
antagonist 
dose response 
(data not 
shown) 
Ascending 
doses of 
ketamine 
Sacrificed  
N= 2 rats D4R/vehicle dose response 
curves: rats randomly 
assigned to receive vehicle 
of D4R agonist first 
Vehicle, A412997, or L745870 pretreatment 30 
minutes before ketamine injection: order of 
treatments randomly assigned 
Sacrificed 
N= 4 rats Ascending 
doses of 
ketamine 
Vehicle, A412997, or L745870 pretreatment 
30 minutes before ketamine injection: order 
of treatments randomly assigned 
Sacrificed  
Table 3. Experimental design.  Randomized drug delivery schedules for each group of rats, with 1 week 
washout between recordings. Rats in the first two groups were randomly assigned to receive the D4R 
agonist or the vehicle dose response curve on week 1, and rats in the second two groups received the 
ketamine pretreatments, 1mL/kg saline, the D4R agonist 3mg/kg A-412997, and the D4R antagonist 
5mg/kg L-745870 in a randomized order. 
 
Experiment Injection 1, 
Time = 0 
minutes 
Injection 2, Time = 
30 minutes 
Injection 3, 
Time = 60 
minutes 
Injection 4, 
Time = 90 
minutes 
D4R dose response 
curve 
0.3mg/kg  
A-412997 
1.2 mg/kg  
A-412997 
1.5 mg/kg  
A-412997 
5 mg/kg  
L-745,870 
Vehicle dose 
response curve 
1mg/mL 
saline 
1 mg/mL saline 1mg/mL 
saline 
5 mg/kg  
L-745,870 
Ascending doses of 
ketamine 
5mg/kg 
ketamine 
1mg/mL saline*  5mg/kg 
ketamine 
 
Vehicle 
pretreatment + 
Ketamine 
1mg/mL 
saline 
10mg/kg ketamine   
L-745,870 
pretreatment + 
Ketamine 
5 mg/kg  
L-745,870 
10mg/kg ketamine   
A-412997 
pretreatment  + 
Ketamine 
3mg/kg  
A-412997 
10mg/kg ketamine   
Final ketamine 100mg/kg 
ketamine 
0.15 mg 
medetomidine# 
  
Table 4. Time course of each recording. Each recording consisted of a 30 minute drug-free baseline followed 
by a 125 minute post injection period. The time course of the injections is indicated in the table. *: injected 
at 45 minutes, # injected between 20 and 30 minutes. 
 
3.2.6 Spectral analysis of local field potential recordings 
LFP power was measured by fast Fourier transform (FFT) with a frequency 
resolution of ~1 Hz and normalized by dividing the power at each frequency by the sum 
of power between 250 and 300Hz in order to compensate for any instrumental 
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fluctuations over time (Brazhnik et al., 2016). For each structure, total power in the low 
gamma (40-59Hz) and high gamma (70-120Hz) frequency ranges was calculated using a 
spike2 script. Additionally, if a significant peak was found between 40 and 70Hz, the 
power was summed from 7Hz below and above the peak to find the total low gamma 
power. A peak was considered significant if its relative maximum was greater than the 
surrounding 14 frequency bins in the low gamma range, the first derivative of the 
spectrum was positive to the left of the peak and negative to the right of the peak, and the 
second derivative at the peak was negative, indicating a downward concavity. LFP power 
from two wires per electrode bundle during two epochs was averaged for each behavioral 
condition. Spectral coherence was calculated for the same set of wires between the mPFC 
and MD thalamus using a Spike2 script and FFT-based spectral coherence. Coherence 
was calculated as in Delaville and colleagues (2015). Using 100 second epochs, any 
coherence over 0.015 was considered significant. Data are reported as mean ± SEM. 
To visualize spectral power changes over time for the selected epochs, time-
frequency wavelet spectra were constructed using continuous wavelet transforms. The 
Morlet wavelet was applied to the LFPs using 128 frequency scales and a time resolution 
of approximately 750 ms (Time-Frequency Toolbox (http://tftb.nongnu.org). Time-
frequency mPFC-MD thalamus coherence was calculated using FFT-based coherence 
over a 10 second (s) sliding window (Chronux: http://chronux.org). The multitaper 
coherence analysis introduced a bias determined by the following formula: 
𝐵 =
1
√𝜈
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B is the bias introduced by the analysis and ν represents the degrees of freedom, 
equivalent in this case to the number of tapers used. This multitaper calculation utilized 
19 tapers, resulting in a bias of about 0.23. To compensate for this, the smallest 
coherence values in the plot were adjusted to 0.23 and the largest to 1.23, rather than 0 
and 1, respectively (Bokil et al., 2007). 
In order to analyze the effects of the different drugs on the LFPs compared to 
baseline recordings, percent change from baseline walk in each frequency bin (for data 
visualization), or for each frequency range (for specific frequency range analysis) was 
used. Percent change was calculated using the formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐶ℎ𝑎𝑛𝑔𝑒 =
𝑃𝑓,𝑡 − 𝑃𝑓,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑃𝑓,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 × 100% 
P is power in the frequency range (f) at a given time (t). Outlier time points for power 
were removed using the ROUT (robust nonlinear regression combined with outlier 
removal) test with Q set to 1% (Motulsky and Brown, 2006) and the average of the other 
rats was used as a replacement value (Dupre et al., 2016).  
The effects of various drug treatments on coherence and power over time within 
specific frequency ranges were assessed during treadmill walking using two-way 
repeated measures analysis of variance (ANOVA) following by Holm-Sidak’s multiple 
comparisons with the level of significance: α = 0.05.  
To test for a bimodal distribution within the firing rates, angular phases and half-
widths of interneurons, a dip test (Hartigan and Hartigan, 1985) was used. When showing 
that mean STWA ratios were significantly different from a randomly ordered spike train 
(with a theoretical value of 1), a permutation test was used. 
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3.2.7 Cell sorting and STWA analysis 
Spike waveforms from the mPFC and the MD thalamus were sorted using 
principal component analysis (PCA) in Spike2. To assess effective sorting for single 
cells, inter-spike interval (ISI) histograms were generated and inspected to ensure that 
sorted cell clusters did not exhibit multiunit behavior by firing within the assumed 
refractory period (1.2 ms). Putative pyramidal neurons and interneurons were separated 
using trough-to-peak intervals (Azouz et al., 1997; Brazhnik et al., 2012; Wilson et al., 
1994). Units with trough-to-peak intervals greater than 0.5ms were classified as putative 
pyramidal neurons (112/147), and those with intervals less than 0.4ms were classified as 
interneurons (31/147). Four neurons did not fit into either category and were left 
unclassified. In this paper, the terms pyramidal neuron and interneuron refer to putative 
pyramidal and putative interneurons, respectively. MD thalamus neurons with narrow 
waveforms were excluded if the recovery phase of the action potential was less than 
0.293ms (mean-2.5SD, n=9 cells) to ensure a homogeneous population of neurons. .  
These 9 neurons showed significant walking-induced increases in firing rate and spike-
gamma LFP relationships (both p<0.05, ratio paired t-tests), similar to those observed in 
the other MD thalamus neurons.   
To assess the temporal relationship between the spiking activity of individual 
neurons and LFPs from the same structure, spike-triggered waveform averages (STWA) 
were calculated for epochs of 100 to 200 seconds. LFPs from the recording wire or one of 
two neighboring wires were band-pass filtered between 40 and 59Hz. For each wire with 
a usable spike train, we calculated its coherence between 40Hz and 59Hz with all the 
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other wires, and ranked each wire from the one with the maximum to the minimum 
coherence. We selected the wire with the maximum coherence and the median coherence 
as the neighboring wires, and refer to them as the maximum wire and median wire, 
respectively.  Peak-to-trough amplitudes of the STWAs at or around the spike (zero time) 
were obtained as a measure of correlation between the spike train and dominant gamma 
oscillation. Twenty shuffled STWAs for the same epochs were created by shuffling the 
interspike intervals of each spike train and used to create 20 normally distributed peak-to-
trough values. The extent of correlation between spikes and gamma-filtered LFPs after 
ketamine or D4R drug treatments during epochs of walking was compared to baseline 
walk epochs using the mean ratio of unshuffled/shuffled peak-to-trough amplitudes 
(mean STWA ratio). Comparisons of firing rate and mean STWA ratio between baseline 
and ketamine administration were assessed using repeated measures one-way ANOVAs 
with Holm-Sidak’s multiple comparisons: α = 0.05. Outlier neurons were removed using 
the ROUT (robust nonlinear regression combined with outlier removal) test with Q set to 
0.1%(Motulsky and Brown, 2006). 
3.2.8 Histology 
After recordings were completed, rats were deeply anesthetized with ketamine 
(100mg /kg, s.c.) and 0.15mg medetomidine and recording sites were marked by passing 
a 10 μA positive current for 15-17 seconds via 3 microwires and 9 seconds via the 
reference electrode. Rats were perfused intracardially with 200 mL cold saline followed 
by 200 mL 4% paraformaldehyde in phosphate buffer solution (PBS). Brains were post-
fixed in paraformaldehyde solution overnight and then immersed in 10% sucrose in 
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phosphate buffered saline (0.1 M, pH 7.4). Coronal sections of 35 μm were collected on 
slides. Sections for electrode placement verification were mounted on glass slides and 
stained with cresyl violet and 5% potassium ferricyanide-9% HCl to reveal the iron 
deposited at the electrode tips. Rats were only included in the analysis if the electrodes 
were properly placed in the prelimbic mPFC and/or the core or shell of the MD thalamus. 
3.3 Results 
To investigate the effects of ketamine on the relationships between behavior, 
gamma power, and neuronal activity in the mPFC and the MD thalamus, the major 
thalamic source of mPFC innervation (Mitchell and Chakraborty, 2013), we recorded 
simultaneously from these two structures during different behavioral states before and 
after ketamine administration (10 mg/kg, Fig 3.1). It has been shown that ketamine 
administration induces a state of hyperactivity and increases cortical gamma activity 
(Hakami et al., 2009). Previous work in our lab has shown that treadmill walking also 
induces an increase in mPFC gamma activity (Delaville et al., 2015). To compare the 
effects of locomotion alone with ketamine’s effects on gamma power, we first examined 
the effects of treadmill walking on LFP activity in rats; then we examined the effects of 
ketamine administration on LFP activity and motor behavior during treadmill walking.  
 
3.3.1 Effects of treadmill-walking and ketamine on gamma power 
The present results confirmed previous observations showing that treadmill 
walking induced an increase in mPFC gamma power (Delaville et al., 2015). Seven days 
post-electrode implantation, during treadmill-off epochs, there was no significant spectral 
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peak in the low gamma range (40-70Hz). During treadmill-on, the power spectra of the 
mPFC showed an increase in LFP power in a relatively narrow band with a mean peak of 
51.1±0.8Hz (Fig 3.1C,E,G). The LFP power in a 15Hz range surrounding this significant 
gamma peak (see Section 3.2.6) increased by 23.8% relative to treadmill-off (p<0.01, 
paired t-test; Fig Fig 3.1F). To gain insight into whether projections from the MD 
thalamus contribute to walking-induced gamma activity in the mPFC during walking, we 
examined its LFP activity. Interestingly, in the MD thalamus, the low gamma power 
increased by 17.5% during treadmill walking in a broader band than observed in the 
mPFC with a mean peak at 48.6 ±0.5 Hz (p<0.01, paired t-test; Fig 3.1C,E-G). Thus, 
treadmill walking induced increases in gamma power in both the MD thalamus and 
mPFC. 
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Figure 3.1. Walking-induced gamma power on the first recording day. A, Histological reconstruction 
(left) and electrode placements marked as red dots (right) of the recording electrodes in the prelimbic 
mPFC (left), and MD thalamus (right). B, Photograph of the rotating circular treadmill. The treadmill 
rotated at 9-11 rotations per minute for recording epochs and the paddle in the back ensured that the rat 
continued walking. C, Representative wavelet-based scalograms represent the time-frequency plots of LFP 
spectral power in the mPFC (left) and MD thalamus (right) from post-surgical day 7 during epochs with 
the treadmill off (white bar) and on. Warmer colors indicate higher power. D, Representative FFT-based 
spectrogram shows coherence between the mPFC and MD thalamus from the first recording day. E, G, 
Representative (E) or averaged (G) LFP power spectra for epochs with treadmill on (black) or off (grey) at 
the first recording day (n=12 rats). Power spectra from 0-20Hz shown in the inset (E). Colored shadows 
indicate SEM (G). F, Mean total gamma LFP power with the treadmill on and off from the first recording 
day. The frequency range of the gamma power was determined by finding the significant gamma peak (see 
methods) between 40 and 70Hz in each epoch during treadmill walking ±7Hz, and kept constant between 
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epochs with the treadmill on and off for each rat. Values are reported as mean ± SEM. **: p<0.01, paired t-
tests. 
 
The present results also confirmed observations that ketamine administration 
increases motor activity (Table S2; Hakami et al., 2009). Rats became significantly more 
active for the first 30 minutes after ketamine administration (p<0.05, t-tests). 
Furthermore, rats exhibited more differences in behavior before and after ketamine with 
the treadmill off, than during epochs of treadmill walking. Indeed, with the treadmill off, 
after ketamine administration, rats became more active, more likely to walk backwards, 
turn within the track, and show stereotypic behaviors, or appear more ataxic compared to 
baseline (all p<0.05, paired t-tests; Table 5). With the treadmill on, ketamine 
administration did not significantly affect the treadmill walking behavior (all p>0.05, 
paired t-tests; Table 5). However, following ketamine administration, it appears that rats 
were more attentive to the walking task, as they made contact with the paddle less often 
(p<0.05, paired t-test; Table 5). Taken together, the rat’s behavior was more consistent 
before and after ketamine administration when the treadmill was on.  
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 Behaviors Pre-ketamine Post-ketamine 
Treadmill-OFF Behaviors 
Hyperactivity Time moving trunk or limbs 
(seconds) 
1.3±0.7 45.8±0.9*** 
Turns 0.1±0.1 2.4±0.6** 
Time walking backwards 
(seconds) 
0±0 2.0±0.7* 
Stereotypy Head-bobs 0.3±0.2 3.3±0.8** 
Ataxia Ataxia Score (0-4) 0±0 1.3±0.2*** 
Treadmill-ON Behaviors 
Hyperactivity Turns 0±0 0.6±0.3 
Attentiveness Paddle Hits 8.7±2.0 3.0±0.6* 
Time touching paddle 
(seconds) 
9.9±2.4 4.8±1.7 
Time per paddle hit 
(seconds) 
0.9±0.2 2.0±0.9 
Table 5. Behavioral measures before and after ketamine during treadmill on and off epochs. 
Quantified measures of behavior from ~15 minutes before and after ketamine administration. Values are 
reported as percentage or mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, paired t-tests. 
 
During treadmill-off epochs, ketamine administration increased gamma power by 
371% relative to the same day’s treadmill-off epochs before ketamine (gamma 
power=42.4±8.7 vs 9.0±0.4, p<0.05, paired t-test; Fig 3.2A,C-E). Specifically, the power 
spectra of the mPFC showed an increase in LFP power in a relatively narrow band with a 
mean peak of 55.9±1.0 Hz (Fig 3.2C,E). Ketamine also induced an increase in gamma 
range activity in the MD thalamus with two significant peaks: 55.2±2.3Hz and 
80.6±1.6Hz (Fig 3.2A,C-E). Power centered around the low gamma peak increased by 
41% after ketamine (from 2.4±0.2 to 3.4±0.4, p<0.05, paired t-test), and power centered 
around the 80Hz peak increased by 79% (from 1.2± 0.1 to 2.1±0.3, p<0.05, paired t-test). 
Thus, as previously shown (Pinault, 2008), ketamine administration increased gamma 
power. 
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To investigate whether ketamine-induced gamma power in the mPFC and MD 
thalamus is correlated with motor activity, we examined gamma LFP oscillations before 
and after ketamine administration during epochs of treadmill walking. With the treadmill 
on, ketamine administration induced an increase in gamma power in the mPFC and MD 
thalamus of 254% and 31% respectively compared to baseline (both p<0.05, Holm-
Sidak’s multiple comparisons; Fig 3.2A,C-E). Ketamine-induced gamma power was not 
significantly greater in the mPFC or the MD thalamus when the treadmill was on 
compared to off (p>0.05, paired t-test; Fig 3.2D). Furthermore, in the mPFC , during 
treadmill-on epochs, there was no difference in the ketamine-induced gamma peak’s 
frequency (55.8 ± 1.4Hz) or the total power surrounding this peak (gamma 
power=43.1±9.5) compared to treadmill-off (both p>0.05, paired t-tests). Likewise, in the 
MD thalamus, neither the frequency of the ketamine-induced gamma peaks (52.4±1.4Hz 
and 80.7Hz ± 1.1Hz), nor the power of the gamma peaks (low gamma power = 3.3±0.4 
and high gamma power = 2.3±0.4) showed significant differences between treadmill-on 
and treadmill-off epochs (p>0.05, paired t-test; Fig 3.2A,C,E). 
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Figure 3.2. Comparison between walking-induced gamma power and ketamine-induced gamma 
power in the medial prefrontal cortex (mPFC) and mediodorsal thalamus (MD). A, Representative 
wavelet-based scalograms represent the time-frequency plots of LFP spectral power in the mPFC (left) and 
MD thalamus (right) 13-17 minutes after 10mg/kg ketamine s.c. during epochs with the treadmill off 
(white bar) and on. Warmer colors indicate higher power. B, Representative FFT-based spectrogram shows 
coherence between the mPFC and MD thalamus 13-17 minutes after 10mg/kg ketamine s.c. C,E, 
Representative (C) and averaged (E) LFP power spectra for epochs 13-17 minutes after 10mg/kg ketamine 
for epochs with the treadmill off (purple) and on (green), and the baseline treadmill walking power from 
the same recording day (black, n=6 rats). Power spectra from 0-20Hz shown in the inset (C). D, Mean total 
gamma LFP power with the treadmill on and off from before (PRE) and 13-17 minutes after 10mg/kg 
ketamine s.c (J, POST). The frequency range of the gamma power was determined by finding the 
significant gamma peak (see methods) between 40 and 70Hz in each epoch during treadmill walking ±7Hz, 
and kept constant between epochs with the treadmill on (ON) and off (OFF) for each rat. F, Ketamine 
increases coherence between the MD thalamus and the mPFC from 0-6Hz.  Linear graph shows averaged 
LFP coherence at baseline walk (black) and 15 minutes after 10mg/kg ketamine (green) (n=5 rats). Colored 
bands indicate SEM. The bar with the star indicates a significant difference at this frequency range using 
multiple t-tests with false-detection rate set to 1%. Values are reported as mean ± SEM. *: p<0.05, paired t-
tests. 
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Our behavioral and electrophysiological results show that treadmill walking did 
not significantly modify ketamine-induced gamma power and allowed us better control of 
the rat’s behavior. Therefore, all further analyses examined epochs with the treadmill on. 
Although increases in low gamma LFP power were seen in a similar frequency 
range in the mPFC and MD thalamus during treadmill walking, coherence between the 
mPFC and MD thalamus (peak between 40-70 Hz ± 7 Hz) did not reach the statistically 
predetermined levels of significance (Rosenberg et al., 1989), nor was there any change 
between epoch with the treadmill on versus off (n=9 rats; Fig 3.2F). Likewise, average 
LFP coherence between mPFC and MD thalamus in the low gamma frequency range 
(peak between 40-70Hz ± 7 Hz) did not reach significance after ketamine administration 
(n= 5, Fig 3.2F). We analyzed the relationship between low (theta) and high (gamma) 
frequencies within the MD thalamus LFP.  Gamma activity sometimes occurs at a 
specific phase in theta oscillations. Measures of phase-amplitude coupling (PAC) can 
also be used to determine if low frequency activity in one structure influences high 
frequency activity in a separate structure. Within the MD thalamus, no PAC was 
observed before ketamine administration, but after ketamine gamma oscillations centered 
~85Hz nested within theta oscillations of 7-9Hz in every rat examined (Fig 3.3A). This 
suggests that in the MD thalamus, a shared mechanism modulates theta and gamma 
oscillations. Furthermore, low frequency oscillations in the MD thalamus (2-6Hz) 
modulated gamma power in the mPFC between 50Hz and 65Hz after ketamine 
administration, but not before (Fig 3.3B). This indicates that the MD thalamus influences 
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the gamma frequency activity of the mPFC through modulation of low frequency 
oscillations. 
 
Figure 3.3. Ketamine increases phase-amplitude coupling within the MD thalamus and between MD 
thalamus and mPFC.(A) Representative comodulograms plot the analytic amplitude of the LFP from the 
MD thalamus (y-axis, 20-100Hz) as a function of the phase of the LFP from the MD thalamus (x-axis, 2-
10Hz) before (left) and 15 minutes after 10mg/kg ketamine injection (right). Warmer colors indicate 
stronger cross-frequency coupling. (B) Same as in (A) except the analytic amplitude of the LFP from the 
mPFC (y-axis) is plotted as a function of the phase of the LFP from the MD thalamus (x-axis). 
 
3.3.2 Spike-LFP correlations in walking-induced gamma power 
To further investigate the neuronal correlates of the increases in LFP gamma 
activity associated with treadmill walking, we examined changes in the firing rates of 
neurons in the mPFC and MD thalamus. Putative pyramidal neurons and interneurons 
from the mPFC were separated using waveform shape and firing rates (Fig 3.4A&B). 
Interneurons were further divided into fast-spiking interneurons, with firing rates above 
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8Hz (n=8) and slower interneurons, with firing rates below 8Hz (n=22). Other than rate, 
we observed no statistically significant differences between the groups in other 
parameters, such as spike-LFP relationships, so all cortical interneurons were analyzed as 
one group for the rest of the analyses. Overall, the firing rates of mPFC pyramidal and 
interneurons, as well as MD thalamus neurons increased during walking relative to 
treadmill-off (Fig 3.4C). The firing rates of pyramidal neurons in the mPFC increased by 
12% from 4.2±0.3Hz to 4.7±0.3Hz with the treadmill-on compared to treadmill-off 
(p<0.05, n=112, paired t-test; Fig 3.4C). Although this increase is modest, 40% of 
pyramidal neurons in the mPFC showed more than a 20% increase in firing rate, while 
16% showed more than a 20% decrease with the treadmill on compared to off (Fig 3.4D). 
Furthermore, the firing rates of interneurons in the mPFC increased by 33% when the 
treadmill was turned on (from 2.7±0.5Hz to 3.6±0.6Hz, p<0.01, paired t-test; Fig 3.4C). 
When examined in detail,  70% of interneurons in the mPFC showed more than a 20% 
increase in firing rate, whereas10% showed more than a 20% decrease with the treadmill 
on compared to off (Fig 3.4D). Similarly, the firing rate of MD thalamus neurons also 
increased by 32% from 3.4±0.5Hz to 4.5 ±0.5Hz during treadmill walking (p<0.001, 
paired t-test; Fig 3.4C). In fact, 56% of MD thalamus neurons showed more than a 20% 
increase in firing rate, while 14% showed more than a 20% decrease with the treadmill on 
compared to off (Fig 3.4D). In summary, increases in the firing rate of neurons in both 
the mPFC and MD thalamus complement walking-induced increases in gamma power. 
  
116 
 
Figure 3.4. Effects of treadmill walking on firing rates and spike-LFP correlation.A, Average waveforms, raw 
signals, and spiketrains from the mPFC (top) and MD thalamus (bottom) with the treadmill on. B, 
Interneurons and pyramidal neurons were separated using trough-to-peak intervals. More interneurons were 
detected on post-surgical day 7 than days 21-42. C, Firing rates of pyramidal neurons (PYR; n=112 
neurons from 12 rats, left) and interneurons (IN; n=25 neurons from 9 rats, middle) from the mPFC and 
neurons from the MD thalamus (n= 64 neurons from 12 rats, right). D, Percentage of neurons showing an 
increase (black, >20%), decrease (grey, <-20%), or no change (white) of rate with treadmill on compared to 
off. E, Mean ratios between peak to trough amplitudes of unshuffled/shuffled spike triggered waveform 
average (STWA) for LFPs recorded from the same wire (left) or the maximum (neighbor) wire (right, see 
methods) filtered from 40-59Hz for mPFC pyramidal neurons (left) and mPFC interneurons (middle) and 
MD thalamus neurons (right). A ratio of 1 (dashed horizontal line) indicates no difference between 
shuffled and unshuffled values. F, Phase plots showing the distributions of phase-relationships between 
mPFC spikes and LFPs from the same wire filtered between 40 and 59Hz for spike trains showing 
significant correlation to the gamma LFP during epochs of treadmill walking in pyramidal (PYR, n=74 
neurons from 13 rats) and interneurons (n=12 neurons from 9 rats) from the mPFC and MD thalamus (n=31 
neurons from 12 rats). Spikes were significantly oriented to gamma LFPs, Rayleigh test: p<0.05. Values are 
reported as mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, paired t-tests. #: p<0.001, unpaired t-tests.  
 
To gain insight into the extent to which spiking activity correlated with gamma 
power in the mPFC and MD thalamus, we examined spike-gamma LFP correlations, a 
measure of synchronization between spike trains and gamma oscillations. Peak-to-trough 
values of the spike triggered waveform averages (STWA) were used to evaluate the 
extent of the correlation between the spike and the simultaneously recorded oscillation 
filtered at 40-59Hz (gamma LFP). Interspike intervals from the same epochs were 
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shuffled 20 times, and after each shuffle, an additional STWA was generated (see 
methods). Spike trains were considered significantly correlated with LFP oscillations 
when the peak-to-trough amplitude of the unshuffled spike train STWA exceeded the 
mean shuffled peak-to-trough amplitude by 3 standard deviations (for an example, see 
Fig 3.6A).  
Figure 3.4E shows a comparison of the mean ratios of the unshuffled to shuffled 
STWA peak-to-trough amplitudes (mean STWA ratio) of pyramidal neurons and 
interneurons from the mPFC, as well as neurons from the MD thalamus referenced to 
gamma LFPs. The spiking of mPFC pyramidal neurons and MD thalamus neurons was 
more correlated to the 40-59Hz oscillation with the treadmill on (mPFC:70%, MD: 72% 
significantly correlated) compared to off (mPFC: 54%, MD: 63% significantly correlated, 
p<0.05, paired t-tests; Fig 3.4E). Specifically, mPFC pyramidal neuron spike-gamma 
LFP correlations increased during walking (mean STWA ratio increased from 2.38±0.12 
to 3.12±0.17, p<0.001, paired-t-test; Fig 3.4E). Additionally, MD thalamus spike-gamma 
LFP correlations increased with the treadmill on versus off (mean STWA ratio 
=4.67±0.46 and 3.59±0.44 respectively, p<0.001, paired t-test; Fig 3.4E). In contrast, 
spikes from mPFC interneurons were not significantly more correlated to the gamma LFP 
during treadmill walking (p>0.05, paired t-test). However, 36% and 33% of the mPFC 
interneurons were significantly correlated to the gamma LFP during treadmill on and 
treadmill off respectively. 
To obtain a measure of the distribution of the LFP oscillations in the area around 
an individual neuron, we referenced a single neuron’s spiking activity to the LFP of a 
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neighboring wire within the recording electrode bundle. For each wire with a usable spike 
train, we calculated its coherence between 40Hz and 59Hz with all the other wires, and 
ranked each wire from the one with the maximum to the minimum coherence. We 
selected the wire with the maximum coherence (average coherence of 0.71±0.03 in the 
mPFC and 0.69±0.02 in the MD thalamus), and the median coherence (average 
coherence of 0.42±0.03 in the mPFC and 0.36±0.03 in the MD thalamus) as the 
neighboring wires, and refer to them as the maximum wire and median wire, respectively. 
Selecting the wire with median coherence prevented selection of a wire that had splayed 
away from the bundle during implantation. During treadmill walking the spike-gamma 
LFP correlation was lower when mPFC pyramidal neurons (-33% p<0.01) or MD 
thalamus neurons (-56%, p<0.001), but not interneurons (p>0.05) were referenced to the 
maximum wire compared to the recording wire (t-tests; Fig 3.4E). Furthermore, fewer 
mPFC pyramidal neurons and MD thalamus neurons were significantly correlated to the 
gamma LFP (40-59Hz) when referenced to the maximum wire versus the recording wire 
(mPFC: 42% vs. 70%; DM: 42% vs. 72%, p<0.01, Fisher’s exact test). This suggests that 
walking-induced gamma power within both the mPFC and MD thalamus is relatively 
localized. 
In order to quantify the temporal relationships between the three different neuron 
populations and ongoing gamma oscillations, we determined the phase preference of 
those spike trains significantly correlated to the gamma LFP from the recording wire. 
Pyramidal neurons in the mPFC spiked during the ascending phase of the 40-59Hz 
filtered LFP oscillation with a preferred angle of 219 degrees (both p<0.01, Rayleigh test; 
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Fig 3.4F, n=74). mPFC interneurons spiked at one of two preferred angles, 238 degrees 
or 344 degrees (dip test revealed a trend towards a bimodal distribution, p = 0.074). MD 
thalamus neurons spiked during the ascending phase of the 40-59Hz filtered LFP 
oscillation with a preferred angle of 207 degrees (p<0.001, Rayleigh test; Fig 3.4F). 
Accordingly, MD thalamus neurons and mPFC pyramidal neurons have similar phase 
relationships to the LFP during walking-induced gamma power. 
 
3.3.3 Effects of 10mg/kg ketamine on single neurons in the mPFC and MD thalamus 
To further investigate the neuronal correlates of the increases in synchronized 
gamma activity associated with ketamine administration, LFPs and spike trains recorded 
from the mPFC and MD thalamus were examined for changes in power, firing rate and 
spike-gamma LFP correlation. First, we examined the time-course of changes in low 
gamma power during treadmill walking in a predetermined frequency band (40-59Hz) 
matching the frequency used for the spike-gamma LFP correlation analysis. Low gamma 
power (40-59Hz) was significantly higher 15 minutes after a 10mg/kg ketamine injection 
in both the mPFC (+170%) and MD thalamus (+30%) compared to baseline (p<0.05, 
Holm-Sidak’s multiple comparisons; Fig 3.5). Gamma power returned to baseline 75 
minutes after ketamine administration (p>0.05, Holm-Sidak’s multiple comparisons; Fig 
3.5).  
We also examined the gamma-range coherence between the wires to study the 
spatial distribution of gamma oscillations. In both the mPFC and MD thalamus, ketamine 
significantly increased the intra-electrode bundle coherence to both the median and 
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maximum wires (all p<0.05, paired t-test), but had a greater influence over the coherence 
to the median wire (both p<0.001, paired t-test, data not shown). Specifically, in the 
mPFC the coherence values of each wire to the median wire increased from 0.42 ±0.03 
before ketamine to 0.51 ±0.03 after ketamine (p<0.001, paired t-test) and the maximum 
wire increased slightly from 0.71 ±0.03 to 0.74 ±0.03 (p<0.05, paired t-test). 
Additionally, in the MD thalamus the coherence values of each wire to the median wire 
increased from 0.36 ±0.03 before ketamine to 0.45 ±0.03 after ketamine (p<0.001, paired 
t-test) and the maximum wire increased slightly from 0.69 ±0.02 to 0.72 ±0.02 (p<0.01, 
paired t-test). Together it appears that ketamine increases the conduction of gamma 
oscillations across a  broader spatial scale after ketamine treatment. 
We then examined the firing rates of neurons from the mPFC and MD thalamus. 
Only two mPFC interneurons were detected during ketamine treatments, perhaps due to 
the fact that these recordings were performed several weeks after surgery. Fifteen 
minutes after 10mg/kg ketamine, the mean firing rate of mPFC pyramidal neurons was 
33% higher than after saline injection (p<0.05, Holm-Sidak’s multiple comparisons; Fig 
3.5A). Seventy-five minutes after ketamine injection firing rates returned to baseline 
levels (p>0.05, Holm-Sidak’s multiple comparisons; Fig 3.5A). In contrast, the firing 
rates of neurons in the MD thalamus decreased by 46% fifteen minutes after ketamine 
administration (p<0.01, Holm-Sidak’s multiple comparisons; Fig 3.5B) despite a 
concurrent, significant increase in low gamma power. Firing rates returned to baseline 
levels 75 min after ketamine injection (p>0.05, Holm-Sidak’s multiple comparisons; Fig 
3.5B). The results show that NMDAR antagonism through ketamine has significant, yet 
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opposite effects on the mean firing rates of mPFC pyramidal neurons and MD thalamus 
neurons.  
 
Figure 3.5. Although ketamine administration induces increases in low gamma power in both the MD 
thalamus and mPFC, it induces increased firing rates in the mPFC and decreased firing rates in the 
MD thalamus.A-B, left, Low gamma (40-59Hz) power in the mPFC (A, n=10 rats) and the MD 
thalamus(B, n=6 rats) during treadmill walking at baseline (black), 15 minutes after saline injection (white), 
15 minutes (green) or 75 minutes after 10mg/kg ketamine (green with diagonal stripes). A-B, right, Firing 
rate of pyramidal neurons in the mPFC (A, n=44 neurons from 6 rats) and the MD thalamus (B, n=37 
neurons from 6 rats). Values are reported as percentage or mean ±SEM. *:p<0.05, **:p<0.01, repeated-
measures one-way ANOVA with Holm-Sidak’s multiple comparisons test. 
 
Next, we examined the relationship between spikes and gamma oscillations. 
Representative unshuffled and shuffled STWAs shown in figure 3.6A from the mPFC 
and MD thalamus demonstrate that spike-gamma LFP correlations increased after 
ketamine administration in the mPFC, but decreased in the MD thalamus. The spike-
gamma LFP correlation of mPFC pyramidal neurons increased 15 minutes after 
ketamine, relative to baseline or saline injection (both p<0.01, Holm-Sidak’s multiple 
comparisons), and returned to baseline 75 minutes after ketamine administration (p>0.05, 
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Holm-Sidak’s multiple comparisons; Fig 3.6B). After ketamine administration, pyramidal 
neurons in the mPFC were more correlated to gamma LFPs from the same wire,  the 
maximum wire, and the median relative to baseline (same wire mean STWA ratio = 
5.05±0.46 vs 2.94±0.20; maximum wire mean STWA ratio = 4.62±0.48 vs 
2.23±0.17,median wire mean STWA ratio = 3.77±0.34 vs 1.81±0.15, all p<0.001, Holm-
Sidak’s multiple comparisons; Fig 3.6B). In contrast to decreases in mean STWA ratios 
between the recording and maximum wire observed during walking-induced gamma, no 
decrease was observed during ketamine-induced gamma (p>0.05, t-test). This 
substantiates the idea that the ketamine-induced gamma is less localized around the 
neuron than walking-induced gamma. Interestingly, while there was no significant 
difference in the percentage of pyramidal neurons significantly correlated to the gamma 
LFP when referenced to the recording wire (p>0.05), a difference between epochs before 
and after ketamine administration became apparent when referenced to the wire with the 
maximum coherence (p<0.01), or the wire with the median coherence (p<0.001, Fig 
3.6B, Chi-Square tests). This was mainly driven by a decrease in the proportion of 
neurons significantly correlated to gamma-filtered LFPs at baseline in both neighboring 
wiResearch Thus it appears that ketamine increases spike-LFP correlations across a 
broader spatial array, and this was accompanied by increases in the average coherence 
between wires in the bundle as well (p<0.05, repeated measures one-way ANOVA). In 
both walking and ketamine-induced gamma power, as gamma power increases, spike-
gamma LFP correlations increase in the mPFC.  
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Figure 3.6. Ketamine increases the spike-gamma LFP correlation in the mPFC and decreases it in the 
MD thalamus.A, Representative spike-triggered waveform averages (STWAs) of an mPFC pyramidal 
neuron (top) and neuron from the MD thalamus (bottom) with LFPs from the recording wire filtered from 
40-59Hz 15 minutes before and after ketamine administration. B, The percentage of neurons significantly 
correlated to low gamma oscillations (40-59Hz, left) from the mPFC (top) and the MD thalamus (bottom), 
when the spike train was referenced to the recording wire (same, blue), and neighboring wires with the 
maximum (purple) and median (coral) coherence (see Section3.2.7). Mean ratios (right) between peak to 
trough amplitudes of the original STWA and the mean of 20 shuffled STWAs for LFPs filtered from 40-
59Hz recorded from the same wire, maximum, or median wire for putative mPFC pyramidal neurons (top) 
and MD thalamus neurons (bottom). A bar with significance stars over it indicates that this bar is 
significantly different from all the other conditions. A ratio of 1 (dashed horizontal line) indicates no 
difference between shuffled and unshuffled values.  Values are reported as percentage or mean ±SEM. 
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*:p<0.05, **:p<0.01, ***:p<0.001, repeated-measures one-way ANOVA with Holm-Sidak’s multiple 
comparisons test, $:p<0.1, ##:p<0.01, ###:p<0.001, chi-square test. 
 
A very different picture emerged in the MD thalamus after ketamine 
administration. As gamma power increased, neurons in the MD thalamus were less 
correlated to gamma LFPs from the same wire and the neighboring wiResearch MD 
thalamus neurons were ~34% less correlated to the MD thalamus gamma LFPs 15 
minutes after 10mg/kg ketamine than at baseline walk when the spikes were referenced to 
the same wire or a neighboring wire (same wire mean STWA ratio = 3.63±0.42 vs 
5.54±0.51; maximum wire mean STWA ratio = 1.63±0.19 vs 2.48±0.33, both p<0.001, 
Holm-Sidak’s multiple comparisons; Fig 3.6B). Spike-gamma LFP correlations 15 
minutes after ketamine were lower than baseline, 15 minutes after saline injection, or 75 
minutes after ketamine (all p<0.01, Holm-Sidak’s multiple comparisons; Fig 3.6B). 
However, when referenced to the median wire, there was no significant difference in 
spike-gamma LFP correlation before and after ketamine administration (p>0.05, Holm-
Sidak’s multiple comparisons, Fig 3.6B). Furthermore, while the percentage of MD 
thalamus neurons significantly correlated to the gamma LFP decreased when referenced 
to the recording wire (p<0.05), this was not observed when referenced to either 
neighboring wire (p>0.05, Chi-Square tests).  This is driven by the decrease in the 
percentage of neurons significantly correlated at baseline, and suggests that the LFP of 
each wire in the bundle in the thalamus may be more influenced by spiking activity than 
the LFP in the mPFC. Taken together, gamma power in the MD thalamus arises from a 
separate mechanism from that observed in the mPFC.  
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To gain further insight into the relationship between the mPFC and MD thalamus, 
we performed STWAs of spike trains from the MD thalamus referenced to the mPFC 
LFPs and vice versa. Less than 5% of MD thalamus spike trains were significantly 
correlated to gamma oscillations in the mPFC and less than 5% of mPFC pyramidal spike 
trains were significantly correlated to MD thalamus LFP before or after ketamine (n=42 
and n= 73 respectively, Fig 3.7). Similarly, neither the correlation of mPFC pyramidal 
spikes referenced to MD thalamus gamma oscillations, nor the correlation of MD 
thalamus spikes referenced to mPFC gamma oscillations were significantly different from 
the mean STWA ratio of random spike trains before or after ketamine (all p>0.05, 
permutation test, Fig 3.7). In conjunction with the absence of coherence between mPFC 
and MD thalamus, these results suggest that mPFC neurons are not driving gamma 
oscillations in the MD thalamus or vice versa. 
  
126 
 
Figure 3.7. Effects of ketamine on spike-LFP correlations between mPFC and MD thalamus.Bar 
graphs show the percentage of neurons significantly correlated to the LFP recorded on the same wire from 
40-59Hz (top), and mean STWA ratio (bottom). The percent of mPFC neurons phase-locked the MD 
thalamus LFP is shown on the left, and the percent of MD neurons phase-locked to the mPFC LFP and the 
STWA ratios of the MD thalamus neurons to mPFC LFP is shown on the right. A ratio of 1 (dashed 
horizontal line) indicates no difference between shuffled and unshuffled values. There were no significant 
differences. 
 
To further explore the relationship between spiking and the high gamma peak in 
the MD thalamus, we performed STWAs of spike trains from the MD thalamus to LFPs 
filtered in the high gamma range from 70-115Hz. As observed in the lower gamma 
frequency range, MD thalamus neurons were less correlated to the MD thalamus high 
gamma LFPs 15 minutes after 10mg/kg ketamine than at baseline walk when the spikes 
were referenced to the same wire or a neighboring wire (same wire mean STWA ratio = 
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5.65±0.62 vs 9.02±0.72; maximum wire mean STWA ratio = 2.98±0.35 vs 3.92±0.43, 
both p<0.001, Holm-Sidak’s multiple comparisons; Fig 3.8). Again, when referenced to 
the median wire, there was no significant difference in spike-high gamma LFP 
correlations before and after ketamine (p>0.05, Holm-Sidak’s multiple comparisons; Fig 
3.8). On a cautionary note, when spike artifacts are not fully filtered from the LFP, the 
trough of spike and the trough of the cycle will align at 180 degrees (Ray, 2015). The 
average phase and cycle of these MD thalamus neurons was 180.7 degrees and 82Hz 
signifying that these data may contain spike-noise contamination rather than real changes 
in spike-high gamma LFP relationships. Furthermore, there is evidence that spiking 
increases high gamma power between 80Hz and 100Hz (Ray and Maunsell, 
2011).However, our results likely do not fit this explanation as firing rates declined in the 
thalamus, gamma power was enhanced.  
 
Figure 3.8. Ketamine decreases the spike-high gamma LFP correlation in the MD thalamus.Left, The 
percentage of MD thalamus neurons significantly correlated to high gamma oscillations (70-115Hz) from 
the MD thalamus, when the spike train was referenced to the recording wire (same, blue), maximum 
(purple) and median (coral) wires (see Section 3.2.7). Mean ratios (right) between peak to trough 
amplitudes of the original STWA and the mean of 20 shuffled STWAs for LFPs filtered from 70-115Hz 
recorded from the same wire, maximum, or median wire for MD thalamus neurons. A bar with significance 
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stars over it indicates that this bar is significantly different from all the other conditions.  Values are 
reported as percentage or mean ±SEM. *:p<0.05, **:p<0.01, ***:p<0.001, repeated-measures one-way 
ANOVA with Holm-Sidak’s multiple comparisons test, $:p<0.1, chi-square test. 
3.3.4 Effects of different doses of ketamine in the mPFC 
3.3.4.1 Dosage effects on gamma power 
To gain further perspective on how a single dose of ketamine may potentiate the 
effects of further ketamine administration, and to compare the two most common doses 
of ketamine used in previous work in this field (5mg/kg and 10mg/kg) the effects of two 
consecutive subanesthetic doses of 5mg/kg ketamine given one hour apart were 
compared to a single 10mg/kg dose. Both doses induced an increase in gamma power in 
low (peak between 40-70Hz ± 7Hz) and high (70-120Hz) gamma frequency ranges. 
However, significant spectral peaks were only evident in the low gamma range (Fig 
3.9C) as shown by representative wavelet-based scalograms of LFP recordings and 
gamma-filtered LFPs (Fig 3.9A-B). Interestingly, during treadmill walking, the gamma 
peak frequency increased from 48.9±0.9Hz before ketamine to 56.4±1.2Hz after 5mg/kg 
ketamine and to 54.9±1.3Hz after the second 5 mg/kg dose (p<0.001, Holm-Sidak’s 
multiple comparisons; Fig 3.9D).  
LFP power increased from baseline in both low (peak between 40-70±7Hz) and 
high (70-120Hz) gamma frequency bands and remained elevated from the first injection 
of ketamine until 65 minutes after the second injection of ketamine (p<0.05; RM one-way 
ANOVA; Fig 3.9E-F). The increase in low gamma power was greater after the second 
5mg/kg dose than the first 5mg/kg dose (p<0.01, paired t-test; Fig 3.9E). With 5mg/kg 
ketamine, the low gamma power increased by 96.4±18.1% and with the cumulative dose 
of 10mg/kg low gamma power increased by 158±24.8% (Fig 3.9E). A single injection of 
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10mg/kg ketamine increased low gamma power significantly more than two consecutive 
doses of 5mg/kg ketamine (+ 262% vs. +158%, p<0.05, t-test).  In contrast, in the high 
gamma range, the power increased by ~40% from baseline walking with both injections, 
and there was no difference between the two doses (p>0.05, paired t-test; Fig 3.9F). 
Furthermore, there was no significant difference between the increases in high gamma 
power after a single injection of 10mg/kg ketamine and after two consecutive doses of 
5mg/kg ketamine (p>0.05, t-test). This indicates that one dose of ketamine potentiates the 
effects of further ketamine administration within the same hour  on low gamma power, 
but not high gamma power in the mPFC. Furthermore, this reveals that a single dose of 
ketamine has greater effects on low gamma power than two consecutive ketamine 
injections that add up to the same dose. 
 
Figure 3.9. Increasing doses of ketamine influence low gamma power, not high gamma power.A, 
Representative wavelet-based scalograms show the time-frequency plots of LFP spectral power in the 
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mPFC during treadmill walking before ketamine injection (baseline), 15 minutes after 5mg/kg ketamine, 15 
minutes after a 2
nd
 dose of 5mg/kg ketamine, and with the treadmill-off at 10 minutes after a cumulative 
dose of 100mg/kg ketamine, and 5 minutes after 0.15mg of medetomidine, a myorelaxant, administered 20-
25 minutes after the cumulative dose of 100mg/kg ketamine. B, Examples of gamma-band pass filtered 
LFP (40-70Hz) in the mPFC at each of the time points mentioned above. C, Averaged LFP power spectra 
15 minutes after each 5mg/kg injection of ketamine (n=8 rats). Colored shadows indicate SEM. Legend 
appears at the bottom. D, Frequency of the spectral peak in the gamma-band (40-70Hz) at each dose of 
ketamine. There was no peak 5 minutes after 0.15mg of medetomidine. E-F, For each rat, the power within 
the low gamma band (E, maximum peak between 40 and 70Hz ±7Hz) or high gamma band (F, 70-120Hz) 
were summed at baseline walk using the average of four 40 to 100 second epochs of artifact-free walking. 
Percent change from baseline power over time is displayed in the low gamma (E), and high gamma (F) 
frequency ranges. Arrows indicate injections of 5mg/kg ketamine. The bar with the star indicates a 
significant change from baseline walking for every time point under the bar. The percent change in low 
gamma power (E, inset) or high gamma power (F, inset) from baseline walking is shown at 15 minutes 
after the first and second 5mg/kg injection of ketamine with lines connecting the doses in each rat. Values 
are reported as percentage or mean ± SEM. *: p<0.05, **: p<0.01, ***: p<0.001, repeated measures one-
way ANOVA with Holm-Sidak’s multiple comparison tests.  
 
3.3.4.2 Dosage effects on neuronal correlates 
As observed with 10mg/kg ketamine, 5mg/kg ketamine increased the firing rate of 
neurons from 4.4±0.6Hz at baseline to 5.4± 0.8Hz (p<0.01, Holm-Sidak’s multiple 
comparisons; Fig 3.10). Furthermore, 5mg/kg ketamine significantly increased the spike-
gamma LFP correlation of pyramidal neurons referenced to the maximum wire relative to 
baseline (mean STWA ratio increased from 1.7±0.1 to 2.3±0.2, p<0.01), but not when 
referenced to the recording wire (p>0.05, Holm-Sidak’s multiple comparisons; Fig 3.10). 
Changes in firing rate were comparable after a single dose of 5mg/kg ketamine (+25%) 
and 10mg/kg ketamine (+33%), but the changes in spike-gamma LFP correlation  to the 
maximum wire were more sizable after 10mg/kg ketamine (+109%) than after 5mg/kg 
ketamine (+35%). 
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Figure 3.10. 10mg/kg ketamine has more consistent effects on the spiking of mPFC pyramidal neurons than 
5mg/kg ketamine.Bar graphs show the effects of ketamine dose on the firing rate of putative pyramidal 
neurons in the mPFC (left),  and the spike-LFP relationship of single neurons to the gamma band using the 
mean STWA ratio from 40-59Hz calculated from the LFP on the recording  wire (middle), and to the 
maximum wire (right, n= 49 neurons). STWA ratios are the ratio of the peak-to-trough amplitude of the 
unshuffled STWA/shuffled STWA of mPFC spike trains to mPFC LFPs. Spike trains were shuffled 20 
times. Values are reported as percentage or mean ± SEM. **:p<0.01, ***:p<0.001, repeated measures one-
way ANOVA followed by Holm-Sidak’s multiple comparison test. 
 
3.3.5 Effects of anesthetic doses of ketamine 
3.3.5.1 Dosage effects on gamma power 
At high doses, ketamine is used as an analgesic and anesthetic in animals and 
children (Lodge and Mercier, 2015). We next examined an ataxia-inducing dose of 100 
mg/kg ketamine to determine the effect of a high dose of ketamine on gamma power and 
further investigate the connection between motor activity and gamma power. Although 
100mg/kg ketamine induced severe ataxia by 10 min after injection, this dose induced a 
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robust increase in low gamma power (peak between 40-70Hz ±7Hz) in the mPFC 
(+277%) compared to baseline (p<0.01, Holm-Sidak’s multiple comparisons, Fig 3.11A). 
Intriguingly, one rat became fully ataxic after 100mg/kg ketamine, but showed less than a 
20% increase in mPFC gamma power. The gamma peak frequency of 46.9±1.3Hz was 
not significantly different from baseline but lower than the peak frequencies observed 
after both 5mg/kg and 10mg/kg ketamine (p<0.001, Holm-Sidak’s multiple comparisons; 
Fig 3.9D). 100mg/kg ketamine also doubled gamma power in the high gamma range (70-
120Hz, p<0.05, Tukey’s multiple comparisons). Subsequent administration of the α2a 
adrenergic agonist and muscle relaxant medetomidine eliminated the gamma peak while 
deeply anesthetizing the rat (Fig 3.11A&C). Five minutes after administration of 
medetomidine mPFC power had increased over 400% in both the theta (4-8Hz) and alpha 
(8-12Hz) frequency ranges compared to baseline (both p<0.001, Tukey’s multiple 
comparisons).  
Although 100mg/kg ketamine appeared to increase gamma power in the MD 
thalamus more than 10mg/kg ketamine (+101% vs. +24%); this increase was not 
significant, perhaps because fewer animals could be included in the analysis (n=5, 
p>0.05, Tukey’s multiple comparisons, Fig 3.11B). Successive administration of 
medetomidine increased gamma power by 130% compared to baseline (p<0.05, Tukey’s 
multiple comparisons, Fig 3.11C). A dose of 100mg/kg ketamine more than doubled 
gamma power in the high gamma range (70-120Hz) in the MD thalamus (p<0.05, 
Tukey’s multiple comparisons, Fig 3.11D), and high gamma power remained elevated 5 
minutes after medetomidine administration (+66% of baseline high gamma power, 
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p<0.05, Tukey’s multiple comparisons, Fig 3.11D). As in the mPFC, medetomidine 
increased MD thalamus power ~400% in both the theta (4-8Hz) and alpha (8-12Hz) 
frequency range compared to baseline (both p<0.001, Tukey’s multiple comparisons). 
These observations reveal a lack of correlation between motor activity and increased 
gamma LFP power after ketamine administration. They also reveal a strong correlation 
between low frequency power and anesthesia. 
 
Figure 3.11. Ataxia-inducing doses of ketamine increase gamma power, and subsequent 
medetomidine eliminates the induced gamma peak. Averaged LFP power spectra in the mPFC (n= 8 
rats, A) and MD thalamus (n=5 rats, B) during untreated treadmill walking,  10 minutes after 100mg/kg 
ketamine (green), and 5 minutes after subsequent 0.15mg medetomidine administration (blue). Colored 
shadows indicate SEM. Legend appears at the right. C, Low gamma power (peak between 40 and 70 Hz 
±7Hz) in the mPFC (left) and MD thalamus (right) at time points from A-B. D, High gamma power (70-
120Hz) in the MD thalamus at time points from A-B. E, Average firing rates of neurons in the mPFC and 
MD thalamus at time points from A-B. Values are reported as percentage or mean ± SEM. *:p<0.05, 
**:p<0.01, ***:p<0.001, repeated measures one-way ANOVA followed by Holm-Sidak’s multiple 
comparison test. 
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3.3.5.2 Dosage effects on neuronal correlates 
To gain further insight into neural correlates associated with changes in gamma 
oscillations after high doses of ketamine and anesthesia, we examined the firing rates of 
neurons from the mPFC and MD thalamus. In the mPFC, 100mg/kg ketamine increased 
the average firing rates of pyramidal neurons by 49% compared to baseline, and 
subsequent medetomidine administration decreased the average firing rates of pyramidal 
neurons by 36% compared to baseline (n=48, both p<0.05, Tukey’s multiple comparisons 
test, Fig 3.11E). In the MD thalamus, unlike after 10mg/kg ketamine, 100mg/kg ketamine 
did not decrease the average firing rates of neurons (p>0.05, Tukey’s multiple 
comparison’s test). However, successive medetomidine administration decreased average 
firing rates by 70% compared to baseline (p<0.001, Tukey’s multiple comparisons test).  
Taken together, these results indicate that medetomidine greatly decreases the spiking 
activity of neurons in multiple brain regions, and this may be related to its anesthetic 
properties. 
Next, we examined the relationship between spikes and gamma oscillations in the 
mPFC using STWAs. Again, we used the LFP from the wire on which the spike train was 
recorded, as well as the maximum and median wire. In every combination of spike trains 
and wires, the mean STWA ratios significantly increased after 100mg/kg ketamine, and 
decreased after 0.15mg medetomidine (all p<0.01, Holm-Sidak’s multiple comparisons, 
Fig 3.12A). The spike-gamma LFP correlation with ketamine and medetomidine together 
was still higher than baseline in every combination of spike trains and wires (all p<0.01, 
Holm-Sidak’s multiple comparisons, Fig 3.12A). Specifically, when referenced to the 
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recording wire, 66% of putative pyramidal neurons were significantly correlated to the 
gamma-filtered LFP (40-59Hz) at baseline. This percentage increased to 91% after 
100mg/kg ketamine, and 72% after ketamine and medetomidine together (p<0.01, Chi-
Square test). Similarly, the spike-gamma LFP correlation increased by 155% after 
100mg/kg ketamine compared to baseline, then decreased by 41% after 0.15mg 
medetomidine ( p<0.01, n= 48, Holm-Sidak’s multiple comparisons). Nevertheless, while 
the animal was anesthetized with 100mg/kg ketamine and 0.15mg medetomidine the 
spike-gamma LFP correlation was still 49% higher than at baseline, even though the low 
gamma power was not significantly different between these conditions. When referenced 
to the maximum wire, 42% of putative pyramidal neurons were significantly correlated to 
the gamma-filtered LFP (40-59Hz) at baseline. This percentage increased to 85% after 
100mg/kg ketamine (a 202% increase in mean STWA ratio), and 69% after ketamine and 
medetomidine together (a 38% decrease in mean STWA ratio, all p<0.01, Chi-Square 
test, Holm-Sidak’s multiple comparisons, Fig 3.12A). Still, the spike-gamma LFP 
correlation was 86% higher than baseline when the animal was anesthetized with 
100mg/kg ketamine and 0.15mg medetomidine (p<0.01, Holm-Sidak’s multiple 
comparisons). Only 17% of putative pyramidal neurons were significantly correlated to 
the gamma-filtered LFP (40-59Hz) from the median wire at baseline. This percentage 
increased to 75% after 100mg/kg ketamine, and 58% after ketamine and medetomidine 
together (p<0.001, Chi-square test). Similarly, the spike-gamma LFP correlation 
increased by 227% after 100mg/kg ketamine compared to baseline, and then decreased 
by 38% after 0.15mg medetomidine (p<0.01, n=48, Holm-Sidak’s multiple comparisons, 
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Fig 3.12A). Nevertheless, while the animal was anesthetized with 100mg/kg ketamine 
and 0.15mg medetomidine the spike-gamma LFP correlation was still 104% higher than 
at baseline. Overall, these findings reveal greater ketamine-induced increases in spike-
gamma LFP correlation across a broader spatial scale than a narrower spatial scale 
because increases were more pronounced when referenced to a median wire rather than 
the recording wire. 
Next, we examined the relationship between spikes and gamma oscillations in the 
MD thalamus during anesthesia.  With both 100mg/kg ketamine, and subsequent 0.15mg 
medetomidine the spike-gamma LFP correlations were significantly reduced compared to 
baseline when referenced to the recording, or maximum wire (all p<0.05, Holm-Sidak’s 
multiple comparisons), but not the median wire (both p>0.05, Holm-Sidak’s multiple 
comparisons), perhaps because baseline spike-gamma LFP correlations were so low in 
the median wire. Specifically, when referenced to the recording wire, 88% of neurons 
were significantly correlated to the gamma-filtered LFP (40-59Hz) at baseline. This 
percentage decreased to 72% after 100mg/kg ketamine, and 59% after subsequent 
administration of medetomidine (p<0.01, Chi-Square test). Similarly, the spike-gamma 
LFP correlation decreased by 38% after 100mg/kg ketamine compared to baseline 
(p<0.001, n=32), but were not significantly affected by subsequent injection of 0.15mg 
medetomidine (+14%, p>0.05, Holm-Sidak’s multiple comparisons, Fig 3.12A). 
Nonetheless, while the animal was anesthetized with 100mg/kg ketamine and 0.15mg 
medetomidine the spike-gamma LFP correlation was 29% lower than at baseline 
(p<0.01), even though the power in the low gamma frequency range was greater than at 
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baseline. When referenced to the maximum wire or the median wire, the percentage of 
neurons significantly correlated to the gamma-filtered LFP (40-59Hz) at baseline did not 
change significantly (p>0.05, Chi-square test,Fig 3.12A). However, the spike-gamma 
LFP correlation decreased by 38% after 100mg/kg ketamine compared to baseline when 
referenced to the maximum wire (p<0.01, Holm-Sidak’s multiple comparisons), but was 
not significantly affected by subsequent injection of 0.15mg medetomidine (+19%, 
p>0.05, n= 32, Holm-Sidak’s multiple comparisons). Furthermore, while the animal was 
anesthetized with 100mg/kg ketamine and 0.15mg medetomidine together the spike-
gamma LFP correlation was still 25% lower than at baseline (p<0.05). Lastly, there were 
no significant differences in the spike-gamma LFP correlations when referenced to the 
median wire (p>0.05, n= 32, Holm-Sidak’s multiple comparisons, Fig 3.12A). Taken 
together, these data show a striking spatial decay in gamma oscillations in the MD 
thalamus. This provides evidence that individual spikes may cause a short resonant 
oscillation at gamma frequencies, but for the most part, gamma oscillations are not 
emanating from local circuits in this region. 
Finally, we examined the spike-LFP correlations to high gamma oscillations 
between 70-115Hz in the MD thalamus since there is a spectral “bump” in this range. As 
observed in the low gamma range, there were no significant differences in the spike-
gamma LFP correlations referenced to the median wire. In contrast, significant decreases 
in spike-high gamma LFP correlation were observed when referenced to the recording 
wire and the wire with maximum coherence (all p<0.05, n= 32, Holm-Sidak’s multiple 
comparisons, Fig 3.12B). Specifically, when referenced to the recording wire, 94% of 
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neurons were significantly correlated at baseline. This percentage decreased to 72% and 
53% after 100mg/kg ketamine and 0.15mg medetomidine respectively (p<0.01, Chi-
square test). Additionally, the spike-high gamma LFP correlation decreased from baseline 
(mean STWA ratio: 5.33 ± 0.48) by 38% after 100mg/kg ketamine (mean STWA ratio: 
3.30 ± 0.31) and decreased from baseline 29% during ketamine and medetomidine 
induced anesthesia (mean STWA ratio: 3.76 ± 0.50) when referenced to the recording 
wire (both p<0.01, n=32, Holm-Sidak’s multiple comparisons). When referenced to the 
wire with the maximum coherence, there was no significant difference in the percentage 
of neurons significantly correlated to the high gamma filtered LFP (p>0.05, Chi-square 
test). Examining spike-high gamma LFP correlations using mean STWA ratios increases 
the accuracy of differences examined and gives greater statistical power. When 
referenced to the wire with the maximum coherence in the 70-115Hz range, the spike-
gamma LFP correlation decreased from baseline (mean STWA ratio: 3.19 ± 0.40) by 
37% after 100mg/kg ketamine (mean STWA ratio: 1.98 ± 0.22), and decreased from 
baseline 26% after 100mg/kg ketamine and 0.15mg medetomidine together (mean STWA 
ratio: 2.37 ± 0.30, both p<0.05, Holm-Sidak’s multiple comparisons, Fig 3.12B). Taken 
together, ketamine has the greatest influence on spike-LFP correlations to gamma when 
referenced to the recording wire in the MD thalamus and the median wire in the mPFC.  
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Figure 3.12. Comparison of recording wires to neighboring wires in the mPFC and MD thalamus 
reveal different spatial relationships in each structure.A, The percentage of neurons significantly 
correlated to low gamma oscillations (40-59Hz, left) from the mPFC (top) and the MD thalamus (bottom), 
when the spike train was referenced to the recording wire (same, blue), maximum (purple) and median 
(coral) wires  (see Section 3.2.7) 10 minutes after 100mg/kg ketamine (ketamine) or 5 minutes after 
subsequent administration of medetomidine (medetomidine). Mean ratios (right) between peak to trough 
amplitudes of the original STWA and the mean of 20 shuffled STWAs for LFPs filtered from 40-59Hz 
recorded from the same wire, maximum, or median wire for putative mPFC pyramidal neurons (top) and 
MD thalamus neurons (bottom). B, Same as in A except the spike trains were referenced to LFPs filtered 
in the high gamma range (70-115Hz). A bar with significance stars over it indicates that this bar is 
significantly different from all the other conditions. A ratio of 1 (dashed horizontal line) indicates no 
difference between shuffled and unshuffled values.  Values are reported as percentage or mean ±SEM. 
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*:p<0.05, **:p<0.01, ***:p<0.001, repeated-measures one-way ANOVA with Holm-Sidak’s multiple 
comparisons test, $:p<0.1, ##:p<0.01, ###:p<0.001, chi-square test. 
3.3.6 Effects of the D4R agonist on gamma power 
Dopamine D4R agonists concurrently increase gamma power and cognitive 
performance in normal animals (Nakazawa et al., 2015) and D4R antagonists reverse 
cognitive deficits induced by chronic NMDAR antagonism (Arnsten et al., 2000). As it 
has been suggested that a drug’s ability to modulate ketamine-induced increases in 
gamma power reflects its therapeutic potential (Jones et al., 2012), we were interested in 
exploring the effects of these D4R-targeting drugs on ketamine-induced increases in 
gamma activity during treadmill walking in the mPFC and MD thalamus.  
To examine the effect of the D4R agonist A-412997 on gamma power during 
treadmill walking in the absence of ketamine, either three ascending doses or three 
vehicle injections were administered 30 minutes apart followed by a 5mg/kg dose of the 
D4R antagonist L-745,870 (see Section 3.2.5). In the mPFC, a cumulative dose of 
1.5mg/kg A-412997 induced a modest but significant 12.1±2.4% increase in gamma 
power (p<0.05, Holm-Sidak’s multiple comparisons; Fig 3.14A). This was not further 
increased by a subsequent 1.5mg/kg injection (p>0.05, Holm-Sidak’s multiple 
comparisons). Indeed a cumulative dose of 3mg/kg A-412997 increased gamma power by 
11.2±1.8% compared to baseline (p<0.05, Holm-Sidak’s multiple comparisons; Fig 3.13). 
Likewise, in the MD thalamus, the cumulative dose of 3mg/kg A-412997 increased 
gamma power by 9.4±5.5% (p<0.05), but the other doses had no significant effect 
(p>0.05, Holm-Sidak’s multiple comparisons; Fig 3.14C). These increases in gamma 
power were reduced by the D4R antagonist in the mPFC (-8.9%, p<0.05, paired t-test; 
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Fig 3.13& 3.14A, and the MD thalamus (-8.8%, p<0.05, paired t-test; Fig 3.14C). 
However, the D4R antagonist did not significantly change gamma power after vehicle 
injections (p>0.05, paired t-tests; Fig 3.14&C). These results are consistent with previous 
findings showing an increase in gamma power with D4R agonists (Kocsis et al., 2014), 
and indicate that walking-induced gamma oscillations are not dependent on D4R activity.  
 
 
Figure 3.13. D4R agonists increase gamma power and D4R antagonists reverse this effect.Averaged 
LFP power spectra for the mPFC (left) and MD thalamus (right), during treadmill walking at baseline 
(black), 15 minutes after a cumulative dose of 3mg/kg A-412997(blue), and 15 minutes after a subsequent 
dose of 5mg/kg L745870 (purple). Colored shadows indicate SEM. 
3.3.7 The D4R agonist and antagonist influence ketamine-induced neurophysiological 
changes 
We next assessed the effects of the D4R agonist (3mg/kg A-412997) and 
antagonist (5mg/kg L-745,870) administered 30 minutes before a ketamine injection on 
ketamine-induced behaviors and gamma power. Neither the D4R agonist nor the D4R 
antagonist had significant influences on measures of attentiveness, hyperactivity, 
stereotypic behaviors, or ataxia after ketamine injection while the treadmill was off or on 
(all p>0.05, one-way ANOVA, n=12 rats). Moreover, in the mPFC, the D4R 
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pretreatments neither influenced the low gamma power (peak between 40 and 70Hz 
±7Hz) 15 minutes after ketamine administration, nor influenced the time course of 
gamma power recovery (p>0.05, RM two-way ANOVA; Fig 3.14E-F). In contrast, in the 
MD thalamus ketamine-induced increases in gamma power were enhanced by the D4R 
agonist pretreatment as compared to the saline pretreatment (Fig 3.14G-H). Fifteen 
minutes after the ketamine injection, low gamma power had increased by an average of 
86.1±20.2% after the D4R agonist pretreatment as compared to 36.9±14.8% after saline 
pretreatment (p<0.001, Tukey’s multiple comparisons; Fig 3.14G-H) . Similarly, 35 
minutes after the ketamine injection, low gamma power had increased by an average of 
37.3±16.1% after the D4R agonist pretreatment as compared to 11.9±8.8% after saline 
pretreatment (p<0.05, Tukey’s multiple comparisons; Fig 3.14H). The D4R antagonist 
neither influenced low gamma power nor the time course of recovery after ketamine 
(both p>0.05, RM two-way ANOVA; Fig 3.14E-H). Taken together, these data show that 
the D4R pretreatments influence ketamine-induced gamma power in the MD thalamus, 
but not the mPFC. 
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Figure 3.14. Effects of the dopamine D4 receptor agonist and antagonist on gamma power in the 
presence and absence of ketamine.Gamma power during treadmill walking in the mPFC (A,B,E,F) and 
MD thalamus (C,D,G,H). (A&C) Percent change in gamma power (peak between 40-70Hz ±7Hz) in rats 
without ketamine treatments. Black arrows indicate injections of saline (black curve) or A-412997, the 
D4R agonist, injected at 0.3mg/kg at the 1
st
 arrow, 1.2mg/kg at the 2
nd
 arrow, and 1.5mg/kg at the 3
rd
 arrow 
(blue curve). The cumulative dose was 3mg/kg A-412997. The red arrow indicates an injection of 5mg/kg 
L-745,870, the D4R antagonist. Red curve shows the effect of the antagonist after saline and purple curve 
indicates the effect of the antagonist after the agonist (n=6 rats). B, D, Averaged LFP power spectra in the 
mPFC (B) and MD thalamus (D) at baseline (black) and 15 minutes after 10mg/kg ketamine (green) with 
saline injection 30 minutes prior (n=6 rats). Colored shadows indicate SEM. E, G, Average percent change 
in LFP power spectra from baseline walking power 15 minutes after 10mg/kg ketamine for each frequency 
in the mPFC (C) and MD thalamus (G). The red trace indicates pretreatment with the antagonist (5mg/kg 
L-745,870), the blue trace indicates the pretreatment with the agonist (3mg/kg A-412997), and the black 
trace indicates the pretreatment with saline. F,H, Changes in low gamma (peak between 40-70Hz± 7Hz) 
power in the mPFC (F) and MD thalamus (H) over time. Data is presented as percent change from the 
rats’s baseline walking power on the recording day. The black arrow indicates the injection of the 
pretreatment (D4R agonist and antagonist or saline), and the green arrow indicates the injection of 10mg/kg 
ketamine. Blue stars indicate a significant change from saline pretreatment with the agonist (n=6 rats). The 
frequency range of the gamma power was determined by finding the frequency of the maximum gamma 
peak between 40 and 70Hz in each epoch and summing power from the surrounding 15Hz range. Values 
are reported as percentage ±SEM. *: p<0.05, **: p<0.01, ***: p<0.001, two-way repeated measures 
ANOVA with Tukey’s multiple comparisons. $: p<0.05, $$$: p<0.001, significant difference from vehicle 
injections, Holm-Sidak’s multiple comparisons test; #: p<0.05, paired t-test comparing percent change in 
power 15 minutes after 3mg/kg A-412997 and 35 minutes after 5mg/kg L-745,870. 
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To assess whether the D4R agonist and antagonist influenced ketamine-induced 
changes in firing rate, we examined neurons in the mPFC and MD thalamus after each 
pretreatment. As described above, ketamine increased firing rates in the mPFC and 
decreased firing rates in the MD thalamus (Fig 3.5B). In mPFC pyramidal neurons, no 
significant differences in ketamine-induced increases in firing rates were observed 
between pretreatments with saline, the D4R agonist, or the D4R antagonist (p>0.05, one-
way ANOVA; Fig 3.15A). Only 6 mPFC interneurons were recorded after any of the 
three pretreatments, so they were not analyzed further. Interestingly, in the MD thalamus, 
the D4R agonist pretreatment attenuated the ketamine-induced decrease in neuronal firing 
rates (p>0.05, RM one-way ANOVA; Fig 3.15B). In contrast, ketamine still reduced the 
firing rates of MD thalamus neurons by 2.1±0.6Hz after saline pretreatment and 
2.2±0.7Hz after the D4R antagonist pretreatment (both p<0.01, Holm-Sidak’s multiple 
comparisons; Fig 3.15B). Likewise, both the saline pretreatment and the D4R antagonist 
pretreatment alone induced a modest yet significant decrease in the MD thalamus 
neuronal firing rate of 0.4±0.2Hz (both p<0.05), but the D4R agonist alone does not 
(p>0.05, Holm-Sidak’s multiple comparisons; Fig 3.15B). Overall, the D4R 
pretreatments had no effect on ketamine-induced changes in firing rate in the mPFC, but 
the D4R agonist modified firing rates before and after ketamine in the MD thalamus.  
The D4R pretreatments had no obvious effect on spike- gamma LFP correlations 
referenced to the same wire in the mPFC or the MD thalamus. As described above, 
ketamine increased spike-gamma LFP correlations in the mPFC and decreased spike-
gamma LFP correlations in the MD thalamus (Fig 3.6). In the mPFC, the D4R-targeting 
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pretreatments neither influenced ketamine-induced increases in spike-gamma LFP 
correlation, nor influenced spike-gamma LFP correlation per se (both p>0.05, one-way 
ANOVAs; Fig 3.15C). Furthermore, in the MD thalamus, none of the pretreatments 
influenced ketamine-induced decreases in spike-gamma LFP correlation, or affected 
spike-gamma LFP correlation per se (both p>0.05, one-way ANOVA; Fig 3.15D). Taken 
together, these data suggest that the D4R agonist may influence the effect of ketamine on 
gamma power and firing rates in the MD thalamus without influencing relationships 
between individual neurons and gamma oscillations.  
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Figure 3.15. Effects of dopamine D4R agonist and antagonist on ketamine induced changes in single 
neuron activity.A-B, Firing rates of putative pyramidal neurons in the mPFC (A) and neurons in the MD 
thalamus (B) at baseline (black), 15 minutes after the pretreatment injection (solid color), and 15 minutes 
after 10mg/kg ketamine (striped) with saline pretreatment (white, mPFC: n=47 neurons from 6 rats, MD 
thalamus: n=39 neurons from 6 rats), the antagonist pretreatment, L-745,870 (5mg/kg, s.c., red, mPFC: 
n=34 neurons from 6 rats, MD thalamus: n=36 neurons from 6 rats), or the agonist pretreatment, A-412997 
(3mg/kg, s.c., blue, mPFC: n= 42 neurons from 6 rats, MD thalamus: n= 32 neurons from 6 rats). C-D, 
Mean ratios between peak to trough amplitudes of the original STWA and the mean of 20 shuffled STWAs 
for LFPs filtered from 40-59Hz recorded from the same wire in the mPFC (C) and MD thalamus (D). There 
were no significant differences between pretreatment groups on ketamine-induced firing rates or spike-LFP 
correlations (p>0.05, one-way ANOVAs). Values are reported as mean ± SEM. *:p<0.05, **:p<0.01, 
***:p<0.001, repeated measures one-way ANOVAs were used for each pretreatment group followed by 
Holm-Sidak’s multiple comparisons test. 
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3.4 Discussion 
In the current study, subanesthetic doses of ketamine were administered to rats to 
examine the relationships between increases in gamma power and spiking activity in 
mPFC and MD thalamus. Ketamine induced a striking increase in gamma power in both 
structuResearch Ketamine also increased the firing rate and correlation between mPFC 
spiking and gamma oscillations. In contrast, in the MD thalamus, ketamine reduced the 
firing rate and correlation between spiking and gamma oscillations. As ketamine-induced 
increases in gamma power, firing rate, and spike-LFP correlation in the mPFC were 
observed in conjunction with an increase in motor activity, the effects of increases in 
motor activity induced by treadmill walking were examined. Treadmill walking alone 
also increased gamma power in both mPFC and MD thalamus, but to a lesser extent than 
ketamine administration and these effects were not additive. In the mPFC, walking 
concurrently increased the firing rates of pyramidal neurons and interneurons and 
increased synchronization between pyramidal neuron spikes and gamma oscillations. 
Moreover, unlike the effect of ketamine in the MD thalamus, walking concurrently 
increased the firing rate and synchronization between spikes and gamma oscillations, 
suggesting a different circuit is responsible for increasing thalamic gamma power 
induced by walking compared to ketamine. 
Dopamine D4R-targeting drugs may have potential for treating cognitive deficits 
in schizophrenia (Furth et al., 2013). As it has been proposed that a drug’s ability to 
modulate gamma power might reflect its therapeutic potential (Anderson et al., 2014; 
Celada et al., 2013; Hudson et al., 2016; Jones et al., 2014; Ma and Leung, 2014), we 
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examined the effects of these D4R-targeting drugs on ketamine-induced gamma activity. 
Neither the D4R agonist nor antagonist significantly influenced ketamine-induced 
gamma oscillations or firing rates in the mPFC. However, in the MD thalamus, the D4R 
agonist increased ketamine-induced gamma and modified neuronal firing rates. 
3.4.1 Neurophysiological correlates of ketamine and locomotion 
Many studies have used ketamine to gain further insight into schizophrenia and 
the treatment of depression (Lodge and Mercier, 2015). In clinical experiments low doses 
of the NMDAR antagonist ketamine (~15% of the anesthetic dose) increase cortical 
gamma power while inducing symptoms of early stage schizophrenia (Anticevic et al., 
2015; Corlett et al., 2013; Driesen et al., 2013b; Krystal et al., 1994; Stone et al., 2008, 
2012). Interestingly, long-term, but not acute treatment with neuroleptics decreases 
ketamine-induced positive and cognitive symptoms in healthy human volunteers (Krystal 
et al., 1999; Lipschitz et al., 1997; Malhotra et al., 1997). Likewise, in rodents, low doses 
of ketamine (~15% of the anesthetic dose) increase cortical gamma power and motor 
activity (Ehrlichman et al., 2009; Kulikova et al., 2012; Lazarewicz et al., 2009; Meltzer 
et al., 2013; Nikiforuk et al., 2016; Pinault, 2008; Saunders et al., 2012; Shaffer et al., 
2014), and long-term, but not acute treatment with neuroleptics decreases ketamine-
induced increases in gamma power and motor activity (Anderson et al., 2014; Jones et al., 
2012). While the circuit by which NMDAR antagonists increase gamma power is still 
mysterious, it is likely that gamma power increases by increases in fast AMPAR-
mediated currents relative to slower NMDAR-mediated currents (Maeng et al., 2008). 
Three pieces of evidence support this idea. (1) Inhibiting NR2A-expressing NMDARs 
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leads to increases in both extracellular glutamate and gamma power (Jiménez-Sánchez et 
al., 2014; Kocsis, 2012) that are not seen when NR2B is inhibited. (2) Ketamine no 
longer increases gamma power when AMPARs are inhibited (Zanos et al., 2016).  (3) 
D4R activation reduces NMDAR-mediated currents more than AMPAR currents (Furth 
et al., 2013), and the effects of D4R activation are occluded by ketamine administration. 
Interestingly, in the MD thalamus, AMPAR expression is low compared to NMDAR 
expression (Salt and Eaton, 1996), while in the cortex AMPA currents predominate 
glutamatergic signaling (Rotaru et al., 2011). This may help explain why ketamine has 
opposite effects on the MD thalamus and mPFC at the single neuron level. 
Notably, ketamine is currently used to rapidly treat depression and reduce suicidal 
idealization resistant to antidepressant treatment at the same doses that that are used to 
induce psychomimetic symptoms in healthy volunteers (Abdallah et al., 2015; Berman et 
al., 2000; Zanos et al., 2016). A recent study implicates (2R,6R)-hydroxynorketamine 
(HNK), a ketamine metabolite, as mediating the acute antidepressant effects of ketamine. 
(2R,6R)-HNK still induces increases in gamma power, but without increasing motor 
activity (Zanos et al., 2016). Increasing evidence suggests that effects of ketamine on 
gamma oscillation power are independent from its antidepressant-like effects. First, other 
NMDAR antagonists, such as MK-801 and PCP increase gamma power without exerting 
antidepressant effects (Autry et al., 2011; Zanos et al., 2016). Second, NR2B antagonists 
alone recapitulate ketamine’s antidepressant effects without altering gamma power or 
extracellular glutamate  in vivo (Jiménez-Sánchez et al., 2014; Kocsis, 2012; Li et al., 
2010; Miller et al., 2016). 
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One recent study suggests that the effects of ketamine on evoked gamma 
oscillations have more predictive power for potential therapeutics than ketamine’s effects 
on ongoing gamma oscillations (Hudson et al., 2016). Given that ketamine induced 
similar increases in gamma power whether the rat was walking, or in the stationary 
treadmill, it is likely that ketamine-induced gamma oscillations during treadmill walking 
better reflect ongoing gamma oscillations than evoked gamma oscillations, although 
more work is needed. Even though we did not examine behavioral correlates of 
schizophrenia, we observed that rats avoided colliding with the paddle within the 
treadmill more effectively after 10mg/kg ketamine, suggesting that gamma power and 
attention are correlated even when induced by ketamine. This confirmed a recent study 
showing that ketamine increases attention in young rodents (Guidi et al., 2015). 
The present study provides two lines of evidence supporting the hypothesis that 
walking and ketamine induced gamma oscillations in the mPFC are locally generated by 
a common pyramidal-interneuron generated gamma (PING) circuit (Cannon et al., 2014; 
Jadi et al., 2015). While power in both low (40-70Hz) and high (70-120Hz) gamma 
ranges increased after ketamine administration, only the increase in low gamma power 
around the significant spectral peak was dose-dependent, and this peak frequency 
(~55Hz) was similar to that observed during the gamma generated by locomotion 
(~51Hz). This confirmed previous work from our lab and others that has shown increases 
in gamma LFP power in the rodent  mPFC and visual cortex during locomotion 
(Delaville et al., 2015; Niell and Stryker, 2010) and arousal (McGinley et al., 2015a; 
Vinck et al., 2015). This finely tuned increase in gamma activity could reflect activity in 
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a local circuit with precise temporal dynamics, such as a PING circuit (Womelsdorf et al., 
2014). The second line of evidence involved measuring synchronization through 
investigation of the peak-to-trough amplitudes of spike triggered waveform averages 
(STWAs). Traditionally, STWAs are thought to reveal relationships between 
postsynaptic currents that generate a spike or local resonance produced by a spike 
(Einevoll et al., 2013; Moca et al., 2014; Reimann et al., 2013). They may also reveal 
network oscillations that bias spike timing (Ray, 2015). As observed in the visual cortex 
(Munk et al., 1996; Vinck et al., 2015),  mPFC pyramidal neurons showed increased 
spiking synchronization to gamma oscillations during walking epochs concurrent with 
increases in gamma power, as would be expected in a circuit where power is enhanced by 
the rhythmic activation of pyramidal neurons (Lee and Jones, 2013). On a cautionary 
note, though interneurons did not show increased spiking synchronization to gamma 
oscillations during walking, as might be predicted in a PING model.  
Other evidence suggests a more complex mechanism of gamma generation after 
ketamine administration than PING. Acute application of NMDAR antagonists increase 
gamma power, increase the firing rates of pyramidal neurons, but decrease the firing rates 
of interneurons over a similar time course (Homayoun and Moghaddam, 2007a; Jackson 
et al., 2004; for a review, see Miller et al., 2016). In order for the disinhibition of 
pyramidal neurons to directly increase gamma power, one would expect these neurons to 
exhibit synchronization with gamma oscillations. In agreement with this, our results 
showed that 5 and 10mg/kg ketamine each increased the firing rates and spike-gamma 
LFP correlations of mPFC pyramidal neurons. However, the magnitude of these increases 
  
152 
was not proportional. While pyramidal neurons showed similar increases in firing rate 
induced by ketamine or walking (33% vs. 11%), increases in gamma power induced by 
ketamine were substantially larger than those induced by walking in the mPFC (254% vs. 
23.8%). Wood and colleagues (2012) also observed a lower correlation between firing 
rates and gamma power in the frontal cortex after administration of the NMDAR 
antagonist MK-801 than before. This would suggest that mechanisms generating gamma 
power differ when gamma power is induced by NMDAR antagonism rather than 
locomotion. In untreated humans, spike-gamma LFP correlations tend to be high when 
neuronal spiking becomes synchronized (Nir et al., 2007); however, MK-801 treatment in 
rats desynchronizes spiking while increasing gamma power in the prefrontal cortex 
(Molina et al., 2014). Thus, the relationship between the pyramidal neuron firing rate and 
abnormal gamma power after ketamine administration remains complex.  
We observed that ketamine significantly increased gamma oscillations in the MD 
thalamus, comparable to increases observed in the rodent ventrolateral thalamus of 
rodents (Hakami et al., 2009), and human thalamus (Rivolta et al., 2015). Increases in 
gamma in the MD thalamus emerged over a broader range than in the mPFC, with two 
spectral peaks, centered at 55Hz and 81Hz. Although mPFC and MD thalamus are 
reciprocally connected (Mitchell and Chakraborty, 2013) and both show spectral peaks 
around 55Hz, we neither observed gamma frequency coherence between these structures, 
nor observed spiking synchronized to gamma oscillations between these structuResearch 
This confirms a finding in healthy humans that ketamine administration did not 
significantly alter prefrontal-MD thalamus functional connectivity (Höflich et al., 2015), 
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although ketamine appears to increase thalamocortical connectivity using different 
measures (Anticevic et al., 2015; Dawson et al., 2013; Driesen et al., 2013a). 
Furthermore, acute NMDAR antagonists administered in the MD thalamus induced 
increases in the delta (0-4Hz) range LFP of the mPFC similar to those induced by 
systemic administration (Kiss et al., 2011a). Contrary to effects seen in the mPFC, 
ketamine simultaneously decreased firing rates and reduced correlations between spikes 
and gamma oscillations in both gamma ranges in the MD thalamus, suggesting that 
gamma power in the MD thalamus may be driven by external inputs rather than locally 
generated resonance (Buzsáki et al., 2012; Kezunovic et al., 2012).  
Spike trains from mPFC pyramidal neurons as well as MD thalamus neurons 
show increased synchronization to gamma range oscillations during walking when spikes 
were referenced to the recording wire. However, this was not observed when MD 
thalamus neurons were referenced to a neighboring wire. One explanation for these 
results is that the LFP around the MD thalamus neurons is more localized than that 
around the mPFC pyramidal neurons (Buzsáki et al., 2012; Reimann et al., 2013). After 
ketamine administration, mPFC pyramidal neurons showed increased synchronization to 
gamma oscillations when referenced to the recording wire or a neighboring wire. This 
suggests that the relationship between spiking activity and gamma is spatially localized in 
walking-induced gamma (Sirota et al., 2008) and more widespread during ketamine-
induced gamma. 
The question remains: how does ketamine increase gamma power in the MD 
thalamus yet decrease the firing rates of neurons in this structure and decrease the 
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correlation between spikes and gamma power? A few possible explanations emerge. 
First, different types of glutamatergic innervation establish different types of anatomical 
connections with thalamic relay neurons (Sherman, 2013). Corticothalamic inputs may 
activate group I metabotropic glutamate receptors (mGluRs) to prolong EPSPs, 
inactivating T-type calcium channels and switching neurons from burst firing, which may 
be highly aligned with gamma oscillations, to tonic firing, which may not align with 
gamma oscillations (Sherman, 2013). Gamma power in this region would thus result from 
coordinated glutamatergic EPSPs, perhaps originating from the basal ganglia or 
amygdala, which both show a prominent increase in gamma power after ketamine 
administration (Hakami et al., 2009; Nicolás et al., 2011). 2) Second, thalamic output is 
sensitive to spatial and temporal dynamics. For instance, low frequency stimulation of 
corticothalamic afferents suppresses the spiking activity of thalamic relay neurons while 
high frequency stimulation of these afferents increases the spiking activity of thalamic 
relay neurons (Crandall et al., 2015). This occurs because monosynaptic excitatory 
corticothalamic input onto thalamic relay cells is relatively weak compared to robust 
disynaptic inhibition from thalamic reticular neurons. NMDA receptor mediated currents 
dominate the majority of excitatory corticothalamic inputs (Deleuze and Huguenard, 
2016), and are responsible for enhancing the excitability of thalamic relay neurons after 
high frequency stimulation (Crandall et al., 2015), supporting the direct hypothesis in the 
thalamus. Therefore, after inhibiting NMDA receptors in thalamic relay neurons, 
repetitive stimulation to these neurons would become inhibitory, further explaining why 
NMDA receptor antagonism decreases the firing rates of MD thalamus neurons. 
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Importantly, gamma oscillations in the barrel cortex induce rhythmic IPSCs in the ventral 
posterior medial nucleus, followed by rhythmic EPSCs (Crandall et al., 2015). With 
NMDA receptor-mediated currents blocked, it is likely that the switch from IPSCs to 
EPSCs never occurs. Thus the gamma power detected in the MD thalamus may simply 
arise from subthreshold currents within relay cells. Finally, it is important to note, that in 
contrast to our findings with ketamine the NMDA receptor antagonist PCP increases the 
spiking of the MD thalamus (Santana et al., 2011) via the preferential reduction in the 
activity of the thalamic reticular nucleus, the major source of inhibitory innervation to the 
MD thalamus (Troyano-Rodriguez et al., 2014). Under normal conditions, the average 
cell in the thalamic reticular nucleus is GABAergic and spikes 10 times faster than the 
average cell in the MD thalamus, which is glutamatergic (Troyano-Rodriguez et al., 
2014). PCP directly reduces the firing rate of thalamic reticular neurons to a greater 
extent than it reduces the firing rate relay neurons, lending support to the disinhibition 
hypothesis in the thalamus.  
 
3.4.2 Relevance of the D4R 
The dopamine D4 receptor (D4R) emerges as a potential target for enhancing 
cognition in psychiatric disorders due to the ability of D4R agonists to increase gamma 
power and cognitive performance (Andersson et al., 2012a, 2012b; Bernaerts and Tirelli, 
2003; Kocsis et al., 2014; Nakazawa et al., 2015; Nayak and Cassaday, 2003; Woolley et 
al., 2008). Interestingly, D4R antagonists have paradoxical promnesic effects at low 
doses (Zhang et al., 2004), but decrease task performance when co-administered with an 
antipsychotic (Murai et al., 2014). However, low doses of D4R antagonists reverse 
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working memory deficits induced by stress or chronic PCP administration in monkeys 
(Arnsten et al., 2000; Jentsch et al., 1999). Furthermore, humans with a subsensitive 
allelic variant of the D4R (D4.7) show abnormal gamma oscillatory activity during a task 
requiring attention (Demiralp et al., 2007), and are more likely to have ADHD (Swanson 
et al., 1998). These findings suggest that D4R activity is finely-tuned to promote optimal 
gamma oscillations and cognitive performance. 
While it has been suggested that basal levels of dopamine may activate D4Rs 
(Rosen et al., 2015b), our results showed that the D4R antagonist had little effect on 
gamma power or firing rates during treadmill walking in the mPFC or MD thalamus. 
However, as observed by Kocsis and colleagues (2014), a D4R agonist increased gamma 
power in both structuResearch Unlike during walking-induced gamma, during D4R 
agonist-induced gamma the correlation between mPFC pyramidal spikes and gamma 
oscillations did not increase, even though the increase in gamma power is similar (24% 
vs. 12%, respectively This may suggest that increases in gamma power after D4R 
activation arose from a different mechanism than walking-induced increases in gamma 
power, but could simply reflect the smaller change in power.  
As ketamine have been shown to increase extracellular dopamine in the cortex of 
rodents (Moghaddam et al., 1997), and the D4R has the highest affinity for dopamine of 
any dopaminergic receptor(Rondou et al., 2010), we predicted that D4Rs would be active 
after ketamine administration, and therefore the D4R antagonist would diminish 
ketamine’s effects on behavior or neurophysiological measures in the mPFC or MD 
thalamus. However, pretreatment with the D4R antagonist had little effect. In contrast, 
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pretreatment with the D4R agonist augmented ketamine’s effects on gamma power and 
reduced ketamine’s effects on firing rates in the MD thalamus. Other investigators have 
shown changes in cortical ketamine-induced gamma power using chronic pretreatment 
with antipsychotics, but not acute (Anderson et al., 2014; Jones et al., 2012, 2014). Thus, 
it remains to be seen whether chronic treatment with D4R-targeting drugs could reduce 
ketamine-induced gamma power.  
The D4R agonist had a greater effect on ketamine-induced gamma power in the 
MD thalamus than in the mPFC. These region specific differences could be explained by 
differences in D4R expression. Indeed, in the cortex (Mrzljak et al., 1996) and the 
hippocampus (Andersson et al., 2012b), D4R expression is highest in parvalbumin-
positive fast-spiking interneurons, but D4R is also sparsely expressed in pyramidal 
neurons (Mrzljak et al., 1996). Less D4Rs are found in the MD thalamus; however, the 
thalamic reticular nucleus, which inhibits dorsal thalamic nuclei, has high D4R 
expression (Ferrarelli and Tononi, 2011; Mrzljak et al., 1996), and inputs into the 
thalamus have presynaptic D4Rs (Gasca-Martinez et al., 2010; Govindaiah et al., 2010).  
3.4.3 Conclusion 
Ketamine increases cortical gamma power and produces cognitive impairments in 
healthy humans similar to the impairments observed in patients with schizophrenia (Hong 
et al., 2010; Krystal et al., 1994). Multiple psychotomimetic drugs and rodent models of 
schizophrenia increase cortical gamma power (Rosen et al., 2015a) and desynchronize 
spiking from oscillations (Wood et al., 2012). In contrast, our results show increased 
spike-gamma LFP correlations in the mPFC and decreased spike-gamma LFP 
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correlations in the MD thalamus. Our results show that gamma oscillations induced by 
walking and ketamine are similar in the mPFC, hinting at a common circuit underlying 
both oscillations. However, the differences in neuronal correlates of walking- and 
ketamine-induced gamma oscillations in the MD thalamus suggest that these oscillations 
arise from different mechanisms. Thus, walking-induced 51Hz gamma oscillations are 
more similar between the mPFC and MD thalamus, while ketamine-induced 55Hz 
gamma oscillations show region-specific differences. 
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CHAPTER FOUR: ErbB receptor signaling in vivo  
4.1 Introduction 
Patients with schizophrenia show deficits in neural oscillation activity and local 
synchrony in the mPFC (Sakurai et al., 2015; Spellman and Gordon, 2015). Furthermore, 
animal models of schizophrenia show impaired synchrony in the gamma frequency range 
(for example, Carlson et al., 2011; Goto and Grace, 2006), or impaired oscillatory 
coherence between the prefrontal cortex and other brain regions such as the hippocampus 
(for example, Sigurdsson et al., 2010). These animal models encompass multiple possible 
etiologies, including genetic manipulation, perinatal infection or stress, and 
pharmacological insults (Rosen et al., 2015a). Altered neural oscillations have been 
proposed as a potential endophenotype observed in both animal models and human 
patients (Spellman and Gordon, 2015). Often these altered oscillations are directly linked 
to behavioral deficits. For example, impaired thalamic-prefrontal  coherence correlates 
with deficits in working memory (Parnaudeau et al., 2013). Thus it is important to have 
better understanding of which neurotransmitter systems have a direct influence on 
gamma oscillation frequency and power.  
Neuregulin 1 and neuregulin 2 are neurotrophic factors that activate the tyrosine 
kinase of ErbB receptors (Buonanno, 2010). Exogenous neuregulin 1β increases kainate-
induced gamma oscillation power in hippocampal slices (Fisahn et al., 2009); however, 
this effect is not observed in the presence of the pan-ErbB antagonist PD158780, or in 
slices from full ErbB4 knockout mice (Fisahn et al., 2009). Additionally, over 50% of 
GABAergic PV+ interneurons, thought to be pivotal in the generation and maintenance 
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of gamma oscillations (Bartos et al., 2007), express ErbB4 receptors. These data make 
ErbB4 a likely candidate for the modulation of gamma oscillations. Moreover, in ErbB4 
knockout mice, PV+ interneuron expression is ~31% lower than in wildtype animals, and 
kainate-induced gamma oscillations have ~60% less power (Fisahn et al., 2009). 
Furthermore, while ErbB4 receptors are expressed in most types of interneurons in a 
layer specific and region specific manner, these receptors have very low expression in 
somatostatin or calbindin positive neurons (Neddens and Buonanno, 2010). Interestingly, 
these same calbindin-expressing interneurons are mostly spared in the brains of SCZ 
patients, while many other interneuron types are reduced  (Lewis et al., 2005), indicating 
that correct ErbB4 signaling may be important for the development of interneurons and 
preventing schizophrenia.  
Mice with transgenic overexpression of NRG1 type 1 show hippocampus-specific 
working memory deficits in adulthood (Deakin et al., 2012) which may be related to 
deficits in neural synchrony. In hippocampal slices from these transgenic mice, the peak 
frequency of carbachol-induced gamma oscillations is reduced by ~4Hz without any 
significant change in power (Deakin et al., 2012). In this preparation, pyramidal neurons 
fired preferentially near the start of the gamma cycle (Deakin et al., 2012), and slices 
show a greater tendency towards epileptiform activity with 60% ending in epileptiform 
activity as compared to 9% of slices from wild-type mice ending in epileptiform activity 
(Deakin et al., 2012). This suggests that inhibitory neurotransmission in mice with 
transgenic overexpression of NRG1 type 1 is impaired. 
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Given the importance of understanding the connection between neuregulin and 
ErbB signaling pathways and the generation of gamma oscillations, other research groups 
have examined the effects of NRG1 and ErbB signaling in vivo. Mice with ErbB4 
genetically removed from all interneurons show higher power in every frequency range 
from theta to gamma in the hippocampus during urethane-anesthesia recordings 
compared to littermate controls (del Pino et al., 2013). Gamma power was also increased 
in the infralimbic region of the prefrontal cortex of these genetically modified mice. 
Interestingly, when anesthetized using ketamine instead of urethane, 50% of the animals 
showed epileptic hypersynchrony (del Pino et al., 2013), similar to the increase in 
epileptiform activity observed in hippocampal slices from mice overexpressing NRG1 
type 1 (Deakin et al., 2012). In awake behaving mice, gamma power was dramatically 
higher in mice lacking ErbB4 receptors in interneurons compared to their littermate 
controls, but all other frequency ranges were not different (del Pino et al., 2013). These 
mice also show cognitive deficits, paired-pulse inhibition deficits, and hyperactivity, 
which all may be related to changes in inhibitory neurotransmission and gamma 
synchrony. As in in vitro preparations, gamma oscillations can also be induced in vivo 
through the systemic injection of kainic acid. In wild type mice with kainic acid-induced 
gamma oscillations, an infusion of 6mM NRG1 into the lateral ventricle triples gamma 
power recorded from prefrontal EEG (Hou et al., 2014). Moreover, this increase is not 
observed in mice with genetic ablation of ErbB4 from interneurons, and kainic acid 
increased gamma power to a lesser extent in these mice (Hou et al., 2014). Hou and 
colleagues examined slices from the prefrontal cortex and observed an increase in 
  
162 
synchrony between pairs of pyramidal neurons, or pairs of interneurons after bath 
application of 5 or 10nM NRG1 (Hou et al., 2014). These changes in synchrony relied on 
intact GABAergic signaling and ErbB4 signaling, because neither effect was observed 
when recorded in the presence of the GABA receptor inhibitor picrotoxin, or in mice with 
genetic ablation of ErbB4 from interneurons (Hou et al., 2014). 
Overall, both overexpression of NRG1 and underexpression of its receptor ErbB4 
can modulate gamma oscillation power. Furthermore, both overexpressing NRG1 and 
genetic deletion of ErbB4 receptors on interneurons induces behavioral deficits (Agarwal 
et al., 2014; Deakin et al., 2012; del Pino et al., 2013; Shamir et al., 2012).  While NRG1 
and ErbB4 have both been implicated in schizophrenia (Mei and Xiong, 2008; Stefansson 
et al., 2002), it is unclear whether manipulation of this receptor system may have 
therapeutic effect in the treatment of the cognitive symptoms, or endophenotypes of 
schizophrenia, such as impaired gamma oscillations. To help clarify the role of ErbB 
receptors, in this study, I examine the effects of an antagonist that inhibits multiple ErbB 
receptors on gamma oscillation power before and after ketamine injection. The ketamine 
injection recapitulates the signal-to-noise problems in gamma oscillation power in a 
similar way to that observed in schizophrenia patients during sensory and cognitive tasks 
(Cho et al., 2006; Saunders et al., 2012). 
4.2 Materials and Methods 
All experimental procedures were conducted in accordance with the NIH Guide 
for Care and Use of Laboratory Animals and approved by NINDS Animal Care and Use 
Committee. We attempted to minimize the number of animals used and their discomfort. 
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4.2.1 Rats and behavioral paradigm 
Male Long Evans rats (Charles River, Frederick, MD, USA), weighing 280–300 
g, were housed with ad libitum access to chow and water in environmentally controlled 
conditions with a 12:12 h light:dark cycle (lights off at 9:00h). Rats were handled daily 
the week before surgery and trained to walk on a circular treadmill as previously 
described (Avila et al., 2010).  
4.2.2 Surgical procedures 
A single guide cannula attached to an electrode was implanted for recording LFP 
and spikes from the left prelimbic medial prefrontal cortex (mPFC). The cannula was 
placed so that when the infusion cannula was inserted into the guide cannula, the infusion 
would occur at the recording site. Rats were anesthetized with 75 mg/kg ketamine and 0.5 
mg/kg medetomidine (intraperitoneal, i.p.) and placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA, USA), with head-fixed with atraumatic ear bars.  Holes were 
drilled in the skull above the target coordinates for the mPFC (AP: +3.6 mm from the 
bregma, ML: +0.6 mm from the sagittal suture and DV: 3.6 mm from the skull surface). 
The electrode bundle consisted of 8 stainless steel teflon-insulated microwires plus an 
additional 9
th
 wire with no insulation on the distal ~1 mm of the recording tip with lower 
impedance serving as a local reference (Brazhnik et al., 2012; Delaville et al., 2015; 
Dupre et al., 2016). It was implanted in the target region and secured to the skull with 
screws and dental cement. A ground wires from the electrode was wrapped around a 
screw located above the cerebellum. After completion of surgery, 0.15% of ketoprofen in 
0.9% NaCl solution was given subcutaneously (s.c.), and atipamezole (0.3-0.5 mg/kg, 
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s.c.) was administered to reverse the effect of medetomidine. During the first week of 
postoperative recovery, the rat’s diet was supplemented with fruit and bacon treats. Rats 
were retrained at the circular treadmill walking task after the fourth postoperative day. 
4.2.3 Behavioral analysis 
A web camera (Logitech) was mounted next to the circular treadmill in order to 
provide behavioral data synchronized with the electrophysiological recordings. To 
quantify how the pan-ErbB antagonist affected ketamine-induced behaviors, an 
independent experimenter assessed the rodent’s behavior using 50-second video epochs 
with treadmill-off and treadmill-on. Behavior with the treadmill-on was scored from 
before the ketamine injection (baseline) and 15 minutes after the ketamine injection, and 
behavior with the treadmill-off was scored from baseline and 13 minutes after the 
ketamine injection. 
When the treadmill was off, the rat was inside the stationary circular treadmill 
track and the paddle was down so that it could not walk the treadmill freely. In this 
condition, untreated rats entered states of attentive or inattentive rest, but ketamine-
treated rats were either hyperactive, or ataxic. To evaluate motor activity, we measured 
the number of seconds that the rat spent moving his trunk or limbs (but not its head). 
Ataxia was scored according to the following scale (adapted from Cho et al., 1991; Cui et 
al., 2014): (0) inactive or coordinated movements, (1) awkward or jerky movements or 
loss of balance while rearing, (2) frequent falling or partial impairment of antigravity 
reflexes, (3) the inability to move beyond a small area and to support body weight and (4) 
inability to move except for twitching movements. The stereotypic rating scale was also 
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adapted from (Cho et al., 1991). Briefly, we quantified the number of head-bobs, turns, 
and the number of seconds spent backpedaling. Head-bobs included side-to-side or 
vertical head movements, and turns involved a 180 degree turn so that the rat’s direction 
in the treadmill had changed.  
During treadmill-on epochs, an independent experimenter recorded the number of 
turns, the number of times that the rat hit the paddle, and the duration the rat spent being 
pushed by the paddle. Paddle hits counted for any of the rat’s body parts other than the tip 
of his tail. Comparisons between baseline and ketamine treatment were made using 
paired t-tests for each behavioral measure. 
2.4 Electrophysiological recordings 
Extracellular spike and LFP recordings were collected for every experiment using 
Plexon (Dallas, TX) and Spike2 (CED, Cambridge, UK) systems as described in 
(Delaville et al., 2015). Both spikes and LFPs were referenced to the scraped 9
th
 wire. 
Spikes were sampled at 40kHz and LFPs were sampled at 2kHz. Action potentials were 
amplified (10,000x) and band pass filtered (0.3-8 kHz). LFPs were amplified (2000x) and 
band pass filtered (0.7-150 Hz). Discriminated spike and LFP signals were digitized, 
stored and analyzed using Spike2 data acquisition and analysis software. 
Baseline recordings consisted of at least two five-minute epochs of 
counterclockwise walking and two 40 second epochs of inattentive rest without artifacts. 
After drug injections, the rat repeated a pattern of walking for 4 minutes and treadmill-off 
for one minute for the first 25 minutes, then the treadmill was turned off for the final 4 
minutes before the next injection. Direct observation and videotaped motor behavior were 
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used to identify artifact-free 100-second intervals within the treadmill walking epochs 
and 40 to 100 second intervals from treadmill-off epochs. Any epoch of either behavior 
showing artifacts was excluded. The circular treadmill‘s speed was set at 9 to 11 rotations 
per minute. 
2.5 Experimental conditions and drugs 
Three of the five rats with proper electrode placement received cannula infusions 
of 10nM neuregulin 2 (source) diluted in ACSF seven days after surgery, and cannula 
infusions of sterile saline diluted in ACSF 10 days after surgery. The infusion volume 
was 400nL administered over 5 minutes, with one minute of rest before pulling out the 
infusion cannula. In the following three weeks, these rats received one of three 
pretreatments, saline (5mL), 5% DMSO (5mL), or 5mg/kg JNJ-28871063 dissolved in 
5% DMSO thirty minutes prior to a 10mg/kg ketamine injection (at 1mL/kg, s.c.). A 
different drug was used each week and recordings were always more than 6 days apart. 
The order of pretreatments was randomized for each rat according to a latin-square 
design. Rats were anesthetized with 100mg/kg ketamine, followed by 0.15 mg 
medetomidine administered 30 minutes later, and then sacrificed. In one rat, the 
grounding electrode broke partway through the experimental recordings, so the 
intrabundle coherence and single neuron data was excluded from this rat after the break.  
Two of the five rats with proper electrode placement received one of five 
pretreatments: 25% DMSO, 5mg/kg JNJ-28871063 dissolved in 25% DMSO, 3mg/kg A-
412997, 5mg/kg L-745,870, 5mg/kg clozapine administered subcutaneously at ~1mL/kg.  
Thirty minutes after the pretreatment injection, 10mg/kg ketamine was injected (at 
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1mL/kg, s.c.) Recordings were performed one week apart. A different drug was used 
each week and the order of pretreatments was randomized for each rat according to a 
latin-square design. For both rats, the first recording used in this analysis was more than 
three weeks after the surgery, and the recordings were performed third and fifth in the 
order of pretreatments. Rats were given a cocktail of D1 and D2 antagonists prior to 
ketamine injection, then anesthetized using a total of 100mg/kg ketamine and 0.15mg 
medetomidine, then sacrificed.  
2.6 Spectral analysis of local field potential recordings 
LFP power was measured by fast Fourier transform (FFT) with a frequency 
resolution of ~1 Hz and normalized by dividing the power at each frequency by the sum 
of power between 250 and 300Hz in order to compensate for any instrumental 
fluctuations over time (Brazhnik et al., 2016). For each structure, total power in the low 
gamma (40-59Hz) and high gamma (70-120Hz) frequency ranges was calculated using a 
spike2 script. Additionally, if a significant peak was found between 40 and 70Hz, the 
power was summed from 7Hz below and above the peak to find the total low gamma 
power. A peak was considered significant if its relative maximum was greater than the 
surrounding 14 frequency bins in the low gamma range, the first derivative of the 
spectrum was positive to the left of the peak and negative to the right of the peak, and the 
second derivative at the peak was negative, indicating a downward concavity. LFP power 
from two wires per electrode bundle during two epochs was averaged for each behavioral 
condition.  
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To visualize spectral power changes over time for the selected epochs, time-
frequency wavelet spectra were constructed using continuous wavelet transforms. The 
Morlet wavelet was applied to the LFPs using 128 frequency scales and a time resolution 
of approximately 750 ms (Time-Frequency Toolbox (http://tftb.nongnu.org).  
In order to analyze the effects of the different drugs on the LFPs compared to 
baseline recordings, percent change from baseline walk in each frequency bin (for data 
visualization), or for each frequency range (for specific frequency range analysis) was 
used. Percent change was calculated using the formula: 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐶ℎ𝑎𝑛𝑔𝑒 =
𝑃𝑓,𝑡 − 𝑃𝑓,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑃𝑓,𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 × 100% 
P is power in the frequency range (f) at a given time (t). Outlier time points for power 
were removed using the ROUT (robust nonlinear regression combined with outlier 
removal) test with Q set to 1% (Motulsky and Brown, 2006) and the average of the other 
rats was used as a replacement value (Dupre et al., 2016).  
  The effects of various drug treatments on coherence and power over time within 
specific frequency ranges were assessed during treadmill walking using two-way 
repeated measures analysis of variance (ANOVA) following by Holm-Sidak’s multiple 
comparisons with the level of significance: α = 0.05. 
2.7 Cell sorting and STWA analysis 
Spike waveforms from the mPFC and the MD thalamus were sorted using 
principal component analysis (PCA) in Spike2. To assess effective sorting for single 
cells, inter-spike interval (ISI) histograms were generated and inspected to ensure that 
sorted cell clusters did not exhibit multiunit behavior by firing within the assumed 
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refractory period (1.2 ms). Putative pyramidal neurons and interneurons were separated 
using trough-to-peak intervals (Azouz et al., 1997; Brazhnik et al., 2012; Wilson et al., 
1994). Units with trough-to-peak intervals greater than 0.5ms were classified as putative 
pyramidal neurons (19/20), and those with intervals less than 0.4ms were classified as 
interneurons (1/20).  Given the low occurrence of interneurons in this data set, statistics 
could not be safely generalize from the behavior of this neuron to the entire population, 
so the behavior of this neuron is not reported. 
To assess the temporal relationship between the spiking activity of individual 
neurons and LFPs from the same structure, spike-triggered waveform averages (STWA) 
were calculated for epochs of 100 to 200 seconds. LFPs from the recording wire or a 
neighboring wire were band-pass filtered between 40 and 59Hz. The coherence between 
each wire and every other wire in the frequency range of 40-59Hz was calculated during 
baseline walk. For each wire, the other wires were ranked from the wire with the most 
coherence to the least coherence. One of the two neighboring wires the wire within the 
electrode bundle with the maximum coherence to the wire on which the spike train was 
recorded. The second neighboring wire was selected by finding the wire with the median 
coherence to the wire on which the spike train was recorded.  Peak-to-trough amplitudes 
of the STWAs at or around the spike (zero time) were obtained as a measure of 
correlation between the spike train and dominant gamma oscillation. Twenty shuffled 
STWAs for the same epochs were created by shuffling the interspike intervals of each 
spike train and used to create 20 normally distributed peak-to-trough values. The extent 
of correlation between spikes and gamma-filtered LFPs after ketamine or D4R drug 
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treatments during epochs of walking was compared to baseline walk epochs using the 
mean ratio of unshuffled/shuffled peak-to-trough amplitudes (mean STWA ratio). 
Comparisons of firing rate and mean STWA ratio between baseline and ketamine 
administration were assessed using repeated measures one-way ANOVAs with Holm-
Sidak’s multiple comparisons: α = 0.05. Outlier neurons were removed using the ROUT 
(robust nonlinear regression combined with outlier removal) test with Q set to 
0.1%(Motulsky and Brown, 2006). 
4.2.8 Histology 
After recordings were completed and the animal was anesthetized, recording sites were 
marked by passing a 10 μA positive current for 15-17 seconds via 3 microwires and 9 
seconds via the reference electrode. Rats were perfused intracardially with 200 mL cold 
saline followed by 200 mL 4% paraformaldehyde in phosphate buffer solution (PBS). 
Brains were post-fixed in paraformaldehyde solution overnight and then immersed in 
10% sucrose in phosphate buffered saline (0.1 M, pH 7.4) for 1 week. Coronal sections of 
35 μm were collected on slides. Sections for electrode placement verification were 
mounted on glass slides and stained with cresyl violet and 5% potassium ferricyanide-9% 
HCl to reveal the iron deposited at the electrode tips. Rats were only included in the 
analysis if the electrodes were properly placed in the prelimbic mPFC, and gliosis around 
the cannula and electrode was not pervasive into the recording site.  
4.3 Results 
We attempted to examine the effects of both the activation and inhibition of ErbB 
receptors on low gamma power. However, technical difficulties related to the cannula 
  
171 
administration of NRG1β and NRG2 at the recording site precluded any reasonable 
analysis of ErbB4 activation. To determine the effects of NRG/ErbB inhibition on 
gamma oscillations, we systemically injected the pan-ErbB antagonist JNJ-28871063 
(5mg/kg s.c.) 30 minutes before an injection of 10mg/kg ketamine. The pan-ErbB 
antagonist had no significant effect on low gamma power (peak between 40 and 70Hz 
±7Hz) or high gamma power (70-120Hz) during treadmill walking (both p>0.05, RM 
two-way ANOVA, Fig4.2). However, after the pan-ErbB antagonist, ketamine 
significantly increased the low gamma power more than after the DMSO vehicle 
injection recorded fifteen minutes after the ketamine injection (representative examples in 
Fig4.1., Ket-DMSO: +125% from baseline vs. Ket JNJ: +235% from baseline, n= 5, 
p<0.05, Holm-Sidak’s multiple comparisons test), This potentiation of ketamine’s 
increase in gamma power was also observed 5 minutes after the ketamine injection (Ket-
DMSO: + 144% of baseline vs. Ket JNJ: 287% of baseline, n= 5, p<0.05, Holm-Sidak’s 
multiple comparisons test), but not 35 minutes after the ketamine injection (p>0.05, 
Holm-Sidak’s multiple comparisons test, Fig4.2). Furthermore, no significant differences 
between drug treatments were observed in the high gamma frequency range (p>0.05, 
Holm-Sidak’s multiple comparisons test, Fig4.2). Taken together, these results show that 
inhibiting ErbB signaling actually increases the effects of ketamine on low gamma 
power, suggesting that inhibition of ErbB receptors could either cause or potentially 
exacerbate the symptoms of schizophrenia.  
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Figure 4.1. Representative example of the pan-ErbB antagonist potentiating ketamine-induced 
gamma power. (A) Representative power spectral density functions displayed over time from 15 minutes 
after 10mg/kg ketamine s.c. injection with DMSO pretreatment (left) and JNJ-28871063 (right) in two 
wires from the mPFC (top) from 0-100Hz. Note the narrow gamma band at 55Hz in each recording. 
Warmer colors indicate greater power. Gamma-filtered LFP waveform from 40-59Hz from the top channel 
in the figure (bottom). (B) Representative LFP power spectra in the mPFC for epochs with treadmill on at 
baseline (blue), 15 minutes after the DMSO (left) or JNJ injection (right, green), and 5, 15, 35, 65, and 95 
minutes after the injection of ketamine.  
 
 
Figure 4.2. Pan-ErbB antagonist potentiates ketamine-induced gamma power (A) Percent change in 
gamma power (peak between 40-70Hz ±7Hz), and high gamma power (70-120Hz, B) in the mPFC of rats. 
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Black line indicates the injection of the pretreatment (5mg/kg JNJ-28871063 or DMSO), and black arrow 
indicates the injection of 10mg/kg ketamine. “Minutes post injection” indicates the time from the injection 
of the pretreatment. Pink curve shows the effect of the pan-ErbB antagonist and the black curve indicates 
the effect of DMSO (n=5 rats). The bar with the star indicates a significant change from baseline walking 
for every time point under the bar. Values are reported as mean ± SEM *:p<0.05, repeated measures one-
way ANOVA with Tukey’s multiple comparisons test. 
 
To assess whether the pan-ErbB antagonist influenced ketamine-induced changes 
in firing rate, we examined neurons in the mPFC after each pretreatment. The pan-ErbB 
antagonist JNJ-28871063 reduced the average firing rates of pyramidal neurons in the 
mPFC by 23% during epochs of treadmill walking relative to epochs of treadmill walking 
before drug administration (1.11±0.24Hz vs. 1.44±0.31Hz, n=17, p<0.05, Dunnett’s 
multiple comparisons test, Fig4.3). The diluted DMSO vehicle had no significant effect 
on the average firing rates of pyramidal neurons in the mPFC during treadmill walking 
(p>0.05, paired t-test). As described in Chapter 3, ketamine increases the firing rates of 
mPFC pyramidal neurons. Accordingly, ketamine increased the average firing rates of 
these neurons by 75% after the diluted DMSO vehicle injection (1.21±0.17Hz vs. 
2.12±0.33Hz, n=17, p<0.05, Dunnett’s multiple comparisons test, Fig4.3). Intriguingly, 
after pretreatment with the pan-ErbB antagonist, ketamine did not significantly increase 
the average firing rates of mPFC pyramidal neurons (+33%, p>0.05, paired t-test). This 
indicates that the pan-ErbB antagonist is capable of diminishing the effects of ketamine 
on single neurons in vivo. Seventy-five minutes after the ketamine injection, firing rates 
were not significantly different from baseline firing rates in either pretreatment condition 
(both p>0.05, Dunnett’s multiple comparisons test). 
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Figure 4.3. Pan-ErbB antagonist reduces baseline firing rates and reduces ketamine’s effects on 
firing rates. Bar graph shows the mean and SEM of firing rates during the recordings from the pan-ErbB 
antagonist JNJ-28871063 (pink) and DMSO (black) pretreatments. The pretreatment values were measured 
15 minutes after the injection. *: p<0.05, **: p<0.01, repeated-measures one-way ANOVA with Dunnett’s 
multiple comparisons tests. 
 
To investigate the spread of gamma oscillations around spiking neurons, the 
coherence between the wires within the bundle was examined. The coherence between 
each wire and every other wire in the frequency range of 40-59Hz was calculated during 
epochs of baseline walk, treadmill walking 15 minutes after the pretreatment injection, 
and treadmill walking 15 minutes after the ketamine injection. For each wire, the other 
wires were ranked from the wire with the most coherence to the least coherence. Overall, 
the coherence values of the maximum wire did not change before and after the 
pretreatments and ketamine injections (with one exception: pretreatment with JNJ: 0.76 
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was significantly lower than 15 minutes after ketamine: 0.82, p<0.05, Tukey’s multiple 
comparisons, all other comparisons p>0.05). In contrast, the coherence values of each 
wire to the median wire significantly increased after ketamine with DMSO pretreatment 
(from an average of 0.46 to 0.52) and after ketamine with the pan-ErbB antagonist 
pretreatment (from 0.51 to 0.61, both p<0.01, Tukey’s multiple comparisons). In 
summary, ketamine increases the gamma frequency coherence within the electrode 
bundle. Therefore, it appears that after ketamine, gamma oscillators influence the power 
and frequency of ongoing brain oscillations across a broader spatial scale than before 
ketamine treatment.  
In Chapter 3, ketamine increased spike-gamma LFP correlations in the mPFC 
after saline pretreatments. However, after the dilute DMSO pretreatment, ketamine failed 
to significantly increase the spike-gamma LFP correlations in the recording wire, or 
either of two neighboring wires in the mPFC (Recording:+18%, Max: +16%, Median: 
+40% 15 minutes after ketamine vs. 15 minutes after pretreatment injection, n=17, all 
p>0.05, Holm-Sidak’s multiple comparisons, Fig4.4). Furthermore, the pan-ErbB 
antagonist pretreatment had no obvious effect on spike-gamma LFP correlations 
referenced to the recording wire, or either of two neighboring wires in the mPFC 
(Recording:+2%, Max: +31%, Median: -26% 15 minutes after ketamine vs. 15 minutes 
after pretreatment injection, all p>0.05, Holm-Sidak’s multiple comparisons). To directly 
compare the effect of the pan-ErbB antagonist pretreatment with the dilute DMSO 
vehicle, we computed the percent change in spike-gamma LFP correlation after ketamine 
injection relative to before the ketamine injection.  There were no significant differences 
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in the percent change in spike-gamma LFP correlations between the pretreatment groups 
before or after ketamine, referenced to the recording wire (JNJ: +6% vs. DMSO: +44%) 
or one of two neighboring wires (Max JNJ:  57% vs. DMSO: +52%, Median JNJ: 42% 
vs. DMSO:57%, all p>0.05, Holm-Sidak’s multiple comparisons, Fig4.4). Prior to 
ketamine injection, pyramidal neurons preferentially spiked in the falling phase of the 
gamma range LFP (~74% of all neurons, 148˚±15˚, p<0.05, Raleigh test). In contrast, 
after the ketamine injection, pyramidal neurons preferentially spiked in the ascending 
phase of the LFP (~64% of all neurons, 215˚±20˚, p<0.05, Raleigh test). These 
represented a significant shift in phase-preference after ketamine (p<0.05, Mardia-
Watson Wheeler Test). In fact, 100% of the significantly correlated neurons spiked in the 
falling phase of the gamma range LFP before ketamine (n=1, phase preference = 148˚), 
and 100% of the significantly correlated neurons spiked in the ascending phase of the 
gamma LFP after ketamine (n= 4, phase preference = 312˚).  Taken together, these data 
suggest that the DMSO pretreatment reduces the effects of ketamine on spike-gamma 
LFP correlation, and the pan-ErbB antagonist has little effect on spike synchronization to 
gamma oscillations. Furthermore, while the pan-ErbB antagonist increases ketamine-
induced low gamma-power, the mechanism for this increase does not seem to involve 
local circuits of pyramidal neurons in the mPFC. 
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Figure 4.4. Pan-ErbB antagonist has no significant effect on spike-gamma LFP correlations. (Left) 
Mean ratios between peak to trough amplitudes of unshuffled/shuffled spike triggered waveform average 
(STWA) for LFPs recorded from the same wire (A) or the neighboring wire with maximum coherence  in 
the bundle (B) or a neighboring wire with median coherence (C, see methods) filtered from 40-59Hz for 
mPFC pyramidal neurons. All pink bars are from the recording with the JNJ-28871063 pretreatment, and 
all black bars are from the DMSO vehicle pretreatment. The pretreatment measures were taken 15 minutes 
after the systemic injection of the DMSO or JNJ-28871063 injection. A ratio of 1 indicates no difference 
between shuffled and unshuffled values. (Right) For each neuron, the percent change from baseline mean 
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STWA ratio was calculated so that the different drug pretreatments could be directly compared. There were 
no significant differences in any of the groups tested. 
 
4.4 Discussion 
In the current study, I systemically administered a pan-ErbB antagonist and 
recorded from the mPFC of rats performing a treadmill walking task before and after an 
injection of ketamine that induces psychotomimetic effects. I analyzed the effects of 
ErbB antagonism on local field potentials and determined that ErbB antagonism 
potentiated the effects of ketamine on low gamma power, but not high gamma power.  
This confirmed previous results showing that NRG1 and ketamine administration only 
influenced low gamma power (Chapter 3, Fisahn et al., 2009). Given that ErbB4 is 
expressed selectively in interneurons (Vullhorst et al., 2009), and that genetic ablation of 
ErbB4 from interneurons increases hippocampal gamma power in awake behaving mice 
(del Pino et al., 2013), the increase in ketamine-induced gamma power was expected. 
Complicating this interpretation, however, is the fact  that NRG1 infusion and therefore 
activation of ErbB4 receptors increases kainate-induced gamma power (Hou et al., 2014). 
One possibility is that endogenous NRG/ErbB signaling pathways are in homeostatic 
balance in vivo, so that either increasing or decreasing the activity of ErbB receptors will 
increase gamma power. Indeed it is important to remember that pan-ErbB antagonism 
had no significant influence on gamma power on its own. Together, these results 
demonstrate that either ErbB antagonism or NRG1 activation has the ability to increase 
chemically induced gamma power. 
I also analyzed the activity of putative pyramidal neurons in the mPFC and 
observed that the pan-ErbB antagonist reduced the firing rates of these neurons compared 
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to baseline, unlike observations made from the hippocampus in vitro (Hou et al., 2014). 
The pan-ErbB antagonist also reduced the canonical ketamine-induced increase in the 
firing rate of pyramidal neurons such that it was no longer significantly different.  In 
Chapter 3, I showed that ketamine increases the spike-gamma LFP correlation of mPFC 
pyramidal neurons. However, after DMSO or JNJ-28871063 pretreatment, this increase 
in synchronization was not observed in the recording wire or either of two neighboring 
wiResearch More work is needed to ascertain whether DMSO has a significant effect on 
the synchronization of mPFC pyramidal neurons to ongoing gamma oscillations.  
A few key differences separate this study from previous studies. First, we 
recorded the LFP from chronically implanted electrodes in the mPFC so we could 
examine the differences between vehicle and pan-ErbB antagonist injections in the same 
animal, unlike the recordings made by Hou and colleagues (2014). Secondly, walking 
increases gamma oscillations, so we could examine the effects of the pan-ErbB 
antagonist on gamma oscillations in the absence of kainic acid or carbachol. To my 
knowledge, we were the first to observe the effects of pan-ErbB antagonism on 
physiological gamma power. Interestingly, ErbB4 deletion from interneurons increases 
gamma power (del Pino et al., 2013), whereas pan-ErbB antagonism had no significant 
effect on gamma power until ketamine was administered.  Finally, most previous work 
has examined hippocampal oscillations evoked by carbachol or kainate in vitro 
(Andersson et al., 2012b; Deakin et al., 2012; Fisahn et al., 2009) whereas here I recorded 
in vivo from the mPFC, and examined both chemically induced oscillations, and 
physiologically induced oscillations.  
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The pan-ErbB antagonist reduced the firing rates of mPFC pyramidal neurons. In 
hippocampal and prefrontal slices, NRG1 increases the firing rates of PV+ interneurons 
(Li et al., 2012), but in cultured hippocampal neurons NRG1 decreases the firing rates of 
ErbB4-expressing interneurons (Janssen et al., 2012). Thus, ErbB antagonism may 
increase the firing rates of interneurons which in turn decreases the firing rates of mPFC 
pyramidal neurons. Unfortunately, we only recorded one interneuron, and this 
interneuron actually showed mild decreases in firing rate (<7%). Further investigations 
are needed to prove the involvement of interneurons. Moreover, the pan-ErbB antagonist 
is capable of reducing the effects of ketamine on pyramidal neuron firing rates in vivo. 
The mechanism underlying this effect remains unclear.  JNJ-28871063 penetrates the 
blood brain barrier and inhibits the multiple ErbB receptors (Emanuel et al., 2008); 
therefore, it is possible that ErbB receptors other than ErbB4 are responsible for some of 
the changes observed after JNJ-28871063 administration. For instance ErbB2 and ErbB3 
play important roles in myelination and behavior (Mei and Nave, 2014), although these 
have been rarely implicated in changing the activity of neurons. Furthermore, given that 
activation of ErbB4 can reduce NMDA currents (Vullhorst et al., 2015), inhibition of 
ErbB receptors may prevent the internalization of NMDA receptors at the synapse, 
allowing for more fully functional receptors after ketamine’s noncompetitive antagonism. 
Finally, in Chapter 3, we observed that ketamine increased spike-gamma LFP 
correlations in the mPFC. In this study, we did not observe this increase after the pan-
ErbB antagonist or DMSO. It is unclear how the DMSO administration could influence 
spike-gamma LFP correlations. Furthermore, because the same effect was observed with 
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the vehicle and the pan-ErbB antagonist, it is not safe to ascribe the reduction in 
ketamine-induced increases in spike-gamma LFP correlation to ErbB inhibition. 
Nevertheless, this data is similar to the finding that transgenic overexpression of NRG1 
type 1 does not significantly influence the spike-gamma LFP correlation of pyramidal 
neurons from hippocampal slices with kainate-induced gamma oscillations (Hou et al., 
2014). Although our results examine the inhibition of this NRG1/ErbB receptor system, 
instead of hyperactivation, we observed changes in firing rate, but not spike-gamma LFP 
correlation. Taken together, it appears that ErbB antagonism has unidirectional effects on 
firing rates, and no effect on spike-LFP correlations.  
The mechanism underlying the potentiation of ketamine-induced gamma power 
after pan-ErbB antagonism is also unclear.  NRG2 promotes ErbB4 clustering with 
GluN2B-containing NMDA receptors, followed by internalization of these receptors to 
decrease NMDA currents (Vullhorst et al., 2015). Similarly, ketamine antagonizes 
GluN2A and GluN2B containing NMDA receptors with equal affinity (Olney et al., 
1999), and NMDAR antagonism increases gamma power. Therefore ErbB4 activation 
and not inhibition should potentiate ketamine-induced gamma oscillations. It is important 
to note that the real increase in gamma power may be related to GluN2A-containing 
NMDA receptors (Kocsis, 2012), or the relative contribution of AMPA currents to 
NMDA currents (see Chapter 1). Overall, these results indicate that the pan-ErbB 
antagonist does not seem to be a promising agent for the cognitive effects observed in 
schizophrenia because this drug does not reduce ketamine-induced gamma power 
(Anderson et al., 2014; Gilmour et al., 2012).  
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CHAPTER FIVE: Discussion 
5.1 Major contributions of this thesis 
Our work adds to the significant body of literature on the relationship between 
cortical gamma oscillations and attention (Benchenane et al., 2011; Cannon et al., 2014; 
Gregoriou et al., 2015). Low gamma power in the mPFC increased during treadmill 
walking, a task that requires attention. Similarly, low gamma power also increased in the 
mPFC after ketamine administration, which made our rats hyper vigilant. This 
corroborated findings by Guidi and colleagues (2015) that ketamine actually increases 
task attentiveness in rodents. Furthermore, we evaluated the utility of three novel agents 
to reduce ketamine-induced gamma power, and evaluated the utility of the acute 
ketamine model of schizophrenia (Gilmour et al., 2012). The importance of our findings, 
their interpretation and their relationship to existing data will be discussed below. 
In Chapter 2, I administered a D4R agonist or D4R antagonist to slices from the 
dhCA1 or mPFC, and recorded inhibitory currents. I determined that D4R activation 
reduced miniature GABAR-mediated currents onto PV+ interneurons, D4R inhibition 
increased the frequency and amplitude of miniature GABAR-mediated currents onto 
pyramidal neurons, and D4R inhibition increased the intrinsic excitability of PV+ 
interneurons.  These results suggest that endogenous dopamine activates D4Rs to restrain 
the intrinsic excitability of PV+ interneurons and lower the probability of GABA release 
onto pyramidal neurons. However, Rosen and colleagues observed that D4R activation 
increased excitatory glutamatergic currents onto PV+ interneurons (2015b), and 
Trantham-Davidson and colleagues observed that D4R activation increases the intrinsic 
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excitability of PV+ interneurons (2014). In these experiments, dopamine release was 
either stimulated optogenetically to simulate tonic dopamine signaling (Rosen et al., 
2015b), or D4R agonists were bath applied at concentrations 200-400 times greater than 
the concentration that we used (Trantham-Davidson et al., 2014). Yet, aligning with these 
findings, activating D4Rs also reduced the inhibition onto PV+ interneurons (Chapter 2), 
which could potentially make these neurons more excitable. These results suggest that 
D4R activation is in homeostatic balance, and that increasing or decreasing its activation 
may increase the activity of PV+ interneurons to potentially increase gamma power. To 
test this hypothesis, we examined the effects of both the D4R agonist and antagonist on 
gamma oscillations in vivo in chapter 3. The agonist increased gamma power and the 
antagonist reversed this effect whether the animal was walking or not walking.  However, 
neither effect was accompanied by firing rate changes in vivo. Therefore, even though the 
D4R agonist and antagonist both have effects in vitro that could result in increases in 
firing rates, and greater oscillatory power (Andersson et al., 2012b; Ceci et al., 1999; Onn 
et al., 2006; Trantham-Davidson et al., 2014), the agonist effectively increased gamma 
power, but the D4R antagonist only decreased gamma power if the D4R has been 
activated. The D4R is a G-protein coupled receptor that inhibits adenylyl cyclase to 
reduce cyclic-AMP (cAMP) production (Rondou et al., 2010). Because G-protein 
receptors use second messengers, the effects of the D4R activation can be expected to last 
minutes to hours. By inhibiting the D4R, other receptors may be able to couple to 
adenylyl cyclase and help restore basal levels of cAMP to reduce effects on gamma 
power. Interestingly, the D4R antagonist did not significantly decrease ketamine-induced 
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gamma power, even though ketamine increases extracellular dopamine concentrations 
(Moghaddam et al., 1997), and likely increases D4R activation. It follows that ketamine-
induced gamma oscillations rely heavily on non-dopamine mediated mechanisms.  As 
ketamine influences multiple receptors with different affinity (see Section 1.3.2), it is 
difficult to predict how ketamine influences second messenger systems. The primary 
mechanism underlying ketamine-induced gamma oscillations will be discussed in Section 
5.4. 
In chapter 3, anesthetic and subanesthetic doses of ketamine were administered to 
rats to examine the relationships between increases in gamma power and spiking activity 
in mPFC and MD thalamus. Gamma power increased substantially in both structures 
after ketamine administration. As observed previously, ketamine also increased the firing 
rate in the mPFC (Homayoun and Moghaddam, 2007a; Jackson et al., 2004), likely due to 
the increases in glutamatergic signaling through AMPARs after NMDAR antagonism 
(Maeng et al., 2008). We also observed an increase in the correlation between mPFC 
spiking and gamma oscillations. In contrast, in the MD thalamus, ketamine reduced the 
firing rate and correlation between spiking and gamma oscillations. This is likely a direct 
effect of removing NMDAR-mediated excitation from thalamic relay neurons. Due to the 
fact that ketamine-induced increases in gamma power, firing rate, and spike-LFP 
correlation in the mPFC were observed in conjunction with an increase in motor activity, 
we also examined the effects of motor activity and attention during a treadmill walking 
task. Treadmill walking alone also increased gamma power in the mPFC, as had been 
previously observed in our lab (Delaville et al., 2015), but to a lesser extent than after 
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ketamine administration. In the mPFC, walking concurrently increased the firing rates of 
pyramidal neurons and interneurons and increased synchronization between pyramidal 
neuron spikes and gamma oscillations. We added to the overall understanding of this 
walking-induced gamma by observing an increase in gamma power across a broader band 
in the MD thalamus during treadmill walking. Moreover, unlike the effect of ketamine in 
the MD thalamus, walking concurrently increased the firing rate and synchronization 
between spikes and gamma oscillations, suggesting a different circuit is responsible for 
increasing thalamic gamma power induced by walking compared to ketamine. In the MD 
thalamus, NMDAR mRNA expression is much greater than AMPAR mRNA expression 
within relay neurons (Salt and Eaton, 1996); therefore, after application of an NMDAR 
antagonist, these neurons become less excitable. Although extracellular glutamate levels 
still increase after ketamine, all of the AMPARs may quickly become occupied, 
preventing further changes in oscillatory activity. By contrast, during a treadmill walking 
task, the corticothalamic loop is important for sensory gating related to the rat’s task 
performance (Guillery and Sherman, 2002). 
As it has been proposed that a drug’s ability to modulate gamma power might 
reflect its therapeutic potential (Anderson et al., 2014; Celada et al., 2013; Hudson et al., 
2016; Jones et al., 2014; Ma and Leung, 2014), we examined the effects of two D4R-
targeting drugs and a pan-ErbB antagonist on ketamine-induced gamma activity in 
Chapters 3 and 4. The D4R agonist and D4R antagonist significantly influenced neither 
ketamine-influenced gamma power nor ketamine-influenced firing rates in the mPFC. 
However, in the MD thalamus, the D4R agonist increased ketamine-induced gamma 
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power and modified neuronal firing rates. Furthermore, the pan-ErbB antagonist 
potentiated the effects of ketamine on low gamma power, but not high gamma power in 
the mPFC, while concurrently reducing ketamine’s effects on firing rates.  The pan-ErbB 
antagonist had no effect on gamma oscillations or single neuron activity before ketamine 
administration. This raises the question: why does exogenous NRG1/ErbB signaling 
affect chemically induced oscillations, as also observed by Hou and colleagues (2014), 
but not physiological oscillations? The most parsimonious explanation is that different 
neural circuits underlie chemically-induced gamma oscillations compared to walking-
induced gamma oscillations, and our results fully support this hypothesis in the MD 
thalamus. In the mPFC, however, the story may be more complicated. 
5.2 Comparison of gamma oscillations induced by walking and by ketamine 
administration 
One of the main findings of this research is that gamma oscillations induced by 
walking and ketamine are similar in the mPFC and different in the MD thalamus.  There 
is general consensus that there is ongoing rhythmic inhibition in the cortex that emerges 
from the activity of interneurons (Börgers et al., 2005; Ray, 2015). Almost any activation 
of interneurons can initiate rhythmic inhibition due to the highly interconnected nature of 
interneuronal networks (Bartos et al., 2007; Buzsaki and Wang, 2012; Cardin et al., 
2009). In the mPFC, therefore, most gamma oscillations have local origins, even if the 
excitatory drive comes from afar, whereas in the MD thalamus, which in the rat lacks 
interneurons (Guillery and Sherman, 2002), most gamma power likely comes from 
synchronized activity projected from other locations (Tiesinga and Sejnowski, 2009).  
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Most previous work examining state-dependent gamma oscillations have focused 
on the primary motor and sensory cortices (for a review, see McGinley et al., 2015a), but 
our work focuses on the mPFC. Increases in arousal  increase gamma band 
synchronization in both the relative membrane potential and local field potential power 
throughout the cortex (Delaville et al., 2015; Lee et al., 2014; McGinley et al., 2015b; 
Reimer et al., 2014; Vinck et al., 2015). These increases in power are accompanied by 
increases in gamma-frequency phase-locking in pyramidal neurons and interneurons 
(Munk et al., 1996; Vinck et al., 2015). This supports the predictions of  the PING and 
ING compuational  models showing that the spiking of pyramidal neurons and 
interneurons can produce gamma oscillations (Börgers et al., 2005). However, our results 
did not reveal significant increases in spike-gamma LFP correlations when the animal 
was completely aroused for the walking task compared to when the treadmill was off. 
This may be because we had less control over our periods of rest than some of the 
previous literature because we were not recording EMG and pupillometry to isolate 
periods of true quiet wakefulness. Therefore, periods of attentive rest, when spike-gamma 
correlations would already be high, may have contaminated the epochs that we used with 
the treadmill off, and therefore changes became harder to observe. Furthermore, a greater 
proportion of pyramidal neurons than interneurons were significantly correlated to 
gamma oscillations in the mPFC. This would support a model in which the firing of 
pyramidal neurons is potentially more important for the generation of gamma power than 
pyramidal neurons. Indeed, the amplitude of gamma oscillations depends in large part on 
the excitation of interneurons (Jadi et al., 2015), and the frequency is typically set by the 
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time constants of inhibitory current decay (Womelsdorf et al., 2014). Nevertheless, only 
one-third of our interneurons were significantly correlated to the ongoing gamma 
oscillation with the treadmill off, and though this percentage did not increase as the 
gamma power increased, these interneurons may be sufficient for the generation of 
gamma oscillations. Interneurons have less immediate influence on the voltage in a given 
location due to their small spherical soma shape as compared to the larger pyramidal 
somas which have a greater spatial distribution between the source and the sink (Einevoll 
et al., 2013).  
We used spike-triggered waveform averages (STWAs) to measure the degree of 
spike correlation to LFPs. However, other studies examining arousal have used measures 
of pairwise phase consistency, or simple vector addition to determine spike-LFP 
relationships (Sigurdsson et al., 2010; Vinck et al., 2015). A few caveats of STWAs 
include the potential influence of extracellular transients related to the action potentials 
on the LFP, and the dependence on the frequency of the LFP band-pass filtering (Ray, 
2015, my own observations).  As the frequency range of the band-pass filtering increases, 
the probability that a spike train will significantly correlate with one of a frequencies 
within the band also increases.  Finally, we have demonstrated repeatedly throughout this 
thesis that the patterns of spike-gamma LFP correlation change depending on which wire 
within the bundle is selected for the LFP. The wire from which the spike train was 
recorded consistently had higher spike-LFP correlations as measured by mean STWA 
ratio and the percentage of significantly correlated neurons compared to the neighboring 
wires with the maximum coherence or median coherence to the wire on which the spike 
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train was recorded. Therefore, STWAs may not be the most robust measure of spike-
gamma LFP correlation, but actually reveal very fine-grained differences between LFPs 
across tens of microns. 
Typically, reductions in delta frequency power, and increases in theta frequency 
power complement increases in gamma power induced by arousal (McGinley et al., 
2015a). Interestingly, in humans, acute, subanesthetic ketamine increased gamma power 
and decreases delta power (Hong et al., 2010), supporting the hypothesis that gamma 
oscillations induced by arousal and  acute, subanesthetic ketamine share a common 
mechanism. However, in some animal models, subanesthetic ketamine actually increased 
delta power (Kiss et al., 2011a, 2011b), which complicates this interpretation. 
Finally, walking-induced gamma oscillations are dependent on intact dopamine 
neurotransmission (Delaville et al., 2015). Following a unilateral 6-hydroxydopamine 
lesion to the substantia nigra and most of the VTA, gamma, power no longer significantly 
increased during the treadmill walking task compared to the treadmill-off conditions 
(Delaville et al., 2015). Surprisingly, three weeks later, the walking-induced gamma band 
recovered, perhaps due to a compensatory mechanism (Delaville et al., 2015). Because 
the D4R has the highest affinity of all the dopamine receptors(Rondou et al., 2010) , we 
had predicted that dopamine signaling through the D4R would be responsible for the 
walking-induced increase gamma power. Therefore, we were surprised that the D4R 
antagonist had little effect on the walking-induced gamma power. Furthermore, the D4R 
antagonist increased the excitability of PV+ interneurons in vitro, which, according to the 
models (Jadi et al., 2015) should increase gamma power. Yet, this was not the case. It is 
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important to remember that endogenous dopamine is released in either tonic or phasic 
form, while D4R agonists and antagonists simply change the relative occupation of the 
different types of dopamine receptors. The importance of these two modes of signaling 
for understanding the data presented in this thesis will be discussed below. 
5.3 Tonic versus phasic dopamine 
NRG1/ErbB4R activation increased extracellular dopamine as detected by 
microdialysis (Kwon et al., 2008). The changes in dopamine concentration that can be 
detected by microdialysis better reflect the high tonic dopamine that activates D2-type 
receptors (Zheng et al., 1999) than the phasic dopamine that activates D1-type receptors 
(Zheng et al., 1999). In vivo, pharmacological activation of dopamine receptors using 
apomorphine, which mimics high tonic dopamine, enhanced gamma power slightly 
(<200%) and increased locomotion (Pinault, 2008). Although D4R activation increases 
gamma power in vitro,  pharmacological activation of other dopamine receptors, or direct 
application of DA, had no effect on gamma power (Andersson et al., 2012b). In fact, 
when dopamine was applied simultaneously with the D1-type receptor blocker 
SCH23390, it increased gamma power in vitro, indicating that relative activity of D1-type 
receptors to D2-type receptors is critically important for generating gamma oscillations 
(Andersson et al., 2012b). Durstewitz and Seamans have proposed that imbalanced 
D1:D2-type receptor activation could be responsible for the cognitive, positive and 
negative symptoms observed in schizophrenia (2008). Mechanistically, low 
concentrations of bath-applied dopamine activate D1-type receptors which increase 
NMDAR-mediated currents whereas high concentrations of dopamine activate D2-type 
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receptors which decrease NMDAR-mediated currents (Yang and Seamans, 1996; Zheng 
et al., 1999). Bath applied dopamine acts more similarly to tonic extracellular dopamine, 
and until recently, it was difficult to mimic phasic dopamine release. However, 
optogenetic stimulation of dopaminergic fibers projecting through the hippocampus can 
induce a brief, and concentrated release of dopamine (Rosen et al., 2015b). These 
investigators determined that tonic dopamine increased the activity of PV+ interneurons 
via D4R receptors which in turn suppressed glutamatergic neurotransmission from the 
Schaeffer collateral pathway onto pyramidal neurons in the CA1 (Rosen et al., 2015b). In 
contrast, brief, highly concentrated dopamine release, simulating phasic dopamine 
increased glutamatergic neurotransmission in the Schaeffer collateral pathway via D1 
receptor activation (Rosen et al., 2015b).  As elaborated in section 1.2.1, patients with 
schizophrenia show reduced signal-to-noise ratios in terms of task-related gamma power. 
If tonic dopamine occupies a majority of the dopamine receptors at a given synapse, it 
can occlude the effects of phasic dopamine, which are related to salience and learning 
(Lauzon et al., 2009). Perhaps the deficits in signal-to-noise ratios could directly relate to 
the temporal signaling of dopamine. Overall, both the proportions of D1 and D4 receptor 
activation, as well as the proportion of tonic and phasic dopamine pathways are important 
to the excitation-inhibition balance, which underlies gamma oscillation generation. Just 
as individual notes, and the rhythm are equally important when playing the piano, both 
the timing of dopamine release, and the activation pattern of the various types of 
dopamine receptors are important for producing neuromodulation. Systemic drug 
administration, or bath application of dopamine are like playing the chords underneath 
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the music, and can obscure the melody if the melody requires hitting the same keys as 
those in the chords. 
Dopamine D4R-targeting drugs have been proposed to have potential for treating 
cognitive deficits in schizophrenia (Furth et al., 2013); however, the present results found 
that these drugs show very limited ability to modulate ketamine-induced gamma activity.  
This raises the question: would these drugs really have little effect on cognition in 
schizophrenia patients, or is the acute ketamine model of schizophrenia not actually a 
useful tool for testing the cognitive benefits of pharmacological agents? Importantly, 
clinical trials to date have not supported the efficacy of the D4R antagonists as 
antipsychotics in the treatment of schizophrenia (Kramer et al., 1998; Bristow et al., 
1998), so the lack of effect of the D4R-targeting drugs in modulating ketamine-induced 
gamma are not inconsistent with the use of this approach as a strategy for probing 
antipsychotic efficacy (Hudson et al., 2016; Jones et al., 2012). It remains to be seen 
whether the acute ketamine model has potential for developing treatments for the 
cognitive deficits related to schizophrenia, and if D4R-targeting drugs may still have pro-
cognitive therapeutic potential in patients with schizophrenia. 
5.4 Improvements over previous work and limitations 
This thesis makes several improvements over existing literature. Firstly, using the 
treadmill walking task gives us better control over the rat’s behavior than allowing the rat 
to roam freely in an open field (del Pino et al., 2013; Hakami et al., 2009). Secondly, by 
using chronic recording electrodes, each rat can be used in multiple recordings, and can 
become his own control. Our microelectrodes have finer spatial resolution than rodent 
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EEG and allowed us to simultaneously probe the activity of single neurons and local field 
potential (Delaville et al., 2015; Homayoun and Moghaddam, 2007b). We also developed 
a novel measure of attention by counting the number of times that the rat hits the paddle 
within the treadmill. Due to the fact that the rats became hyperactive as they improved at 
the treadmill-walking task it is hard to tease apart whether ketamine reduced the number 
of paddle hits by increasing attention, or simply by increasing the rat’s activity. However, 
as the rat became more active, it increased its overall touching of the walls of the 
treadmill and decreased the number of times that it touched the paddle (Chapter 3). 
Therefore it is likely that the ketamine actually improved the rat’s attention to the task, as 
had been observed previously by Guidi and colleagues (2015).   
There are many animal models of the phenotypes present in schizophrenia, but we 
chose to use an acute, subanesthetic dose of ketamine to examine the effects of various 
drugs on gamma power. We had three key reasons for choosing this model: (1) This 
model has been used previously to test antipsychotic treatments (Anderson et al., 2014; 
Hudson et al., 2016; Jones et al., 2012, 2014; Ma and Leung, 2014). (2) This model has 
been well-established and is commonly used in both rodents and humans, yet the 
mechanisms underlying its effects are largely unknown (Frohlich and Van Horn, 2014; 
Kocsis et al., 2013). We hoped to increase the understanding of the mechanisms 
underlying this model, especially as ketamine is becoming more prevalent for the 
treatment of depression as well. (3) This model is easily reproducible and multiple 
experiments can be performed in the same rats, unlike after chronic NMDAR antagonist 
administration (Kittelberger et al., 2012; Wang et al., 2006). Whereas chronic ketamine 
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administration recapitulates more of the effects of chronic schizophrenia, such as 
parvalbumin depletion (Behrens et al., 2007; Kinney et al., 2006), acute ketamine mimics 
more of the diagnostic endophenotypes, such as cognitive, positive, and negative 
symptoms, and decreased signal to noise in gamma power (Cho et al., 2006; Hong et al., 
2010; Krystal et al., 1994; Saunders et al., 2012). Furthermore, to my knowledge, there 
are no controlled studies of chronic ketamine use in humans, perhaps due to ethical 
considerations. As such data from the acute ketamine model in rodents can directly 
inform hypotheses about acute ketamine in humans, whereas the chronic ketamine model 
does not directly relate to human studies. Furthermore, there is also a multitude of genetic 
models of the phenotypes present schizophrenia (Rosen et al., 2015a), but these studies 
are limited to one specific etiology, and are restricted by breeding capacity, and species. 
Genetic models are typically generated in mice and all of our equipment was designed for 
rats.  
5.5 A unifying hypothesis for mechanisms underlying increased gamma power 
To conclude this thesis I will attempt to bring together the evidence reviewed in 
Chapter 1 and experimental results from chapters 3 and 4 into a coherent theory on how 
ketamine, D4R activation, and ErbB4R activation all increase cortical gamma 
oscillations.  
 I propose that increasing the synaptic AMPA/NMDA current ratio increases 
cortical gamma power, specifically by decreasing NMDAR activity. Activation of 
ErbB4Rs and D4Rs both promote the internalization of NMDARs (Beazely et al., 2006; 
Vullhorst et al., 2015). The two predominant types of NMDARs in the adult 
  
195 
hippocampus and prefrontal cortex are those that contain NR2A and NR2B subunits. 
NMDARs with NR2A subunits have faster deactivation kinetics than NMDARs with 
NR2B subunits (Kim et al., 2005), and AMPAR s have the fastest decay kinetics.  
Notably,  ErbB4R activation decreases NR2B-containing NMDAR-mediated currents 
(Vullhorst et al., 2015), and D4R activation reduces long-term potentiation of AMPAR-
mediated currents via a NR2B-containing NMDAR mediated mechanism (Herwerth et 
al., 2012). NR2B-containing NMDARs are typically extrasynaptic (although they can 
move to the synapse during LTP and LTD, and are also synaptic in early postnatal 
development), and are not responsible for increasing gamma power, or extracellular 
glutamate when antagonized (Jiménez-Sánchez et al., 2014; Kocsis, 2012; Miller et al., 
2016).  NR2B and NR2A have opposite effects on the surface expression of AMPARs as 
well: NR2A-NMDARs promote the surface expression of GluR1 whereas NR2B-
NMDARs inhibit GluR1 surface expression (Kim et al., 2005). Thus, by internalizing 
NR2B-NMDARs, more AMPARs can stably remain at the membrane. NMDAR 
antagonists also appear to increase gamma power by increasing the AMPA/NMDA 
current ratio. NMDAR antagonists excite pyramidal neurons (Jackson et al., 2004) by 
elevating extracellular glutamate transmission through AMPARs (Maeng et al., 2008). 
Inhibiting NR2A-NMDARs also increases extracellular glutamate and gamma power 
(Jiménez-Sánchez et al., 2014; Kocsis, 2012). Additionally, ketamine increases AMPAR-
mediated currents in hippocampal slices (Nosyreva et al., 2013).  Finally,  AMPAR 
signaling is essential for gamma oscillations, as NMDAR antagonists have little effect on 
gamma power in the presence of an AMPAR antagonist (Zanos et al., 2016).  
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 If the AMPA/NMDA current ratio is pivotal for setting gamma power,  and the 
D4R agonist augments gamma power by reducing NMDAR-mediated currents in 
hippocampal pyramidal neurons (Beazely et al., 2006) and prefrontal cortical pyramidal 
neurons (Trantham-Davidson et al., 2014; Wang et al., 2003, 2006), then D4R agonists 
would have little to no effect on gamma oscillations after ketamine administration, since 
this pharmacological manipulation already increased the AMPA/NMDA current ratio.  
Indeed, the D4R agonist did not increase gamma power after an NMDAR antagonist in 
vitro (Andersson et al., 2012a), nor in vivo (Chapter 3). Along these lines, acute or 
chronic treatment with the NMDAR antagonist phencyclidine blocked the effect of the 
D4R on NMDARs in cortical pyramidal neurons (Wang et al., 2006). Interestingly, 
inhibiting the D4R increased evoked NMDAR-mediated currents in pyramidal neurons of 
the hippocampus (Kotecha et al., 2002), indicating that the D4R has a small ongoing 
effect that can increase with increased receptor activation. To my knowledge, no one has 
studied the effects of D4R activation on NMDAR-mediated currents in PV+ interneurons.  
Moreover, it remains unclear whether modulation of NMDAR or AMPAR-mediated 
currents must occur in pyramidal neurons, fast-spiking interneurons, or combinations of 
these neuronal types to generate changes in local field potentials. Previous work has 
examined the effects of NMDAR antagonism on mice with interneuron-specific deletion 
of NMDARs (Belforte et al., 2010; Korotkova et al., 2010). However, this fails to 
account for secondary effects, such as the extracellular increase in glutamate over a 
longer time scale. In future experiments, glutamate uncaging could be coupled with mice 
with cell-type specific ablation of NMDARs to determine whether the AMPA/NMDA 
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current ratio in PV+ interneurons, pyramidal neurons, or both types of neurons is 
important for determining the power of gamma oscillations.  
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